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Abstract
Costs and outcomes of increasing access to bariatric surgery
for obesity: cohort study and cost-effectiveness analysis
using electronic health records
Martin C Gulliford,1,2* Judith Charlton,1 Helen P Booth,1
Alison Fildes,1 Omar Khan,3 Marcus Reddy,3 Mark Ashworth,1
Peter Littlejohns,1 A Toby Prevost1,2 and Caroline Rudisill4
1Department of Primary Care and Public Health Sciences, King’s College London, London, UK
2National Institute for Health Research (NIHR) Biomedical Research Centre, Guy’s and
St Thomas’ NHS Foundation Trust, London, UK
3Department of Surgery, St George’s University Hospital NHS Foundation Trust, London, UK
4Department of Social Policy, London School of Economics and Political Science, London, UK
*Corresponding author martin.gulliford@kcl.ac.uk
Background: Bariatric surgery is known to be an effective treatment for extreme obesity but access to
these procedures is currently limited.
Objective: This study aimed to evaluate the costs and outcomes of increasing access to bariatric surgery
for severe and morbid obesity.
Design and methods: Primary care electronic health records from the UK Clinical Practice Research
Datalink were analysed for 3045 participants who received bariatric surgery and 247,537 general
population controls. The cost-effectiveness of bariatric surgery was evaluated in severe and morbid obesity
through a probabilistic Markov model populated with empirical data from electronic health records.
Results: In participants who did not undergo bariatric surgery, the probability of participants with morbid
obesity attaining normal body weight was 1 in 1290 annually for men and 1 in 677 for women. Costs
of health-care utilisation increased with body mass index category but obesity-related physical and
psychological comorbidities were the main drivers of health-care costs. In a cohort of 3045 adult obese
patients with first bariatric surgery procedures between 2002 and 2014, bariatric surgery procedure rates
were greatest among those aged 35–54 years, with a peak of 37 procedures per 100,000 population per
year in women and 10 per 100,000 per year in men. During 7 years of follow-up, the incidence of
diabetes diagnosis was 28.2 [95% confidence interval (CI) 24.4 to 32.7] per 1000 person-years in controls
and 5.7 (95% CI 4.2 to 7.8) per 1000 person-years in bariatric surgery patients (adjusted hazard ratio was
0.20, 95% CI 0.13 to 0.30; p< 0.0001). In 826 obese participants with type 2 diabetes mellitus who
received bariatric surgery, the relative rate of diabetes remission, compared with controls, was 5.97
(95% CI 4.86 to 7.33; p< 0.001). There was a slight reduction in depression in the first 3 years following
bariatric surgery that was not maintained. Incremental lifetime costs associated with bariatric surgery were
£15,258 (95% CI £15,184 to £15,330), including costs associated with bariatric surgical procedures of
£9164 per participant. Incremental quality-adjusted life-years (QALYs) were 2.142 (95% CI 2.031 to 2.256)
per participant. The estimated cost per QALY gained was £7129 (95% CI £6775 to £7506). Estimates
were similar across gender, age and deprivation subgroups.
Limitations: Intervention effects were derived from a randomised trial with generally short follow-up and
non-randomised studies of longer duration.
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Conclusions: Bariatric surgery is associated with increased immediate and long-term health-care costs but
these are exceeded by expected health benefits to obese individuals with reduced onset of new diabetes,
remission of existing diabetes and lower mortality. Diverse obese individuals have clear capacity to benefit
from bariatric surgery at acceptable cost.
Future work: Future research should evaluate longer-term outcomes of currently used procedures, and
ways of delivering these more efficiently and safely.
Funding: The National Institute for Health Research (NIHR) Health Services and Delivery Research
programme. Martin C Gulliford and A Toby Prevost were supported by the NIHR Biomedical Research
Centre at Guy’s and St Thomas’ Hospitals. Peter Littlejohns was supported by the South London
Collaboration for Leadership in Applied Health Research and Care. The funders did not engage in the
design, conduct or reporting of the research.
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Plain English summary
Rates of severe and morbid obesity are rising quickly. Bariatric surgery is an effective treatment for severeobesity, but is currently offered to just a small number of the patients who might benefit. This study
looked at the costs and health outcomes of increasing access to bariatric surgery for obesity treatment.
Patient electronic health records were used to investigate obesity and the use of bariatric surgery. We found
that patients who are obese and do not have surgery rarely maintain weight loss. The cost of health care for
the obese is largely due to obesity-related disease and depression. Bariatric surgery is being used more
frequently over time, with older and heavier patients now being treated. Women still account for 75% of
surgeries but the gender imbalance is decreasing. Bariatric surgery was found to reduce the onset of type 2
diabetes by 80%, and in patients who had diabetes already almost six times more went into remission
compared with those who did not have surgery. Bariatric surgery patients often have psychological
difficulties and surgery may not help these. Morbidly obese patients who have bariatric surgery can expect
to live for longer overall, and for longer without diabetes, than those who do not have surgery. Overall,
bariatric surgery was associated with higher health-care costs, but also improved health status, meaning
that overall it was a cost-effective treatment. It was slightly more cost-effective in patients with diabetes.
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Scientific summary
Background
Severe and morbid obesity are increasing rapidly in the UK. Bariatric surgery, the use of surgical procedures
for treatment of obesity, is considered to be an effective intervention for severe and morbid obesity but most
clinical trials have been of short duration (less than 2 years’ follow-up) and have often evaluated intermediate
outcome measures, including body weight. In 2006, the National Institute for Health and Care Excellence
(NICE) recognised that there is a large gap between population need, measured in terms of the prevalence of
obesity, and service delivery within the NHS. The National Obesity Observatory reported that there were fewer
than 7000 inpatient bariatric surgical procedures performed in England in 2009/10, but more than 1 million
patients are potentially eligible for this form of intervention. NICE recommended a gradual expansion of
bariatric surgery utilisation for patients with morbid obesity, as well as for patients with severe obesity when
comorbidity is present. The International Diabetes Federation recently advocated more widespread use of
bariatric surgery in the management of obese patients with poorly controlled type 2 diabetes mellitus (T2DM).
Definitions
In this report, ‘bariatric surgery’ refers to surgical procedures for obesity including laparoscopic-adjustable
gastric banding (LAGB), gastric bypass (GBP) and sleeve gastrectomy (SG). ‘Morbid obesity’ refers to
persons with body mass index (BMI) ≥ 40 kg/m2. ‘Severe obesity’ refers to persons with BMI between
35.0 and 39.9 kg/m2.
Objectives
This study aimed to inform decision-makers of the costs and outcomes of increasing, or not increasing,
access to bariatric surgery for severe and morbid obesity.
Setting
The setting for the study was the general population with obesity, aged ≥ 20 years, in the UK.
Perspective
The research took the perspective of the NHS. Health service costs were included. Wider societal costs,
including changes in productivity, which are hard to estimate precisely, were not included. The research
adopted a lifetime time horizon. Utilisation of bariatric surgical procedures in the private sector was not
explicitly considered.
Outcomes
The primary outcome was quality-adjusted life-years (QALYs), after taking into account the incremental
costs associated with intervention. Net health benefits were estimated at a threshold value of £30,000 per
QALY. Secondary outcomes included incidence of T2DM, remission of T2DM, prevalence of depression
and years lived with diabetes, coronary heart disease (CHD), stroke, cancer or depression.
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Data source
The UK Clinical Practice Research Datalink (CPRD) provided the source of electronic health records (EHRs)
for this study. The CPRD is the world’s largest primary care database comprising anonymised longitudinal
patient records from UK family practices. Data held within CPRD are considered to be broadly
representative of the UK population.
Ethical and scientific approval
Scientific and ethical approval of the protocol for the study was given by the CPRD Independent Scientific
Advisory Committee (ISAC protocol 13_089).
Methods
A health economic model was designed. Empirical data inputs to the model were provided through
analysis of EHRs for a large population registered in primary care, derived from the CPRD. Estimates for the
clinical effectiveness of bariatric surgery were derived from CPRD data analysis and updated systematic
reviews. Probabilistic simulations, run using the model, provided estimates of lifetime incremental costs and
health outcomes aggregated across the population at risk.
Three cohorts of participants were selected from CPRD.
Bariatric surgery cohort
This comprised a cohort of adult obese patients, aged ≥ 20 years, with first bariatric surgery procedures
performed, including all participants with LAGB, GBP or SG recorded before 30 April 2014. The earliest
procedure was performed in 2002.
Reliability study
A sample of 102 participants who had bariatric surgery recorded in their CPRD records was selected for a
reliability study in which EHR data were compared with general practitioner-reported information.
General population cohort stratified by body mass index category
We sampled a second cohort of participants from CPRD to act as a general population comparison sample.
The sample was drawn from the list of all acceptable patients who were registered with CPRD practices
that contributed to the data linkage scheme at any time between 1 January 2008 and 31 December 2014.
A stratified random sample was taken of up to 50,000 participants in each category of BMI, including
normal weight (18.5–24.9 kg/m2); overweight (25.0–29.9 kg/m2); obese (30.0–34.9 kg/m2), severe obesity
(35.0–39.9 kg/m2); morbid obesity (40.0–44.9 kg/m2) and super-obesity (≥ 45.0 kg/m2). Participants with
bariatric surgery recorded who were excluded from the sample leaving 257,187 patients for further
analysis. There were 247,537 participants eligible for linkage of Hospital Episode Statistics (HES) and
deprivation data.
Sample for analysis of the probability of attaining normal body weight
In order to conduct in-depth analysis of BMI transitions, we drew a sample that enabled analysis over a
longer period of time, with the inclusion of participants with a larger number of BMI records. The cohort
comprised a stratified random sample of participants with at least three BMI values recorded between
1 November 2004 and 31 October 2014, with 278,982 participants for analysis.
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Statistical analysis
Analyses were conducted to estimate mortality and the incidence and prevalence of comorbidity for BMI
categories ranging from normal weight to morbid obesity. Health-care utilisation was estimated from EHRs
in CPRD with linked HES data. Unit costs from reference sources were used to estimate health-care costs,
using a two-part econometric model.
Markov model
A probabilistic Markov model was employed to conduct a cost–utility analysis comparing discounted costs
and QALYs for bariatric surgery against standard non-surgical management for obesity. Model states
included ‘at risk’ with no morbidity, diabetes mellitus, CHD, stroke and cancer. Each state was further
subdivided into ‘depressed’ and ‘not depressed’. Each state was stratified by BMI category, as well as by
gender and single year of age. Death was included as an absorbing state. There were therefore 101 states
in the model. Costs and outcomes were compared under conditions in which no patients received bariatric
surgery or all patients received bariatric surgery. Costs and QALYs were discounted at 3.5%. A wide range
of sensitivity analyses was conducted.
Results
Weight changes in the absence of bariatric surgery
We analysed data for 76,704 obese men and 99,791 obese women who did not receive bariatric surgery.
During a maximum of 9 years’ follow-up, 1283 men and 2245 women attained normal body weight. In
simple obesity, the annual probability of attaining normal weight was 1 in 210 for men and 1 in 124
for women, increasing to 1 in 1290 for men and 1 in 677 for women with morbid obesity. The annual
probability of achieving a 5% weight reduction was 1 in 8 for men and 1 in 7 for women with morbid
obesity. Among participants who lost 5% body weight, 52.7% [95% confidence interval (CI) 52.4% to
53.0%] at 2 years and 78.0% (95% CI 77.7% to 78.3%) at 5 years had BMI records that indicated weight
gain to values above the 5% weight loss threshold.
Obesity and the costs of health-care utilisation
There was a general trend of increasing cost as BMI category increased but ‘normal’ weight was
sometimes associated with greater costs than overweight. Analysis showed that physical comorbidities,
which were more frequent in obese patients, were the greatest predictors of annual health-care costs
(adjusted mean additional cost £1366, 95% CI £1269 to £1463) followed by depression (£1044, 95% CI
£973 to £1115). At a given level of comorbidity, morbid obesity was associated with mean additional costs
of £456 (95% CI £344 to £568) higher than normal weight.
Epidemiology of bariatric surgery in the UK
There were 3045 adult obese patients with first bariatric surgery procedures recorded, including 3039
of defined type, between 2002 and 2014, including LAGB, 1297; GBP, 1265; and SG, 477. Annual
procedures increased from one in 2002 to a maximum of 525 in 2010. Intervention rates were greatest
among those aged 35–54 years, with a peak of 37 procedures per 100,000 population per year in women
and 10 per 100,000 per year in men. The mean age and BMI of participants undergoing surgery increased
during the period, as did the proportion of men and proportion with diabetes. Between 2002 and 2006,
LAGB accounted for > 90% of procedures; in 2014, GBP accounted for 52% and SG accounted for 26%.
Among patients initially receiving LAGB, rates of band removal were 1.6 (95% CI 1.3 to 2.0) per 100
patient-years; rates of a second procedure of a different type were 1.2 (95% CI 0.9 to 1.5) per 100
patient-years.
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Bariatric surgery and Incidence of type 2 diabetes mellitus
During a maximum of 7 years of follow-up (median 2.8 years, interquartile range 1.3–4.5), 38 new
diagnoses of diabetes were made in bariatric surgery patients and 177 were made in controls. By the end
of 7 years of follow-up, 4.3% (95% CI 2.9% to 6.5%) of bariatric surgery patients and 16.2% (95% CI
13.3% to 19.6%) of matched controls had developed diabetes. The incidence of diabetes diagnosis was
28.2 (95% CI 24.4 to 32.7) per 1000 person-years in controls and 5.7 (95% CI 4.2 to 7.8) per 1000
person-years in bariatric surgery patients; the adjusted hazard ratio was 0.20 (95% CI 0.13 to 0.30;
p< 0.0001). This estimate was robust after varying the comparison group in sensitivity analyses, excluding
gestational diabetes, or allowing for competing mortality risk.
Bariatric surgery in the management of type 2 diabetes mellitus
There were 826 obese participants with T2DM who received bariatric surgery, including LAGB 220, GBP
449 and SG 153, with four procedures undefined. Mean glycated haemoglobin (HbA1c) declined from
64mmol/mol (8.0%) before bariatric surgery to 48mmol/mol (6.5%) in the second postoperative year; the
proportion with HbA1c < 48mmol/mol (< 6.5%) increased from 17% to 47%. The adjusted relative rate of
remission over the first 6 postoperative years was 5.97 (95% CI 4.86 to 7.33; p< 0.001) overall; for LAGB
3.32 (95% CI 2.27 to 4.86); for GBP 7.16 (95% CI 5.64 to 9.08); and for SG 6.82 (95% CI 5.05 to 9.19).
Rates of remission were maintained into the sixth year of follow-up.
Bariatric surgery and clinical depression
Before surgery, 36% of bariatric surgery participants, and 21% of controls, had clinical depression:
between-group adjusted odds ratio (OR) 2.02 (95% CI 1.75 to 2.33; p< 0.001). In the second
postoperative year 32% had depression: adjusted OR, compared with time without surgery, 0.83 (95% CI
0.76 to 0.90, p< 0.001). By the seventh year, the prevalence of depression increased to 37%: adjusted OR
0.99 (95% CI 0.76 to 1.29; p= 0.959).
Cost-effectiveness analysis
In persons with morbid obesity aged 20–74 years, bariatric surgery was associated with increased longevity
and reduced time living with diabetes. Incremental costs associated with bariatric surgery were £15,258
(95% CI £15,184 to £15,330), including costs of bariatric surgical procedures of £9164 per participant.
Incremental QALYs were 2.142 (95% CI 2.031 to 2.256) per participant. The estimated cost per QALY
gained was £7129 (95% CI £6775 to £7506). Net monetary benefits valued at a threshold of £30,000 per
QALY were £49,016 (95% CI £45,720 to £52,414) per participant. Estimates were similar across gender,
age and deprivation subgroups. Bariatric surgery was slightly more cost-effective in patients with morbid
obesity and diabetes at £6176 (95% CI £5894 to £6457) per QALY, and slightly less cost-effective in
severe obesity, at £7675 (95% CI £7339 to £8037).
Limitations
Intervention effects were estimated from non-randomised studies because there have not been sufficient
clinical trials that evaluated substantive clinical outcomes over more than a few years of follow-up. It is
uncertain whether or not benefits from surgery will be maintained in the long-term. We modelled
scenarios in which benefits from surgery declined rapidly over time and showed that conclusions were
robust to varying assumptions. The health economic model included diabetes, cardiovascular disease,
cancer and depression but did not include other forms of obesity-related comorbidity that might also
benefit from bariatric surgery. The study only considered NHS health-care costs. Data were analysed for
bariatric surgery patients who are presently highly selected and outcomes may differ if bariatric surgery is
more widely utilised. EHRs contain frequent missing values and recording of data may be biased in relation
to outcomes of interest.
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Conclusions
For patients with morbid obesity, the chance of attaining normal weight or maintaining clinically relevant
weight loss is very low. Present obesity treatment frameworks grounded in community-based weight
management programmes appear to be ineffective. Health-care costs are increased in obesity, primarily
because of the greater burden of comorbidity.
Bariatric surgery is associated with reduced incidence of clinical diabetes in obese participants without
diabetes at baseline, and remission of diabetes in obese patients with diabetes. Psychological comorbidity
is frequent among individuals selected to undergo bariatric surgery, but any modest improvement over the
initial postoperative years is not maintained.
Bariatric surgery is cost-effective relative to standard weight management across a wider range of BMI
levels than currently recommended, and is more cost-effective in diabetes mellitus, with results robust to
gender, age and deprivation differences.
In a primary care organisation with a population of 250,000 adults aged 20–75 years, there may be 7000
people with morbid obesity. This number may be as high as 11,000 in a deprived area or as low as 4500
in an affluent area. There may be 1500 with morbid obesity and diabetes. If 1000 bariatric surgical
procedures are commissioned over a period of time, the immediate financial cost will be approximately
£9.2M. Total additional NHS costs may be £15.3M over the patients’ lifetime, as a result of increased
longevity. If bariatric surgery procedures are allocated equally to people with and without diabetes, there
will be 112 fewer patients developing diabetes over the next 10 years, while 200 patients with diabetes
may experience remission of the condition. The expected health gain over the patients’ lifetime is 2142
QALYs, from reduced mortality, reduced incidence of diabetes, cardiovascular disease and cancer, and
increased well-being. Valued at a threshold of £30,000 per QALY, these benefits amount to £64M, with a
net monetary benefit of £49M. Based on equitable patient selection, health gains will generally be directed
to more deprived groups but diverse population groups have capacity to benefit from increased access to
bariatric surgery at acceptable cost.
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Chapter 1 Introduction
Obesity is a growing global health concern1 and is second to smoking as a leading cause of preventabledeath globally. The prevalence of obesity is increasing in most countries, with especially rapid increases
in high- and middle-income countries.1 There is some evidence that the rate of increase in obesity may
have decelerated in recent years.2 This is not so for severe obesity, with body mass index (BMI) ≥ 35 kg/m2,
and morbid obesity, with BMI ≥ 40 kg/m2, which continue to increase very rapidly. People with morbid
obesity are at increased risk of several forms of morbidity, including type 2 diabetes mellitus (T2DM),
cardiovascular diseases and depression, leading to the development of multiple morbidity at young ages3
and heightened risk of mortality.4 These processes lead to reduced quality of life and reduced longevity,
as well as increased health-care costs.
Surgical interventions for obesity, referred to as bariatric surgery, have emerged as offering important
potential benefits. Randomised controlled trials (RCTs) with generally small samples, and up to 2 years’
follow-up, have shown important early reductions in body weight,5 with a mean weight reduction of 26 kg
following the procedure. Remission of T2DM is also well documented.6 Longer-term follow-up in cohort
studies has suggested reduced incidence of T2DM7,8 and other long-term conditions,9 as well as reduced
mortality.5,10 The types of surgical procedure used have evolved over time, with declining use of adjustable
gastric banding and increasing use of gastric bypass (GBP) and sleeve gastrectomy (SG) procedures.11
New evidence has emerged concerning longer-term outcomes and costs12,13 of bariatric surgery, including
effects on mortality,10 disease incidence7 and diabetes remission.14,15 This has been accompanied by a
growing recognition that the primary purpose of bariatric surgery is not a cosmetic one of reducing body
weight; use of surgery should aim to improve the prognosis of patients with morbid obesity by reducing
the incidence, and improving the control, of long-term conditions through incompletely understood
mechanisms that are not entirely weight-dependent.
Overweight and obesity in the UK
In England, the proportion of adults who are overweight or obese has increased from 52.9% in 1993 to
62.8% in 2010, while obesity has increased from 14.9% to 26.1% of adults over the same period.16
Individuals with obesity are classified as having severe obesity when their BMI is 35–39.9 kg/m2 and morbid
obesity when their BMI is ≥ 40 kg/m2. The increase in severe and morbid obesity in England has been
extremely rapid. From 1993 to 2010, morbid obesity increased eightfold from 0.2% to 1.6% of all men,
and nearly tripled from 1.4% to 3.8% of all women.16 Cardiovascular mortality is declining, and life
expectancy is increasing, but these favourable trends are threatened by the increase in obesity
and diabetes.
Obesity is associated with a wide range of negative health consequences, and these risks increase with
increasing BMI. Severe and morbid obesity are independently associated with increased incidence of
long-term conditions including T2DM, cardiovascular diseases and multiple cancer types.17,18 In the UK,
obesity may account for 4% of all cancers in men (including 27% of oesophageal cancer and 25% of
kidney cancer) and 7% of cancers in women (including 9% of breast cancers and 34% of endometrial
cancers).19 Symptomatic conditions associated with obesity include asthma, joint problems, back pain
and depressive symptoms. Obesity is associated with states of elevated risk and pre-disease including
hypertension and hyperlipidaemia. Morbidity generally begins at younger ages in obese people and
multiple morbidity becomes frequent as the condition progresses.3 Increasing BMI is associated with
shorter lifespan, with each additional 5 kg/m2 related to a 30% increase in mortality.20 Excess weight has
been estimated to account for 8% of premature deaths in men and 12% in women, with these figures
rising to 18% when smokers are excluded.21 The impacts of obesity are unequally distributed, being more
frequent in women and lower socioeconomic groups, contributing to inequalities in health.22
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Severe and morbid obesity are associated with substantial increases in health-care utilisation and costs
related to the management of obesity and associated comorbidities. The health-care costs of diabetes
alone are estimated to be about £14B per year in the UK. In 2006–7 it was estimated that over £5B was
spent on ill health due to overweight and obesity.23 More recently, it has been predicted that an excess
545,000 cases of diabetes, 331,000 of coronary heart disease (CHD) and stroke, and 87,000 of cancer will
occur in the UK as a result of the continuing increase in obesity. This would amount to an additional
£613M in health-care spending by 2020.24 These estimates do not consider the substantial indirect costs
of obesity.25 Given the negative impact of severe and morbid obesity on health and health-care costs,
weight loss has been proposed to lead to important health and economic benefits. The Office for Health
Economics estimated that wider use of obesity surgery may give economic benefits through reduced
welfare payments and additional paid work.26
Management of obesity
Reductions in the body weight of overweight and obese individuals are associated with improvements
in cardiovascular risk factors such as cholesterol and blood pressure. A reduced risk of death from
cardiovascular disease, cancer and T2DM together with lower risk of new-onset T2DM have also been
linked to intentional weight loss.27 The majority of obesity management interventions utilise lifestyle
changes focused on diet and physical activity to reduce body weight, with weight-loss drugs also playing a
more limited role. At present only a small proportion of obese patients access these interventions through
UK primary health-care services, with > 80% of obese and > 50% of morbidly obese patients having no
weight management intervention recorded over a 7-year period.28 When these interventions are utilised,
clinically meaningful weight loss is rarely achieved, with systematic reviews identifying only small reductions
in body weight, with weight regain being frequent.29,30
Bariatric surgery for obesity
An alternative and increasingly used strategy for the treatment of obesity is bariatric surgery.
The term bariatric surgery refers to surgical procedures that are designed to promote weight loss in obese
individuals. A number of different bariatric surgical procedures are in current use; these have traditionally
been classified as ‘restrictive’, ‘malabsorptive’ or ‘mixed’ procedures. Restrictive procedures reduce gastric
volume, leading to reduced dietary intakes. Laparoscopic-adjustable gastric banding (LAGB) was the most
common procedure before 2009 but now accounts for < 20% of procedures.11 LAGB is associated with
fewer complications than more invasive procedures, but also has a smaller effect on body weight. The
Roux-en-Y GBP operation employs a mixed approach, with the creation of a reduced stomach pouch
connected to the distal small intestine. The GBP procedure generally has a greater effect on body weight,
but carries a greater risk of short- and long-term complications than a restrictive procedure. In the USA,
GBP accounts for half to two-thirds of procedures, while in the UK it accounts for 46.6%.11 However, the
use of SG, where a large portion of the stomach is removed, has been increasing and now makes up 21%
of operations at UK centres.11 Publication of the UK National Bariatric Surgery Register (NBSR) data, which
covered the years 2011–13, found that these three operations constitute 95% of bariatric surgeries in the
UK. These operations are conducted laparoscopically in 95.4% of cases.11
Weight loss after bariatric surgery can lead to a mean weight reduction of 26 kg [95% confidence interval
(CI) –31 kg to –21 kg] when compared with non-surgical treatment6 and this effect can be maintained over
10 years.5 GBP and SG are associated with greater weight loss than gastric banding, although operative
complication rates are lower with the latter procedure.31,32 Surgery is associated with lower incidence of
comorbidity than non-surgical management,33 and mortality is reduced.5 Resolution of comorbidity may be
more relevant to health-care costs than weight loss, and is not always directly associated with weight loss.
After GBP surgery there is a high rate of early resolution of T2DM which may precede maximal weight loss.
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The literature suggests that bariatric surgery is generally more costly than non-surgical management of
obesity.31 Ackroyd et al.34 reported incremental costs of more than £2000 per participant over the first
5 years. This highlights a concern for policy-makers: that the health-care costs of surgical intervention are
generally immediate or short-term while gains, in terms of health benefits and costs, are delayed. A Health
Technology Assessment conducted by Picot et al.31 in 2009 investigated the clinical effectiveness and
cost-effectiveness of bariatric surgery for obesity. Their findings showed a low to moderate probability
that surgery is cost-effective within 2 years, but that over a 20-year time horizon there is a very high
probability that bariatric surgery will prove cost-effective at thresholds of £20,000 or £30,000 per
quality-adjusted life-year (QALY).31,34 The Picot review investigated use of surgery for obesity from an
individual patient perspective, which this analysis will complement by estimating the cost-effectiveness of
different levels of surgery uptake from a population perspective. In addition, we will utilise more recent
evidence from the growing literature on bariatric surgery and our own epidemiological analyses to update
the findings of Picot et al., in areas where there were previously few data reported. The value of estimates
varies in different health-care systems and according to the type of surgical procedure and duration of
follow-up. However, although a range of estimates have been produced by different studies,25 most
suggest that bariatric surgery will generally be cost-effective in the treatment of individuals with severe or
morbid obesity. An Office for Health Economics26 model reported that economic impacts were appreciable
when indirect costs including estimated hours worked and welfare benefits were considered.
Adverse effects of bariatric surgery
The mortality rate associated with GBP surgery is approximately 0.5%. In addition, there are longer-term
morbidity concerns associated with bariatric operations. Gastric banding is associated with a significant risk
of erosion and band slippage rate; GBP patients can re-present with internal hernias. Other complications
may include vomiting, leaks and gastrointestinal symptoms. Patients who have received bariatric surgery
require long-term monitoring and this has significant cost implications.
Eligibility and access to bariatric surgery
The increasing evidence for the clinical effectiveness and cost-effectiveness of bariatric surgery raises
questions concerning the selection of patients for surgery. The National Institute for Health and Care
Excellence (NICE),35 in its guidelines on obesity, recommended that bariatric surgery should be considered
(1) for individuals who have a BMI ≥ 40 kg/m2, or (2) for individuals with BMI 35–40 kg/m2 if comorbidities
that could be improved through weight loss are present, and (3) if non-surgical management has not
achieved sufficient weight loss over 6 months, the individual is committed to long-term follow-up, is fit for
surgery and can be treated in a specialist surgical service.
Presently, access to bariatric surgery in the UK is restricted. Based on the age-specific prevalence for
morbid obesity reported in the Health Survey for England,16 there were approximately 336,000 men and
806,000 women with morbid obesity alone in England in 2010, of whom 303,000 men and 676,000
women were aged 25–74 years. Approximately 8000 procedures for obesity are implemented annually in
England,36 accounting for about 0.5% of morbidly obese individuals. This contrasts with about 28,000
coronary artery bypass grafts performed annually. Bariatric operation rates vary widely among English
regions37 and there is also significant uptake of surgery in the private sector.36 Based on a combination of
epidemiological data, current clinical practice and expert opinion, NICE guidance suggested a population
benchmark rate for bariatric surgical procedures, to be achieved in 5 years’ time, of 0.01% of the general
population per year.38 This implies that only a small minority of people with severe or morbid obesity
would receive bariatric surgery. However, the long-term costs and outcomes of deploying bariatric surgery
across the population at the rate suggested by NICE, or other rates, are not known.
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The International Diabetes Federation (IDF) has recently challenged prevailing thinking by advancing a more
liberal approach to the use of bariatric surgery in relation to diabetes. The IDF39 now recommends surgery
for people with type 2 diabetes and a BMI of ≥ 35 kg/m2 and suggests surgery may be considered as a
treatment option in patients with a BMI between 30 and 35 kg/m2 and poorly controlled T2DM on medical
treatment. Its position statement proposes a significant expansion in the criteria for utilisation of bariatric
surgery, specifically for people who have both T2DM and obesity.
At the population level, the role of surgery in the treatment of obesity will depend on the costs and health
benefits achieved at different levels of uptake of bariatric surgery in the population at risk. Thus, a
population strategy for bariatric surgery should consider the benefits, harms and costs that accrue both to
those who do not receive surgery, and to those who do. This requires consideration of the impact of
intervention on the prevalence of different categories of obesity, the occurrence of morbidity and mortality
and the impact on the quality and duration of life in relation to the expenditure of health-care resources.
The societal distribution of outcomes and costs in terms of inequalities in health must also be considered.
Groups who live in conditions of social and material deprivation have a higher prevalence of morbid
obesity, especially in women, as well as higher mortality and shorter healthy life expectancy. This suggests
that obesity surgery is likely to be more cost-effective in lower socioeconomic groups or in areas of greater
deprivation. We acknowledge that the private sector plays a significant role in the delivery of bariatric
surgery. According to the NBSR, approximately one-third of the operations registered were done in the
private sector, although this may underestimate the true level of activity. We do not explicitly consider
private sector activity in this report.
The research asks to what extent a publicly funded health-care system, such as the NHS, should facilitate
access to bariatric surgery? What are the impacts of different levels of bariatric surgery activity on
health-care costs and health outcomes across the population at risk? This research will provide
policy-makers and commissioners of services with evidence on the potential cost-effectiveness of
facilitating access to bariatric surgery in a population, such as England, that has a high prevalence
of severe and morbid obesity.
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Chapter 2 Aims and objectives
This project aims to evaluate the extent to which the NHS, as a publicly funded health-care system,would be justified in facilitating increased access to bariatric surgery, and for which groups of patients.
Specific objectives
The research aimed to develop a Markov model to evaluate the costs and outcomes of bariatric surgery in
order to estimate the cost-effectiveness of the procedure.
The research specifically aimed to evaluate three intervention strategies:
1. Expanding access within existing recognised indications for bariatric surgery as defined by NICE.
2. Expanding access to bariatric surgery for people with T2DM as proposed by the IDF.
3. Expanding access with a focus on the distributional consequences of different intervention strategies.
The research aimed to evaluate to what extent health outcomes and costs of bariatric surgery vary
by gender, age group and among socioeconomic groups, thus evaluating the potential impacts on
inequalities in health related to obesity.
The research drew on analysis of electronic health records (EHRs) data for a large population. These
analyses, required for the health economic model, enabled us to address several other substantive research
questions, including:
1. What is the probability of an obese person transitioning to normal body weight, or maintaining clinically
important weight loss, in the absence of bariatric surgery?
2. What are the health-care costs associated with obesity? What are the drivers of health-care costs in
obese people?
3. What are the current rates of utilisation of bariatric surgery? What complications may follow bariatric
surgery procedures?
4. What effect does bariatric surgery have on the development of new T2DM in obese people?
5. What are the long-term effects of bariatric surgery on diabetes control and antidiabetes drug utilisation
in obese people with T2DM?
6. What effect does bariatric surgery have on measures of clinical depression?
The outputs from this research aimed to provide those responsible for commissioning and organising
surgical services, as well as patients and the public, with evidence to inform policies on the utilisation of
bariatric surgery for populations in which severe and morbid obesity are frequent.
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Chapter 3 Methods
Design and conceptual framework
The overall design of the research is outlined in Figure 1. A Markov model was designed. Empirical data
inputs to the model were provided through analysis of data for a large population registered in primary
care, derived from the Clinical Practice Research Datalink (CPRD) (formerly known as General Practice
Research Database). Estimates for the clinical effectiveness of bariatric surgery were derived from CPRD
data analysis and updated systematic reviews. Probabilistic simulations, run using the model, provided
estimates of lifetime incremental costs and QALYs aggregated across the population at risk.
Setting
The setting for the study was the general population with obesity, aged ≥ 20 years, in the UK.
Perspective
The research took the perspective of the NHS. Health service costs were included but social care costs were
excluded. Wider societal costs, including changes in productivity, which are hard to estimate precisely,
were not included. The research adopted a lifetime time horizon. Utilisation of bariatric surgical procedures
in the private sector was not explicitly considered, though evidence emerged that a substantial proportion
of procedures recorded in primary care electronic records may be performed privately.
CPRD
Literature reviews
Estimates of intervention
 effects and costs for BS
Estimates of incidence of long-term 
conditions, prevalence of symptomatic 
conditions, mortality rates and health-care
 costs of model states
Estimates of lifetime incremental costs 
and QALYs aggregated across the 
population at risk for different levels 
of uptake of BS
Start population 
for model
Markov model
Stratification by age, 
gender and IMD quintile
FIGURE 1 Schematic diagram outlining research. BS, bariatric surgery; IMD, Index of Multiple Deprivation.
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Outcomes
The primary outcome was QALYs, after taking into account the incremental costs associated with
intervention. Some simulations might be associated with negative incremental costs (where the
intervention is cost saving) or negative incremental QALYs (as when standard care dominates), net health
benefits40 were, therefore, estimated as:
Net health benefit = incremental QALYs− (incremental costs=threshold), (1)
where the threshold is the maximal acceptable value of cost per QALY; in the UK this is often taken as
£30,000 per QALY.41 Cost-effectiveness acceptability curves were also constructed using a range of values
for the threshold.
Data source
The UK CPRD provided the source of EHRs for this study. The CPRD is the world’s largest primary care
database, comprising anonymised longitudinal patient records from UK family practices. The CPRD
presently holds more than 80 million person-years of research-quality data from 1990 onwards from more
than 600 family practices. Data held within CPRD are considered to be broadly representative of the
UK population based on the demographic characteristics of patients and the size and distribution of
practices.42,43 Scientific and ethics approval of the protocol for the study were given by the CPRD
Independent Scientific Advisory Committee (ISAC 13_089).
Patient and public involvement
We organised a meeting for patients who had undergone bariatric surgery at St George’s Hospital to give
an overview of the research, elicit any thoughts or concerns they had over the project and receive any
potential research ideas. Interim findings were disseminated through new media as well as through
scientific publications and meetings.
Empirical analysis of electronic health records data
The registered population of the CPRD was used to represent the target population for the study. CPRD
general practices are located throughout the UK. CPRD data have been shown to be representative of the
UK population in terms of age and sex distribution and deprivation category. The annual count of the
CPRD registered population aged ≥ 20 years peaked at 3.7 million during this period, with a total of
7.1 million individual participants aged ≥ 20 years registered at any time between 2004 and 2014. Clinical
diagnoses recorded into CPRD have high validity.42 We have recently reported on clinical BMI recording in
CPRD.44 These analyses showed that there is under-recording of BMI in primary care, but individuals
without BMI records have a low incidence of morbidity which suggests that under-recording may be more
frequent in healthy individuals with normal body weight. A sample of CPRD general practices in England
participate in the data-linkage scheme and offer linked data including Index of Multiple Deprivation (IMD)
2010 deprivation scores45 at individual participant postcode level, and Hospital Episode Statistics
(HES) data.46
Three cohorts of participants were selected from CPRD.
Bariatric surgery cohort
The sample comprised a cohort of adult obese patients with first bariatric surgery procedures performed,
including all participants with LAGB, GBP or SG recorded before 30 April 2014. The date of the first
procedure was taken as the index date. The earliest index event was in 2002. Participants were excluded if
they were < 20 years of age. A lower age limit of 20 years was specified in the study protocol because we
aimed to evaluate the use of bariatric surgery in adults. Use of bariatric surgery for individuals in their teens
may be viewed as an outcome of childhood obesity and requires separate consideration. The mean age
of 14 patients excluded was 18.5 years, range 17–19 years. Procedures recorded within 1 year of the
METHODS
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participant start date in CPRD were also excluded because such records might refer to procedures
performed before the patient’s registration at a CPRD practice. (When a patient joins a general practice,
their previous notes are summarised and any significant diagnoses noted. A record of bariatric surgery
within 12 months of joining a practice may refer to a procedure performed before the patient joined the
practice.) Participants were excluded if they did not have a BMI record for obesity (BMI ≥ 30 kg/m2) prior to
surgery. A minimum BMI value of 30 kg/m2 was employed to ensure that all participants were obese, but
some BMI records dated from several years before operation and might not reflect preoperative BMI.
Baseline BMI values were recorded a median of 1.6 years [interquartile range (IQR) 0.6 to 5.4 years] before
surgery. Participants with gastric band removal recorded before the index date were also excluded.
Additional exclusion criteria were employed in selected analyses, which are described in Figure 2. In the
estimation of rates of bariatric surgical procedures, six participants with more than one procedure type
coded on the index date were also excluded. In the analysis of T2DM incidence following bariatric surgery,
participants with diabetes diagnosed on or before the index date were also excluded. In the analysis of
bariatric surgery and diabetes remission, we included only participants diagnosed with T2DM prior to the
index date. A diagnosis of T2DM was taken as the earlier of a medical diagnosis of diabetes, a prescription
for antidiabetes medicines or a glycated haemoglobin (HbA1c) value of 48mmol/mol (> 6.5%). Participants
who were diagnosed with polycystic ovary syndrome and prescribed diabetes medicines, but not
diagnosed with diabetes, were excluded from a diabetes diagnosis. Participants who were ever recorded as
having a medical code for gestational diabetes were also excluded from these analyses. Blood glucose
values were not used for diagnosis, nor assessment of remission, because distinctions between fasting or
post-meal values are rarely clear in clinical records.
CPRD
Participants with BS
 before 30 April 2014
(n = 4793)
Participants with diabetes
 at index 
(n = 878)
Participants not diagnosed 
with diabetes at index
(n = 2167)
Participants with index 
BS 2002–14
(n = 3045)
Analysis
Effect of BS on T2DM
Analysis
Incidence of T2DM after BS
Analysis
Epidemiology of BS
Impact of BS on clinical depression
• Surgery < 1 year of participant start, n = 1324
• Participant aged < 20 years, n = 14
• No BMI record/BMI < 30 kg/m2, n = 401
• Gastric band removal < index date, n = 9
Excluded
(n = 1748)
Excluded 
(n = 52)
• Gestational diabetes, n = 52
FIGURE 2 Selection of bariatric surgical cohort. BS, bariatric surgery.
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Reliability study
A sample of 102 participants who had bariatric surgery recorded in their CPRD records was selected for a
reliability study in which EHR data were compared with general practitioner (GP)-reported information.
The sample selected for study included approximately equal numbers of participants with EHR records for
LAGB, SG or GBP. LAGB patients who had records of gastric band removal and GBP and SG patients who
had repeat procedures were oversampled. Participants specifically selected included all 16 patients with
GBP or SG who had repeat procedures recorded; all 43 LAGB patients who had band removal recorded
and the initial procedure was in 2008 or later; and a random sample of 40 each with GBP and SG who
had index date in 2008 or later. Participants with procedures from 2008 or later were selected because
these were more likely to remain registered with the same general practice than patients treated longer
ago. This gave 139 participants, of whom one was duplicated between the first and third criterion, and
138 participants remained eligible for the validation study. However, 36 were excluded because their
general practice no longer contributed to CPRD, leaving 102 for further evaluation. The GP for each
patient was sent a questionnaire (see Appendix 1) which included items concerning whether or not the
patient had bariatric surgery, the date of surgery, the type of procedure, complications experienced, gastric
band removal, operation reversal and repeat procedures. Multiple reminders were sent in order to optimise
the response rate.
General population cohort stratified by body mass index category
We sampled a second cohort of participants from CPRD to act as a general population comparison sample.
The sample was drawn from the list of all acceptable patients who were registered with CPRD practices that
contributed to the data linkage scheme at any time between 1 January 2008 and 31 December 2014. For
each participant, the mean of all of his or her BMI records was estimated. Then a stratified random sample
was taken of up to 50,000 participants in each category of BMI: normal weight (18.5–24.9 kg/m2);
overweight (25.0–29.9 kg/m2); obese (30.0–34.9 kg/m2); severe obesity (35.0–39.9 kg/m2); morbid obesity
(40.0–44.9 kg/m2); and super-obese (≥ 45.0 kg/m2). Full CPRD data records were then extracted for this
sample. There were 1819 participants who ever had bariatric surgery recorded who were excluded from the
sample, together with one participant with undefined gender, leaving 257,187 patients for further analysis.
The distribution of the sample by gender and BMI category is shown in Table 1. For selected analyses, we
further restricted this sample to those participants who were eligible for linkage of IMD quintile and linked
HES data to CPRD records. There were 250,046 participants eligible for HES data linkage and 247,537
eligible for linkage of IMD 2010 deprivation category.
The start was the later of 1 January 2008, the participant registration date, or the general practice CPRD
start date. The end date was the earliest of 31 October 2014, the date death or end of registration, or the
last data collection date for the general practice.
TABLE 1 Distribution of the general population cohort at data extraction. Data are frequencies (column %)
BMI category (kg/m2)a
Gender
TotalMale Female
18.5–24.9 19,939 (18.6) 30,058 (20.1) 49,997
25.0–29.9 26,850 (25.0) 23,139 (15.5) 49,989
30.0–34.9 24,080 (22.4) 25,855 (17.3) 49,935
35.0–39.9 19,114 (17.8) 30,604 (20.4) 49,718
40.0–44.9 12,552 (11.7) 27,317 (18.2) 39,869
≥ 45.0 4934 (4.6) 12,745 (8.5) 17,679
All 107,469 149,718 257,187
a BMI category is based on the mean of all recorded values in that participant.
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Sample for analysis of the probability of attaining normal body weight
Analysis of the general population sample yielded transition probabilities required for the health economic
model. We recognised that further in-depth analysis of BMI transitions in this sample would be of interest.
We therefore drew a sample that enabled analysis over a longer period of time, with the inclusion of
participants with a larger number of BMI records.
There were 2,006,296 patients registered in CPRD between 1 November 2004 and 31 October 2014, who
were aged ≥ 20 years and had three or more BMI records. A minimum of three BMI records per patient
was required to estimate weight changes, including weight regain following weight loss, but most obese
patients had more than three BMI records. Participants were classified according to the BMI value of their
first record into the categories: 18.5–24.9 kg/m2 (normal weight); 25.0–29.9 kg/m2 (overweight);
30.0–34.9 kg/m2 (simple obesity); 35.0–35.9 kg/m2 (severe obesity); 40.0–44.9 kg/m2 (morbid obesity);
and ≥ 45.0 kg/m2 (super obesity). A random sample of up to 30,000 participants was selected, using the
‘sample’ command in Stata version 13 (StataCorp LP, College Station, TX, USA), from each category of BMI
and gender, resulting in a total of 314,477 participants. There were fewer than 30,000 women with BMI
≥ 45 kg/m2 and fewer than 30,000 men with either BMI 40–45 kg/m2 or ≥ 45 kg/m2. Full CPRD data records
were then extracted for this sample. Data were analysed for research quality records for each participant.
The start was the later of 1 November 2004, the participant registration date, or the general practice CPRD
start date. The end date was the earliest of 31 October 2014, the date death or end of registration, or the
last data collection date for the general practice. There were 2738 (1%) participants with bariatric surgery
who were excluded, as were 32,757 (10%) who had fewer than three BMI values recorded between
1 November 2004 and 31 October 2014, leaving 278,982 participants for further analysis.
Sample size considerations
The large size of the general population cohort was sufficient to provide precise estimates of the
parameters required for the Markov model. Estimates were expected to have acceptable precision, even
after stratification by gender and six age groups. Table 2 provides our initial estimates, but the anticipated
sample size was generally exceeded in this study.
Statistical analysis methods
The aim of statistical analyses was to provide empirical inputs requires for the Markov model.
Body mass index probability analysis
In order to estimate the probability of a person transitioning to normal body weight in the absence of
bariatric surgery, a longitudinal analysis of BMI records was conducted using a general population sample
as outlined above. The start date for each participant was the later of 1 November 2004 or the beginning
of the patient’s CPRD record. The end date was the earlier of 31 October 2014 or the end of the patient’s
CPRD record. The first BMI record after the participant start date was used as the index BMI and the date
of this record was used as the index date. The number of BMI records was evaluated for each BMI
TABLE 2 Parameter estimates for the economic model
Measure Assumptions
Precision (2 × standard error)
Sample in obesity category Stratified by age group and gender
Number 80,000 6667
Prevalence 50% ±0.35% ±1.2%
Prevalence 2% ±0.1% ±0.34%
Incidence, stroke 1 per 100047
Person-years analysis over 5 years’ data Upper limit: 1.10 Upper limit: 1.4
Lower limit: 0.91 Lower limit: 0.7
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category and the number of records showing either an increase or a decrease in BMI category was
calculated. For patients who showed a decrease in BMI category, we evaluated whether subsequent
changes in BMI category represented increases or further decreases. Data were analysed in a time-to-event
framework to evaluate, first, the proportion of patients from each starting BMI category who attained
either normal body weight, or, second, a 5% reduction in body weight during 9 years’ follow-up. A 5%
reduction in body weight was not envisaged in the original study protocol but was added as a minor
amendment because this is a widely recommended target for body weight reduction.35 In the first analysis,
the annual probability of attaining normal body weight was estimated. The number of events (BMI
category recorded as < 25 kg/m2) and the person-years of follow-up were used to estimate the annual
rates, and their CIs, which were converted to annual probabilities using the formula, 1-exp-rate. Among
participants who reduced BMI category, the direction of the next change in BMI category was evaluated.
In the second analysis, to examine the participants who had lost 5% of body weight, the development of a
body weight that was more than 95% of the initial body weight was also evaluated in a time-to-event
framework. Analyses were conducted in Stata version 13 using the stset, sts list and stcox commands.
Health-care costs in obesity
To assess costs related to obesity in the general population sample, person-time was allocated to BMI
category according to the most recent BMI value, combining records ≥ 40 kg/m2 into a single group to
represent morbid obesity. Comorbidity status was evaluated using medical diagnoses coded into EHRs
during general practice consultations. Person-time was classified according to morbidity status using the
first diagnosis of T2DM, CHD, stroke or cancer. Depression was re-evaluated in each year of follow-up and
patients were considered to have depression if they were diagnosed with depression in year or if they were
prescribed antidepressants in year and were ever diagnosed with depression. Morbidities, including
T2DM,48 CHD,49 stroke50 and depression,51 were evaluated using medical codes reported previously, while
cancer diagnoses were evaluated using codes for malignant neoplasms.
Health-care utilisation was estimated from participants’ EHRs, with linked HES data. Primary and secondary
care utilisation was evaluated including primary care consultations at the practice, by telephone, at home,
emergency and out-of-hours. Secondary care utilisation included admissions to hospital, outpatient,
day-case and emergency visits. All drug prescriptions issued by the practice were evaluated. Utilisation
rates were calculated using person-time at risk. Age-standardised rates were estimated using direct
standardisation and the European Standard Population for reference.
The costs of health-care utilisation were evaluated for participants by morbidity and depression status
within BMI categories for the period 2008 to 2013. The annual costs were estimated by multiplying the
health-care utilisation associated with each state by the costs of each unit of health care. Unit costs were
derived from reference sources based on 2013 price estimates. The Personal Social Service Research Unit
(PSSRU) publication Unit Costs of Health and Social Care 2013 was used as the main reference source
(Table 3).52 The same unit costs were applied across different ages, genders, BMI categories and morbidity
TABLE 3 Unit costs of health-care utilisation
Type of care Unit cost 2013 (£) Comment
GP consultations 45 Includes emergency consultations
Telephone consultations 27
Home visits 114
Day case 697
Emergency referral 135 From outpatient
Inpatient 1400 Weighted average of all stays
Outpatient 135 Weighted average of all outpatients
METHODS
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status. Primary care GP consultation, emergency or out-of-hours, home visit and telephone consultations
were priced at £45, £45, £114 and £27, respectively. Unit costs of secondary care inpatient, outpatient,
day-case and emergency visits were priced at £1400, £135, £697 and £135, respectively. To assess
prescription costs, drug codes for prescriptions in the EHRs were linked with costs from a dictionary
compiled by RESIP UK (RESIP UK, Chertsey, Surrey, UK).
A two-part model53,54 was used to analyse health-care utilisation costs. In the first stage, a probit model
was employed to estimate the probability of health-care utilisation being non-zero. In the second stage, a
generalised linear model (GLM) with a log link and gamma errors was used to evaluate the distribution of
costs in participants who utilised health care. This approach provided estimates of the predicted mean
costs for men and women in different BMI and morbidity categories for each year of age. In the final stage
of analysis, a linear regression model was employed to estimate the effects of BMI category, comorbidity
and depression on predicted health-care costs controlling for patient gender and age. Interaction terms for
comorbidity and depression and for comorbidity and BMI category were included. In order to make the
data sufficiently concise for presentation, diabetes, CHD, stroke and cancer were combined into a single
category of ‘comorbidity’ present or absent for the linear regression analysis. We combined ‘comorbidity’
into a single category in order to facilitate interaction terms with BMI status.
Epidemiology of bariatric surgery
The bariatric surgical cohort was analysed in order to understand the epidemiology of bariatric surgery over
the period of study. The rate of utilisation of bariatric surgical procedures was estimated for men and
women and for three age groups: 20–34 years, 35–54 years and 55–84 years. These represented young,
middle-aged and older adults. The denominator was person-years at risk for the general population
registered in CPRD. Participants were classified, according to the procedure recorded on the index date,
into LAGB, SG or GBP. Utilisation of the three procedures, as a proportion of all bariatric surgical
procedures, was evaluated from 2002 to 2014. Bariatric surgical codes recorded after the index date were
evaluated and participants were classified as having a second operation if a procedure of a different type
was recorded more than 30 days after the index date. In participants whose initial procedure was LAGB,
we evaluated whether or not a code for removal of gastric band was recorded. The occurrence of repeat
operations and band removal were evaluated in a time-to-event framework and annual incidence rates
were estimated. Records of body weight, height and BMI were identified in order to estimate changes in
body weight following the index date.
Type 2 diabetes mellitus incidence
The bariatric surgical cohort was analysed to evaluate the incidence of diabetes following the procedure.
Matched controls for comparison were drawn from the general population cohort, which included
103,502 obese non-diabetic individuals sampled from CPRD who did not receive bariatric surgery and
were not older than the maximum age of the bariatric surgery participants. Controls were matched for
age, BMI, sex, index year and HbA1c category. The maximum HbA1c value before the index date was
included using the categories < 42mmol/mol (6%), 42–47mmol/mol (6.0–6.49%) and not known. Nearest
neighbour matching was performed without replacement.14 The index date for controls was the date of
the earliest BMI record on which the patient attained their highest BMI category.
For bariatric surgery participants and controls, new diagnoses of clinical diabetes were identified using
medical diagnoses, drug prescriptions and HbA1c values. Participants were identified as being diagnosed
with clinical diabetes if a medical code for diabetes was recorded or if insulin or oral hypoglycaemic drugs
were prescribed or, using World Health Organization criteria,55 if a HbA1c value was 48mmol/mol (> 6.5%).
Oral hypoglycaemic drugs included sulphonylurea drugs, metformin, acarbose, dipeptidyl-peptidase-4
inhibitors, glitazones and glinide drugs. Participants with recorded diagnoses of polycystic ovary syndrome,
who were prescribed antidiabetic drugs but never diagnosed with diabetes, were coded as non-diabetic.
The date of the earliest medical, therapy or test event was taken as the diabetes diagnosis date. All new
diagnoses of diabetes were included because different diabetes phenotypes cannot always be clearly
distinguished in clinical practice. We evaluated new cases of diabetes for the recording of codes for type 1
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diabetes, for prescription of insulin within 6 months of the diagnosis date and for diagnoses of gestational
diabetes. The latter were excluded as a sensitivity analysis. The index BMI was the most recent recorded
value prior to the index date. Records for smoking status, blood pressure and cholesterol were identified
and the most recently recorded prior to the index date were used to describe baseline values. Depression,
CHD and stroke were identified using previously described medical codes.49–51
Baseline characteristics of the bariatric surgery participants and controls were described. A time-to-event
framework was used to assess T2DM onset, using the Cox proportional hazards model. Failure was a new
diagnosis of T2DM. Records were censored at the end of participants’ registration, the last date of CPRD
data collection or death. Follow-up was censored after 7 years because few participants remained. Models
were adjusted for matching variables, prevalent CHD, stroke and depression ever diagnosed, smoking
status, whether or not total cholesterol was > 5mmol/l, blood pressure > 140/90mmHg, use of statins and
antihypertensive drugs before surgery. Quadratic terms for age and BMI did not improve goodness of fit.
Indicator variables were used for missing data on blood pressure and cholesterol. However, 591 (27%) of
controls and 18 (1%) of bariatric surgery participants had missing values for blood pressure and 1466
(68%) of controls and 557 (26%) of bariatric surgery participants had missing values for cholesterol. The
proportional hazards assumption was evaluated with no evidence that this was violated. Robust variance
estimates were employed to allow for clustering of responses by family practice. Several sensitivity analyses
were performed: using the unmatched cohort of 103,502 obese non-diabetic individuals for comparison;
excluding participants diagnosed with diabetes within 12 months of the index date; and excluding
participants diagnosed with gestational diabetes. An analysis was performed to evaluate the impact of
competing risk from mortality using the method of Fine and Gray.56
Diabetes treatment
The bariatric surgical cohort was used to evaluate changes in T2DM control and remission after surgery by
selecting participants who had diabetes diagnosed prior to the index date. Control participants were
selected from the general population cohort who never had bariatric surgery recorded, but were obese
and had T2DM diagnosed before the index date. As the distribution of BMI differed greatly between
bariatric surgery cases and the CPRD obese population, control participants were individually matched with
cases using nearest neighbour matching on BMI, age, sex and index year. The index date for controls was
the date of the first BMI record on which they entered their highest recorded BMI category. Participant
records ended if they terminated their registration with a CPRD general practice; if their general practice
ended participation in CPRD; if the latest data collection date was reached; or if the patient died.
Glycated haemoglobin records and prescriptions for oral hypoglycaemic drugs and insulin were evaluated
for bariatric surgery cases and controls. The person-time for each participant was divided into study years
from 3 years before the procedure to 6 years after the procedure. This allowed us to conduct an interrupted
time-series analysis. Follow-up was censored at 6 years because few cases remained under follow-up for SG
and GBP. The highest HbA1c value and the total number of diabetes prescriptions were evaluated in each
study year. For each year of follow-up, participants were classified as being in remission if the maximum
HbA1c value recorded in year was 48mmol/mol (< 6.5%) and there were no diabetes prescriptions issued in
the year. This is consistent with the definition of ‘complete and partial remission’ suggested by Buse et al.57
Complete remission [HbA1c 42mmol/mol (< 6.0%) and not on medication] was also evaluated. Relative
rates were estimated for each year following the bariatric surgery procedure by using a Poisson model with
person-time as the exposure. Interpretation of these results requires consideration of the relationship
between year of procedure and duration of follow-up, with longer duration follow-up being available only
for patients operated on longer ago. A model was fitted to evaluate the effect of group (bariatric surgery or
control) and time after surgery, included as indicator variables for each postoperative year.58 Confounders
included age, gender, BMI, quartile of diabetes duration before surgery, whether CHD, stroke or depression
were diagnosed before the index date, whether blood pressure was ≥ 140/90mmHg or serum total
cholesterol was ≥ 5mmol/l, and whether or not antihypertensive drugs and lipid-lowering drugs were
prescribed before the index date, and smoking status recorded before the index date. Missing values for
covariates were accounted for using indicator variables.
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Changes in depression
A controlled interrupted time-series study was conducted, drawing on data from the bariatric surgery
cohort and matched control participants from the general population cohort, by evaluating multiple time
points both before and after the bariatric surgical procedure. EHRs from primary care were evaluated for
clinical diagnoses of depression and prescription of antidepressant drugs in the 3 years before, and 7 years
after, bariatric surgery.
Clinical depression was identified through medical diagnoses for depression recorded in clinical or referral
records as well as through prescriptions for antidepressant drugs. Participant records were divided into
person-years before and after surgery. Individuals were classified as having clinical depression in a given
person-year if they had a medical diagnosis of depression recorded in that year, or if they were prescribed
antidepressant drugs in the year and were ever diagnosed with depression.51 BMI was categorised
using the World Health Organization criteria55 using the most recent record prior to the index date.
Comorbidities were evaluated including stroke, CHD and T2DM. Records for hypertension (blood pressure
≥ 140/90mmHg), high cholesterol (total cholesterol ≥ 5mmol/l) and current smoking status were
evaluated. Participants were also classified according to whether they were treated with antihypertensive
or lipid-lowering medications.
Baseline characteristics in the surgery and control groups were compared. Participant records were divided
into 1-year periods from up to 3 years before, to a maximum of 7 years after, the index date. The presence
or absence of clinical depression was evaluated for each 1-year period. A multiple logistic regression
analysis was conducted using person-years as observations and the presence or absence of clinical
depression in each year as the outcome. A model was fitted to evaluate the effect of group (bariatric
surgery or control), study year from 3 years before to 7 years after surgery, and time after surgery,
included, for improved goodness of fit, as indicator variables for each postoperative year.58 The reference
category was all person-time without surgery from the control group and the bariatric surgery group
before operation. The model was adjusted for gender, age, baseline BMI, index year, type of bariatric
surgery procedure, prevalent diabetes mellitus, CHD and stroke, smoking status, high blood pressure and
cholesterol, and treatment with antihypertensive or lipid-lowering drugs. Robust variance estimates were
employed to adjust standard errors for clustering of person-years by participant.
Data analysis to inform health economic modelling
Data to populate the health economic model were derived using epidemiological analysis of the general
population cohort, among whom obese patients may have received weight management interventions
available in routine primary care. The incidence, prevalence, mortality and costs of health-care utilisation in
this group were estimated for each state in the model. Incidence and mortality rates were estimated in a
time-to-event framework using a Weibull model. Covariates were age, age squared, gender and BMI
category. The prevalence of depression was estimated for each state in the model.51 Health-care utilisation
and associated costs were estimated for each state in the model as described above.
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Evidence search and synthesis
The research drew on previous systematic reviews and primary research publications to provide evidence of
the health outcomes and cost-effectiveness of bariatric surgery.
Purpose
The purpose of the review was to systematically retrieve, appraise and synthesise available research
evidence. We aimed to provide information for the model by determining the projected short- and
long-term effects of bariatric surgical procedures on health states included in the model.
Eligibility criteria
We conducted a rapid review of previous systematic reviews that evaluated bariatric surgery as an
intervention for obesity. Subsequently, we identified literature not included in the reviews because of later
publication dates or restrictive inclusion criteria of reviews. A single literature search was conducted to
identify both systematic reviews and primary reports. We included systematic reviews, controlled clinical
trials and controlled observational studies published in English. Modelling studies were included for
cost-effectiveness evaluations. Participants were obese adults. The intervention was a bariatric surgical
procedure; and a comparator of standard care or comparisons between different surgical procedures were
accepted. The study outcomes were incidence of T2DM, CHD, stroke and cancer; remission of T2DM and
changes in depression; long-term mortality (more than 30 days post surgery); and cost-effectiveness.
Search strategy
We used the following search terms: (obes* or overweight) and (bariatric surgery or weight*loss surgery or
gastric band or gastric bypass or sleeve gastrectomy) and (diabetes or coronary heart disease or CHD or
stroke or depression or cancer) or (cost-effectiveness or cost-utility). We searched for papers published
after 2000 as there were sufficient recent systematic reviews. The searches were implemented in EMBASE
(1980–present), MEDLINE (1946–present), MEDLINE In Process & Other Non-Indexed Citations, PubMed
and the Cochrane Database of Systematic Reviews. Reference lists of included studies were checked for
further publications.
Study selection and data extraction
The search results were checked for eligibility by one reviewer. The full text was consulted when eligibility
was not evident from the abstract alone. Data were abstracted by one reviewer and checked by a second
reviewer. For disease incidence, T2DM remission and mortality, the summary measure was ideally
presented as a risk ratio, although we also considered odds ratios (ORs) and hazard ratios (HRs). We also
included publications which presented rates in the intervention and control groups. Changes in continuous
measures, such as changes in fasting blood glucose in T2DM or depression scales, were not included.
For the cost-effectiveness data the summary measures were incremental cost-effectiveness ratios (ICERs)
or costs per QALY. The data were abstracted by one reviewer into a spreadsheet.
Quality assessment
The AMSTAR (Assessing the Methodological Quality of Systematic Reviews) checklist was used to assess
the quality of systematic reviews.59 The assessment of study quality is presented in Table 4.
Data synthesis
A narrative synthesis was conducted summarising results included in systematic reviews and summarising
primary research studies of significance.
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Markov modelling for health economic evaluation
Model structure
A Markov model was employed to conduct a cost–utility analysis to compare a strategy in which all eligible
participants received bariatric surgery, with standard non-surgical weight management. A diagrammatic
representation of the Markov model is shown in Figure 3. The model structure was informed by previously
reported research86 and enabled us to include the main influences on costs and outcomes of bariatric
surgery identified in the literature search. Healthy subjects, referred to as ‘at risk’, may develop one of the
disease states of interest, including T2DM, CHD, stroke and cancer. Onset of disease was irreversible
except for diabetes which was allowed to remit with individuals returning to the ‘at risk’ state. Individuals
who entered remission then had the same risk of diabetes as all others in the ‘at risk’ state. Participants
in each state were allowed to progress to depression, with each main state divided into substates
representing ‘not depressed’ and ‘depressed’. Depression was included because it occurs frequently in
chronic illness and is associated with higher health-care costs.51 The model was stratified by BMI category,
comprising morbid obesity, severe obesity, simple obesity, overweight and normal weight, and allowed
participants to transition between BMI categories. There were, therefore, 50 states in the model that
represented all potential combinations of the included BMI categories, morbidities and depression. Each
state was further stratified by single year of age and gender. All states might lead to death. The
perspective of the model is that of health-care services and only health-care costs were included. Inputs to
the model for the standard care group were derived from the sources presented in Table 5.
Model estimation
The probabilistic Markov model was estimated by cohort simulation, implemented through a program
written in R software (The R Foundation for Statistical Computing, Vienna, Austria). The initial population
had ages ranging from 20 to 74 years, as we observed that there were few bariatric surgical procedures
over the age of 74 years in CPRD. The proportion of the start population with morbidity was also informed
by analysis of a CPRD cohort.
All simulations were stratified by single year of age with the initial population ageing by 1 year per cycle.
Participants exited the model when they died or reached 100 years of age. The model was run for each
sex separately. Outcomes and costs were compared for scenarios in which all participants received bariatric
surgery in the first annual cycle of the model or no participants received bariatric surgery. Annual transition
probabilities for the model were obtained by sampling from the beta-binomial distribution, using CPRD
data as inputs. The costs of each state were sampled from the gamma distribution, with the predicted
mean value estimated from a two-part model as outlined above. Utilities for each state were obtained
from data published in a compendium of values.87 Utility values for each state were stratified by single year
of age but were the same for men and women. Utility values were sampled from the beta distribution.
The utility values used in the model are presented in Table 6. Total costs and QALYs were obtained by
summing across the 81 cycles of the model included in each simulation. There were 1000 simulations run
for each scenario. Results are expressed as rates per 1000 participants entering the model. Mean costs,
and the 95% range, were obtained from the data for 1000 simulations. Costs and QALYs were discounted
using a rate of 3.5%, but undiscounted values and values discounted at 1.5% are also shown as sensitivity
analyses.88 Net monetary benefits and net health benefits were estimated at threshold values of £20,000
and £30,000 per QALY.88
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TABLE 6 Utility values used in model. Source: Sullivan et al.87
Condition Utility
Mean adult utility at age 43 years 0.828
Age (per year increase) –0.00029
T2DM –0.0714
CHD –0.0671
Stroke –0.1171
Cancer –0.04347
Depression –0.1123
BMI category (kg/m2)
30–34 –0.085
35–39 –0.17
≥ 40 –0.255
TABLE 5 Summary of data sources for comparison group (standard weight management) in the Markov model
Measure Data source Comment
Base population CPRD Data for approximately 250,000 adults aged ≥ 20 years,
stratified by age, sex, IMD quintile and BMI category
Incidence of long-term conditions CPRD Diabetes, heart disease, stroke, obesity-related cancer
Prevalence of symptomatic conditions CPRD Depression
Mortality CPRD Mortality for each state estimated from CPRD
Health-care utilisation CPRD Estimated from CPRD records for each state
Unit costs of health-care utilisation PSSRU52 Reference source. Additional costs of surgery will also
be estimated from NHS sources
Unit prescription costs for medicines RESIP UK Dictionary of costs provided by RESIP UK
Utility values Sullivan et al.87 Compendium of values provides utility of each state
Intervention effects Literature reviews and CPRD analysis
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Intervention effects and costs of bariatric surgery
The effect of bariatric surgery was modelled as a reduction in disease incidence and mortality. The effect of
bariatric surgery on the incidence of T2DM was drawn from CPRD data analyses7 that gave very similar
results to data from the Swedish Obese Subjects (SOS) study.9 Effects on incidence of CHD, stroke and
cancer were also drawn from the SOS study,9,89 which showed a reduction in cancer incidence in women
but not in men.89 The effect on depression prevalence was drawn from CPRD data analyses90 and is also
consistent with other reports. Based on CPRD data analyses (see Chapter 8), 40% of T2DM patients were
estimated to enter remission following the procedure. Bariatric surgery was modelled as being associated
with a positive impact on patient utility equivalent to a two-unit change in BMI category.6,91 However, this
effect was modelled to decline over time, according to year–0.25, consistent with the known reduction in the
initial quality of life improvement following bariatric surgery.92 The costs of bariatric surgery were drawn
from NHS tariffs and included preoperative weight management, the cost of the procedure, and
postoperative reviews (Table 7). Bariatric surgery was assumed to comprise one-third each of gastric
banding, GBP and SG. The cost of leaks was included as an average cost across all patients.93 Two per cent
of patients were assumed to require repeat procedures each year, slightly higher than the 1.2% observed
in CPRD records. Mortality from surgery was estimated at 0.07% from the NBSR report.11 Costs of
health-care utilisation were estimated from CPRD. Costs of health-care utilisation following bariatric
surgery were determined by age, sex and morbidity category, and were not modelled as associated with
body weight reduction, consistent with the results of empirical studies.12,13
TABLE 7 Estimated cost of bariatric surgery, UK£ 2014
Item
Adjustable gastric
banding GBP SG All
Proportion 0.3333 0.3333 0.3333 1
Preoperative Tier 3 weight
management programme (£)
1024 1024 1024
Surgical procedure
Tariff: code FZ05A FZ04A FZ04A
Tariff: cost (£) 3620 8713 8713
Postoperative reviews (£) 875 875 875
Total (£) 5519 10,612 10,612
Average total (£) 8914.50
Cost of leaks (£)a 250
Total (£) 9164.50
Cost of reoperations (£)b FZ05A 3620 2% of patients per year
a Applies to GBP patients.
b Includes band slippage, removal, internal hernia, etc.
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Subgroup and sensitivity analyses
In the base case we investigated the effect of bariatric surgery in participants with BMI ≥ 40 kg/m2,
compared with no participants undergoing surgery. This was because the majority of bariatric surgery
procedures are performed for morbid obesity at present. The initial population included 19% with T2DM
and 4% with CHD, similar to the distribution observed in CPRD at the start of the study period (see
Chapter 6). Additional simulations were performed to estimate costs and outcomes separately for men and
women; for separate age groups, including 20–34 years, 35–54 years and 55–64 years; and categories of
deprivation, comparing the most- and least-deprived quintiles of deprivation according to the IMD 2010
score. IMD scores were linked at patient lower super-output area level.94 A summary of the simulations
performed is presented in Table 8.
Sensitivity analyses were implemented to explore the effects of varying the unit costs of bariatric surgery,
including values 50% and 100% higher than the base case; varying the discount rate including values
of 0%, 1.5% and 3.5% following NICE recommendations; and to estimate outcomes assuming that
intervention effects following bariatric surgery might diminish with time following the operation. This was
implemented by allowing intervention effects from bariatric surgery to diminish by year–0.25 or year–0.5.
The former implies that the effect of bariatric surgery will decline by 44% over 10 years, while the latter
indicates that the intervention effect will decline by 68% over 10 years. Sensitivity analysis was also used
to test intervention cost-effectiveness for patients with severe obesity (BMI 35–39 kg/m2) or with morbid
obesity and T2DM.
TABLE 8 Summary of simulations performed
BMI category
(kg/m2) Condition Category Start population
≥ 40 All Synthetic population of 100,000 each of men
and women, aged 20–74 years, with morbid
obesity, including 19% with T2DM and 4%
with CHD
≥ 40 Gender Men 100,000 men with morbid obesity as above
Women 100,000 women with morbid obesity as above
≥ 40 Age group (years) 20–34 Synthetic population of 100,000 each of men
and women, in the specified age group, with
morbid obesity including 19% with T2DM and
4% with CHD
35–54
55–74
≥ 40 Deprivation category Least deprived As in ‘All’ above
Most deprived As in ‘All’ above
≥ 40 Diabetes BMI ≥ 40 kg/m2 BMI ≥ 40 kg/m2 Synthetic population of 75,000 each of men
and women, in the specified age group, with
morbid obesity and T2DM
35–39 BMI 35–39 kg/m2 BMI 35–39 kg/m2 Synthetic population of 75,000 each of men
and women, aged 20–74 years, with morbid
obesity and no comorbidity
≥ 40 Costs of procedure 50% higher As in ‘All’ above
100% higher As in ‘All’ above
Zero procedure cost As in ‘All’ above
≥ 40 Decline of intervention
effect over time
Year–0.25 As in ‘All’ above
Year–0.50 As in ‘All’ above
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Chapter 4 What is the probability of an obese
person attaining normal body weight?
Introduction
This chapter describes changes in body weight of obese participants who did not undergo bariatric
surgery. It assesses possible body weight trajectories among obese patients who are managed in primary
care and provides a context against which bariatric surgery may be compared. A target of 5% body
weight loss is often recommended for obese subjects who intend to lose weight.95 In practice, access to
weight-management interventions may be limited28 and systematic reviews show that weight-management
interventions have only small and poorly maintained effects on body weight.29,96 In order to understand the
frequency with which reductions in BMI may occur in a large population, this part of the study aimed to
estimate the probability of an obese individual attaining normal body weight, or a reduction of 5% in body
weight in the absence of bariatric surgery. The results of this study have been published open access in the
American Journal of Public Health (© American Public Health Association).97
Results
The analysis comprised 278,982 participants, including 129,194 men and 149,788 women, who were
registered between 1 November 2004 and 31 October 2014, and had three or more BMI records recorded
during this period. The initial distribution of the sample by gender and BMI is shown in Table 9. Mean age
was 55 years for men and 49 years for women. At the index date (date of the first BMI record in the
study period) there were a minimum of 25,000 male and 23,000 female participants each for the BMI
categories 18.5–24.9 kg/m2 (normal weight), 25.0–29.9 kg/m2 (overweight), 30.0–34.9 kg/m2 (obese) and
35.0–39.9 kg/m2 (severely obese). There were similarly high numbers of female participants with an index
BMI of 40.0–44.9 kg/m2 (morbidly obese) but fewer male participants in this category at baseline (14,767).
There were 6481 men and 18,451 women with a baseline BMI ≥ 45.0 kg/m2 (super obese).
Table 9 also shows the frequency and proportion of participants recorded as having no change in BMI
category, increases in BMI category, decreases in BMI category or weight cycling (both increases and
decreases) over 9 years following first BMI record. The number of BMI records per participant increased
with baseline BMI category. The proportion of participants showing no change was greatest among
participants in the normal weight category (men 57%; women 59%) and decreased with higher baseline
BMI, with the exception of those initially categorised as super obese. Only 14% of all men and 15% of
women showed decreases in BMI category without increases over the same period. The proportion of
participants with records indicating only decreases in BMI increased with baseline BMI category, with the
highest proportions observed for those initially categorised as morbidly obese (men 19%; women 19%)
and super obese (men 21%; women 19%). A small proportion of participants (12% each of men and
women) had only BMI category increases recorded, with the highest proportion found among those
initially categorised as normal weight (men 20%; women 18%). Weight cycling was observed in over
one-third of participants (35% of men; 38% of women) and was most common among severely obese
(men 46%; women 47%) and morbidly obese (men 51%; women 52%) participants.
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Table 10 shows the frequency of transitioning to normal body weight during up to 9.9 years’ follow-up
after the first BMI record. During a maximum of 9 years’ follow-up, 1283 men and 2245 women attained
normal body weight records. The annual probability of achieving normal body weight was 1 in 210 for
men and 1 in 124 for women with simple obesity. The probability declined with increasing BMI category.
In patients with morbid obesity, the annual probability of achieving normal weight was 1 in 1290 for men
and 1 in 677 for women. In women, the probability of achieving normal weight among super-obese
participants was 1 in 608, similar to that observed in morbid obesity. In the smaller number of super-obese
men, the probability was higher, at 1 in 362.
Annual probabilities of achieving a clinically relevant 5% reduction in body weight are shown in Table 11.
The annual probability of experiencing a 5% weight reduction was 1 in 12 for men and 1 in 10 for
women with simple obesity. Probability increased with increasing BMI category. For patients with morbid
obesity, the annual probability of achieving 5% reduction in body weight was 1 in 8 for men and 1 in 7
for women. The highest annual probability was observed among patients with super obesity (1 in 5 for
men and 1 in 6 for women). However, among participants who lost 5% body weight, 52.7% (95% CI
52.4% to 53.0%) at 2 years, and 78.0% (95% CI 77.7% to 78.3%) at 5 years, had BMI records that
indicated weight gain to values above the 5% weight loss threshold.
TABLE 9 Number of BMI records per participant and proportions showing no change, increase, decrease or weight
cycling over 9 years following first BMI record
Initial BMI
category
(kg/m2) n
Mean
(SD) age
(years)
Number of
BMI records,
median
(IQR)
All records
show no
change
in BMI
category,
n (%)
One or more
decreases in
BMI category
and no
increases,
n (%)
One or more
increases in
BMI category
and no
decreases,
n (%)
Records show
both increases
and decreases
in BMI
category,
n (%)
Men
18.5–24.9 25,082 58 (18) 5 (3–7) 14,217 (57) 799 (3) 5032 (20) 5034 (20)
25.0–29.9 27,408 58 (15) 5 (3–8) 13,281 (48) 3243 (12) 3428 (13) 7456 (27)
30.0–34.9 27,966 56 (14) 6 (4–10) 10,320 (37) 4620 (17) 2901 (10) 10,125 (36)
35.0–39.9 27,490 53 (13) 7 (4–12) 7200 (26) 5070 (18) 2525 (9) 12,695 (46)
40.0–44.9 14,767 50 (13) 8 (4–14) 2761 (19) 2810 (19) 1596 (11) 7600 (51)
≥ 45.0 6481 47 (13) 8 (4–14) 2828 (44) 1353 (21) N/A 2300 (35)
All 129,194 55 (15) 6 (4–10) 50,607 (39) 17,895 (14) 15,482 (12) 45,210 (35)
Women
18.5–24.9 23,640 46 (20) 4 (3–7) 14,047 (59) 844 (4) 4346 (18) 4403 (19)
25.0–29.9 26,357 52 (19) 5 (3–8) 10,140 (38) 3696 (14) 4197 (16) 8324 (32)
30.0–34.9 27,251 52 (17) 6 (4–10) 8275 (30) 4621 (17) 3626 (13) 10,729 (39)
35.0–39.9 27,373 49 (16) 7 (4–11) 6322 (23) 4910 (18) 3304 (12) 12,837 (47)
40.0–44.9 26,716 48 (15) 7 (4–13) 4680 (18) 5009 (19) 3108 (12) 13,919 (52)
≥ 45.0 18,451 46 (14) 8 (5–14) 8945 (48) 3472 (19) N/A 6034 (33)
All 149,788 49 (17) 6 (4–10) 52,409 (35) 22,552 (15) 18,581 (12) 56,246 (38)
N/A, not applicable to highest BMI category; SD, standard deviation.
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Among patients with a recorded decrease in BMI category over the study period, Figure 4 shows the
percentage of men and women whose later BMI records revealed an increase, a further decrease or no
change in BMI category. The majority of patients (men 61%; women 59%) whose records showed a
decrease in BMI category went on to record a subsequent increase in BMI category. These proportions
were similar for men and women and across BMI categories. The proportion of patients who showed a
second decrease in BMI category was highest among patients with morbid (men 16%; women 19%) and
super obesity (men 23%; women 24%) and was considerably less frequent in lower BMI categories.
Overweight patients and those with simple obesity were the most likely to display no further BMI category
change following a recorded decrease.
TABLE 11 Annual probability of achieving a 5% reduction in body weight by initial BMI category and gender
Initial BMI
category
(kg/m2)
Number of
participants
Number of person
years during
follow-up
Number attaining
5% reduction in
body weight
Annual probability of
attaining 5% reduction
in body weight
Men
30.0–34.9 27,966 135,394 11,869 1 in 12
35.0–39.9 27,490 118,266 13,805 1 in 9
40.0–44.9 14,767 57,099 8100 1 in 8
≥ 45.0 6481 20,900 4177 1 in 5
Women
30.0–34.9 27,251 123,567 12,792 1 in 10
35.0–39.9 27,373 116,042 13,972 1 in 9
40.0–44.9 26,716 103,849 15,208 1 in 7
≥ 45.0 18,451 63,397 11,340 1 in 6
TABLE 10 Annual probability of achieving normal body weight (BMI < 25 kg/m2) by initial BMI category and gender
Initial BMI
category
(kg/m2)
Number of
participants
Number of
person-years
during
follow-up
Number
attaining
normal BMI
Annual probability of attaining normal BMI
Estimate
Lower 95%
confidence limit
Upper 95%
confidence limit
Men
30.0–34.9 27,966 179,746 857 1 in 210 1 in 197 1 in 225
35.0–39.9 27,490 174,386 249 1 in 701 1 in 619 1 in 797
40.0–44.9 14,767 91,528 71 1 in 1290 1 in 1023 1 in 1651
≥ 45.0 6481 38,367 106 1 in 362 1 in 300 1 in 442
Women
30.0–34.9 27,251 173,066 1398 1 in 124 1 in 118 1 in 131
35.0–39.9 27,373 175,356 408 1 in 430 1 in 390 1 in 475
40.0–44.9 26,716 170,483 252 1 in 677 1 in 599 1 in 769
≥ 45.0 18,451 113,540 187 1 in 608 1 in 527 1 in 704
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Discussion
Summary of findings
Analysis of primary care EHRs for a large population based sample of men and women over a 9-year
period revealed that the probability of obese patients attaining normal weight was very low. The annual
probability of patients with simple obesity attaining a normal body weight was only 1 in 131 for women
and 1 in 225 for men. The likelihood of attaining normal body weight declined with increasing BMI
category, with the lowest probability observed for patients with morbid obesity. The smaller group of
patients with super obesity represented a departure from this trend, but nevertheless showed a low
probability of attaining normal body weight. Although the probability of patients achieving a 5% reduction
in body weight was considerably higher, the majority of these patients went on to regain lost weight, as
evidenced by BMI records of > 95% of the initial value, within 2–5 years of the first record that was lower
than 95% of the initial value.
These findings raise questions concerning whether or not current obesity treatment frameworks, grounded
in weight management programmes accessed through primary care, may be expected to achieve clinically
relevant and sustained reductions in BMI for the vast majority of obese patients and whether or not they
could be expected to do so in the future. The lack of sustained BMI reductions could be driven by low
intervention uptake rates or their lack of effectiveness. In a previous study, we reported that weight-loss
interventions are currently offered only to a minority of patients in primary care.28 Efforts are under way to
improve this situation, with the proportion of patients with obesity offered multicomponent weight-loss
interventions included among potential new indicators in the 2016/17 consultation for the Clinical
Commissioning Group Indicator Set (CCG OIS).98 However, even when treatment is accessed, evidence
suggests that behavioural weight-loss interventions focusing on caloric restriction and increased physical
activity are unlikely to yield clinically significant reductions in body weight.29,99 A recent series of reviews
documented the limited progress in reversing the global obesity epidemic and called for regulatory actions
from governments as well as co-ordinated efforts across industry and society to reduce obesity.100–103 Dietz
et al.104 warn that preventative strategies are unlikely to reduce weight in people living with severe obesity
and stress the need for changes in the delivery of care for these patients. In combination with previous
research, this study highlights the current failures in combating existing obesity cases at a population level.
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FIGURE 4 Changes in BMI category following an initial decrease in BMI category. Data are presented by gender
and initial BMI category.
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Comparison with other results
Reductions in BMI category were observed more frequently among patients with a higher baseline BMI but
these decreases were more likely to be followed by subsequent increases rather than further decreases or
stability in BMI category. Weight cycling, evidenced by both increases and decreases in BMI category,
was most common among men and women with baseline BMIs in the morbidly obese category. Greater
instability in weight trajectories among patients with higher BMIs has been reported previously.105 Weight
cycling has been linked to a higher risk of morbidity and mortality compared with stable obesity,106–108
although evidence of causality remains inconclusive.109
The higher likelihood of decreases in BMI category and of 5% weight loss among the more severely obese
participants in this study is consistent with results from clinical trials110 and previous cohort studies111 in
which higher BMI predicted greater weight loss. The increased probability of weight reduction among
patients with more severe obesity may reflect more accurate perceptions of personal weight status112,113
and higher treatment rates among these patients. It is also possible that BMI decreases in severely obese
patients reflect unintentional weight loss resulting from greater comorbidity. The finding that a high
proportion of patients in this analysis experienced a period of weight regain following weight loss is also
consistent with previous research. At least 50% of patients who achieved 5% weight loss were shown to
have regained this weight within 2 years. It has previously been reported that approximately 80% of
people who intentionally achieve weight loss ≥ 10% of their body weight will regain that weight within
1 year.114
Strengths and limitations
This analysis had the strengths of a large population-based cohort with prolonged follow-up.
Slightly lower numbers at the highest levels of BMI might have made these estimates slightly less precise.
Data are presented for adults aged > 20 years. Inspection of age-specific values revealed, as expected,
greater weight gain at younger ages and a somewhat greater tendency to weight loss at older ages. It was
not possible to evaluate intentionality of weight loss. Previous studies have reported that the majority of
obese individuals would like to lose weight and a large proportion are actively attempting to reduce
their weight,115,116 so a relatively high level of intentionality among obese participants may be assumed.
Additionally, monitoring of BMI among obese patients in primary care has been shown to positively predict
treatment.117 Patients in the present study were required to have a minimum of three BMI measurements
recorded, suggesting that an inflated proportion of patients in this sample might have been involved
in and interested in weight-management interventions. Nevertheless, we acknowledge that unintentional
weight loss was also included and might result from physical disorders such as cancer, or psychological
concerns such as bereavement.118–120 Additional in-depth analyses might evaluate patterns of weight
change in relation to comorbidity.
Recording of body weight in primary care is generally opportunistic and dependent on patients attending
the practice. We acknowledge that weight measurements in EHRs may be associated with error and bias
including measurement error; confounding by indication, if weight changes prompt weight measurements;
variation between professionals and family practices in measurement recording;44 and weight-management
strategies.28 Higher patient baseline BMI was associated with a higher frequency of BMI measurements
recorded over the study period. UK general practices have contractual financial incentives to provide a
register of adult patients who have a BMI ≥ 30 kg/m2 measured in the last 15 months121 which may lead to
more frequent recording of BMI for obese patients. We reported on the recording of BMI in primary care
in a previous study.44 For this study, we selected participants with a minimum of three BMI records. We
acknowledge that participants with fewer than three BMI records may show different patterns of weight
change and the present results might be biased through their omission. However, we believe that this is
one of the largest studies yet reported on body weight changes in the general population. The relatively
high levels of comorbidity seen in obese compared with normal weight patients would also likely result in
more regular consultations and more frequent recording of BMI. However, it is possible that patients from
all BMI categories with three or more BMI measurements recorded over the 9-year study period represent
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a biased, less healthy sample than the general population. If this is the case then unintentional weight loss,
along with comorbidities contributing to weight gain such as mobility impairment, may have influenced
BMI changes disproportionately in the current sample.
Conclusions
Findings from this analysis indicate that current non-surgical obesity treatment strategies are failing to
achieve sustained weight loss for the majority of obese patients. For patients with a BMI of ≥ 30 kg/m2,
maintaining weight loss was rare and the probability of achieving normal weight was extremely low.
Research to develop new and more effective approaches to obesity management and prevention are
urgently required. Obesity treatment programmes should prioritise prevention of further weight gain, along
with the maintenance of weight loss in those who achieve it. However, in the absence of effective
interventions targeted at the level of the individual, the greatest opportunity for tackling the current
obesity epidemic may be found outside primary care. Research to develop wider-reaching public health
policies is needed to prevent obesity at the population level.
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Chapter 5 Costs associated with obesity in
primary care
Introduction
This chapter presents data for health-care costs in relation to obesity in order to assess the key drivers of
costs relating to obesity. This will help to establish the impact that increasing the level of bariatric surgery
offered to obese patients might have on associated costs. This analysis investigated the association
between BMI category and health-care costs, focusing on the question of whether it is BMI, obesity-related
comorbidity and/or depression that determines costs related to obesity. The results in this chapter were
published in the journal Clinical Obesity in April 2016122 under the terms of the Creative Commons
Attribution Licence CC-BY-NC.
Results
A breakdown of the cohort characteristics by person-years is presented in Table 12. The sample was
majority female (62%) and person-time was distributed evenly among age groups and BMI categories.
TABLE 12 Distribution of person-years by BMI category, comorbidity and depression
Variable Category Person-years Per cent of total
Total 873,809 100
Gender Male 335,610 38
Female 538,199 62
Age group (years) 20–34 118,364 14
35–44 151,810 17
45–54 170,562 20
55–64 170,362 19
65–74 143,723 16
75–84 90,972 10
≥ 85 28,017 3
BMI category (kg/m2) 18.5–24.9 130,806 15
25.0–29.9 171,622 20
30.0–34.9 181,283 21
35.0–39.9 173,470 20
≥ 40.0 216,629 25
Comorbidity None 573,998 66
Diabetes 144,089 16
CHD 76,144 9
Stroke 19,978 2
Cancer 59,600 7
Depression Not depressed 731,526 84
Depressed 142,282 16
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Person-time was mostly spent with no comorbidities (66%). Depression was prevalent in 16% of
person-years. The results from the two-part model used to estimate health-care costs based on the CPRD
cohort are presented in Table 13. More strongly positive coefficients indicate greater probability of utilising
health care (probit model) or greater health-care costs (GLM) associated with that covariate. Significant
interactions between BMI category and comorbidity and between comorbidity and depression on predicted
health-care costs were identified.
The predicted costs by BMI category, gender, comorbidity and depression status are presented in Table 14.
Depression was consistently associated with greater health-care costs in all states. Overall, there is a largely
positive linear relationship between health-care costs and BMI category. However, there are some notable
exceptions to this trend which are more suggestive of a ‘J’-shaped relationship. Normal-weight participants
frequently had higher predicted health-care costs than their overweight counterparts. In participants
with diabetes this result is further pronounced, with normal-weight men and women, with or without
depression, showing higher predicted health-care costs than all but the most obese category of
participants. In men with depression and diabetes, the normal-weight participants had the highest
estimated cost of all BMI categories, at £3940 compared with £3796 in the morbidly obese category.
Similarly, in men with stroke and depression the annual estimated cost was highest in the normal-weight
category, at £4442 compared with £4385 in the morbidly obese category. Stroke appears to be related to
the highest overall costs, with the exception of not-depressed men with a BMI ≥ 25 kg/m2 who have been
diagnosed with cancer and not-depressed women who are obese and have been diagnosed with cancer.
TABLE 13 Two-part regression model for costs of health-care utilisation
Predictor Probit model coefficient (95% CI) p-value GLM coefficient (95% CI) p-value
Age per year –0.019 (–0.022 to –0.17) < 0.001 –0.017 (–0.020 –0.015)
Age-squared 0.00034 (0.00031 to 0.00037) < 0.001 0.00027 (0.00025 to 0.00030) < 0.001
Gender
Female 0.033 (0.031 to 0.034) 0.02 (–0.00 to 0.03) 0.094
BMI category (kg/m2)
18.5–24.9 Reference Reference
25.0–29.9 0.08 (0.06 to 0.10) < 0.001 0.01 (–0.02 to 0.03) 0.660
30.0–34.9 0.18 (0.16 to 0.20) < 0.001 0.11 (0.08 to 0.14) < 0.001
35.0–39.9 0.21 (0.19 to 0.23) < 0.001 0.18 (0.15 to 0.21) < 0.001
≥ 40.0 0.25 (0.23 to 0.27) < 0.001 0.29 (0.26 to 0.32) < 0.001
Depression
Present 1.68 (1.56 to 1.80) < 0.001 0.61 (0.54 to 0.67) < 0.001
Comorbidity
None Reference Reference
Diabetes mellitus 0.64 (0.53 to 0.75) < 0.001 0.84 (0.70 to 0.98) < 0.001
CHD 0.54 (0.44 to 0.65) < 0.001 0.79 (0.69 to 0.89) < 0.001
Stroke 0.35 (0.21 to 0.49) < 0.001 1.01 (0.81 to 1.21) < 0.001
Cancer 0.35 (0.28 to 0.43) < 0.001 0.84 (0.78 to 0.89) < 0.001
BMI × depression χ2= 11.9, df= 4 0.018 χ2= 1.6, df= 4 0.81
BMI × comorbidity χ2= 33.6, df= 16 0.006 χ2= 54.5, df= 16 < 0.001
Comorbidity × depression χ2= 112.4, df= 4 < 0.001 χ2= 130.1, df= 4 < 0.001
df, degrees of freedom.
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Linear regression identified having a comorbidity as the single largest predictor of health-care costs with a
£1366 (95% CI £1296 to £1463) mean increase in annual patient costs if a morbidity is present (Table 15).
The second greatest predictor was depression, at £1044 (95% CI £973 to £1115) per patient per year.
The remaining factors included in the analysis, including BMI group, have a demonstrably lower influence
on patient costs, but are nonetheless measurable and important influences. BMI group was positively
associated with health-care costs but at a much smaller magnitude, with a £456 increase in morbidly
obese participants compared with normal weight. Being overweight did not increase average health-care
costs. An illustration of the increase in costs associated with comorbidity and depression by BMI group in
women aged 46 years is presented in Figure 5. Age and female gender were related to higher costs but of
a lower magnitude (£51 per year and £113 in females). Finally, there was evidence of a multiplicative
effect on costs with the presence of depression or high BMI alongside a comorbidity. Having depression
alongside a comorbidity was associated with an additional cost of £243 (95% CI £164 to £322) per year,
while being obese, severely obese or morbidly obese increased costs by a further £168, £152 or £199,
respectively. Depression had a greater additive effect on cost in conjunction with a comorbidity than BMI.
The additive cost impact of a comorbidity was also greatest for those at normal weight.
TABLE 14 Predicted costs by BMI category, gender and condition. Figures are mean values (UK£) across ages 20 to
100 years
Gender Depression Condition
BMI category (kg/m2)
18.5–24 25–29 30–34 35–39 ≥ 40
Men Not depressed At risk 997 1016 1134 1206 1376
DM 2471 2242 2267 2356 2559
CHD 2341 2121 2469 2602 2871
Stroke 2864 2551 2882 2962 3074
Cancer 2406 2566 2936 3059 3280
Depressed At risk 1985 1981 2128 2282 2506
DM 3940 3527 3530 3621 3796
CHD 3645 3204 3719 3876 4227
Stroke 4422 3876 4339 4343 4385
Cancer 3458 3690 4097 4227 4274
Women Not depressed At risk 1057 1072 1194 1289 1439
DM 2548 2306 2332 2421 2659
CHD 2421 2177 2537 2667 3061
Stroke 2983 2676 3020 3054 3229
Cancer 2505 2662 3040 3162 3419
Depressed At risk 2040 2029 2225 2441 2602
DM 4007 3588 3617 3786 4055
CHD 3741 3276 3810 4001 4513
Stroke 4492 3969 4407 4528 4750
Cancer 3577 3759 4207 4435 4527
DM, diabetes mellitus.
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TABLE 15 Estimated effects of gender, age, depression, BMI group and comorbidity on health-care costs
Variable Category Adjusted mean difference (£) (95% CI) p-value
Gender Male Reference
Female 113 (81 to 144) < 0.001
Age Per year 51 (50 to 52) < 0.001
Depression Not depressed Reference
Depressed 1044 (973 to 1115) < 0.001
BMI category (kg/m2) Reference
25–29 5 (–117 to 107) 0.934
30–34 146 (34 to 258) 0.011
35–39 280 (168 to 392) < 0.001
≥ 40 456 (344 to 568) < 0.001
Comorbiditya Absent Reference
Present 1366 (1269 to 1463) < 0.001
Comorbidity × depressionb 243 (164 to 322) < 0.001
Comorbidity × BMI categoryc 18.5–24 232 (106 to 35) < 0.001
25–29 Reference
30–34 168 (43 to 293) 0.009
35–39 152 (17 to 277) 0.017
≥ 40 199 (74 to 325) 0.002
BMI category × depression 18.5–24 121 (20 to 221) 0.018
25–29 Reference
30–34 76 (–24 to 176) 0.137
35–39 125 (25 to 225) 0.014
≥ 40 116 (16 to 216) 0.024
a Includes T2DM, CHD, stroke or cancer.
b Additional cost associated with co-occurrence of comorbidity and depression.
c Additional cost associated with co-occurrence of comorbidity and stated BMI category.
COSTS ASSOCIATED WITH OBESITY IN PRIMARY CARE
NIHR Journals Library www.journalslibrary.nihr.ac.uk
34
050
0
10
00
15
00
20
00
25
00
30
00
<
 2
5
25
–2
9
30
–3
4
35
–3
9
>
 4
0
Annual cost (£)
B
M
I (
kg
/m
2 )
N
o
 c
o
m
o
rb
id
it
y
D
ia
b
et
es
 m
el
lit
u
s
D
ia
b
et
es
 a
n
d
 d
ep
re
ss
io
n
FI
G
U
R
E
5
C
o
st
s
o
f
h
ea
lt
h
-c
ar
e
u
ti
lis
at
io
n
b
y
B
M
I
ca
te
g
o
ry
in
w
o
m
en
ag
ed
46
ye
ar
s.
DOI: 10.3310/hsdr04170 HEALTH SERVICES AND DELIVERY RESEARCH 2016 VOL. 4 NO. 17
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Gulliford et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
35
Discussion
Summary of findings
This analysis investigated health-care costs in relation to BMI and is the first we are aware of to isolate
depression as a cost separate from other common obesity-related morbidities. Previous studies
investigating health-care costs relating to obesity using patient cohorts have attempted to estimate the
marginal effect of obesity on costs.123,124 Understanding the causal association between BMI and
health-care utilisation is important; however, in the context of treating patients in a clinical environment
there is little benefit in divorcing obesity from related morbidities and socioeconomic factors.
We found that having a comorbidity was the greatest predictor of increased health-care costs, at £1366
per year, followed by clinical depression at £1044 per year. Of the four obesity-related morbidities we
assessed, stroke was found to be associated with the highest absolute costs, which is likely to be a result
of acute secondary care required after a stroke. This finding is supported by a previous paper that
identified cardiovascular diseases and cardiovascular agents as the biggest drivers of health-care claims
costs per unit of BMI.125
We found that depression was the second greatest driver of costs and its presence increased costs in all
states, in line with a previous investigation conducted into depression and health-care utilisation.51 Overall,
having high BMI in addition to a comorbidity appeared to increase costs exponentially, although having
depression was an even greater contributor to high health-care costs alongside a comorbidity. In spite of
this, being overweight was not associated with higher health-care costs than normal weight, and in fact,
participants who were normal weight and diabetic had similar costs as diabetic participants who were
morbidly obese. A majority of adults are now either overweight or obese. ‘Normal’ weight may sometimes
result from weight loss associated with comorbidity and this might account for elevated health-care
utilisation in this group. Therefore, diabetes and not just weight alone appears to be behind cost figures.
Comparison with other results
There is large variation in cost estimates for obesity based on population sample studies, ranging from an
additional €160 per year for severe obesity compared with normal weight,124 to US$2741 for any obesity
compared with normal weight.123 Our findings estimated an increase of £146 per year for mild obesity in
comparison with normal weight, and £456 for morbid obesity. These estimates were for the influence of
BMI separate from the considerations of obesity-related morbidities and depression.
One unexpected finding was the high cost of health care in normal-weight diabetic patients compared
with obese diabetics. In fact, this phenomenon has been reported elsewhere, and the possibility of greater
morbidity in diabetics who are normal weight has been suggested as an explanatory factor.126,127 The lack
of statistically significant difference in costs between normal and overweight BMI categories has also been
found in other studies.128,129
Strengths and limitations
This analysis has a number of strengths that make it a valuable addition to the literature on health-care-related
costs of obesity. First, it is based on a large, longitudinal, nationally representative data set and uses costs
associated directly with provision of care rather than based on insurance claims, which are an indirect measure
of morbidity and may be less accurate. It is also one of few analyses to use clinically measured height and
weight values in the calculation of BMI rather than self-reported values which are prone to reporting bias.130
This is also the only analysis we are aware of to use UK sample data to estimate the health-care costs
associated with obesity. One possible limitation of the study is selection bias from inclusion of participants with
a BMI recorded during a clinical consultation, who may be more frequent users of health-care services and,
therefore, less healthy. Participants’ morbidity status was classified using the first diagnosis they received
and we have not accounted for additional diagnoses. The costs associated with the conditions we have
highlighted may represent costs from multiple morbidities, which are more frequent in obese patients and we
know were present in 18% of the observations.3
COSTS ASSOCIATED WITH OBESITY IN PRIMARY CARE
NIHR Journals Library www.journalslibrary.nihr.ac.uk
36
The economics literature has moved towards using an instrumental variables approach to examine the
causal effect of obesity on medical costs by using the weight of a biological relative as an instrument.123,124
The argument for this method is that the instrument predicts the participants’ weight, but not their
morbidity status, meaning that the effect of weight on costs can be isolated. Such papers have found
higher health-care costs for obesity than non-instrumented methods, so it is possible that our models
underestimate the magnitude of the relationship.
Conclusions
The findings of this analysis emphasise that health-care costs for obesity are largely driven by a few key
obesity-related morbidities and not by high BMI alone. Persistently high obesity rates and evidence from
the literature7 suggest that preventative and reactive treatment strategies are currently of limited use. Until
greater success is observed in lowering obesity levels, perhaps clinical focus should be on prevention of
secondary conditions as a way of improving the health status of obese patients and lowering resulting
costs. In particular, increasing uptake of successful diabetes prevention programmes131 may prove
beneficial given the high costs observed across BMI categories in this analysis. Similarly, successful
interventions to focus on the mental health of obese might also stem resultant health-care and
non-health-care costs related to depression.
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Chapter 6 Epidemiology of bariatric surgery in
the UK
Introduction
This chapter contributes to the epidemiological context for the research by evaluating the epidemiology of
bariatric surgery from 2002 to 2015. The analysis provides a population-based investigation of the
changing epidemiology of bariatric surgery in the UK, drawing on primary care EHRs. We estimate
utilisation rates for different procedures, changes in case mix over time, and the rate of reoperation.
A reliability study was also performed to compare EHR data with GP questionnaire responses for the same
patients. The results in this chapter were published in the journal Obesity Surgery in January 2016132 under
the terms of the Creative Commons Attribution 4.0 International Licence (http://creativecommons.org/
licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided
the original work is properly cited.
Results
Reliability study results
Completed questionnaires were received for 78 patients (Table 16). All 78 responses confirmed that
bariatric surgery had been performed on the date indicated in EHR data. The type of bariatric surgical
procedure was confirmed for all 30 (100%) patients recorded with LAGB, for 24 out of 25 (96%) patients
recorded with SG, and for 19 out of 23 (83%) patients recorded with GBP. Gastric band removal was
confirmed for 27 out of 30 (90%) of cases. Among nine patients with second procedures recorded in EHRs
following GBP or SG, six were confirmed in GP questionnaire responses. The most common complications
after surgery reported by GPs were infection and wound site problems (13%), digestive issues including
diarrhoea and vomiting (10%), pain (8%) and difficulties with the throat and swallowing (6%). High rates
of complication in this group may be expected as patients requiring further procedures were oversampled.
GPs reported that the surgery was privately funded in 32 (41%) of cases.
TABLE 16 Reliability study of bariatric surgery comparing primary care EHR with responses from GP questionnaires.
Figures are frequencies unless otherwise indicated
Measure EHR GP questionnaire Per cent agreement (95% CI)
Bariatric surgery performed 78 78 100 (–)
Surgery type
Adjustable gastric banding 30 30 100 (–)
GBP 23 19 83 (61 to 95)
SG 25 24 96 (80 to 100)
Gastric band removal 30 27 90 (73 to 98)
Procedure secondary to GBP 3 1 33 (1 to 91)
Procedure secondary to SG 6 5 83 (36 to 100)
Difference in date, days (median, IQR)
Date of primary bariatric surgical procedure 0 (0–0)
DOI: 10.3310/hsdr04170 HEALTH SERVICES AND DELIVERY RESEARCH 2016 VOL. 4 NO. 17
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Gulliford et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
39
Utilisation of bariatric surgical procedures
The number of procedures recorded increased over time, with only 104 procedures recorded between
2002 and 2005; 607 between 2006 and 2008; 1406 between 2009 and 2011; and 922 between 2012
and April 2014 (Table 17). The rate of surgery was highest in men and women aged 35–54 years. Rates of
bariatric surgical procedures by age group and gender are presented in Figure 6. Rates of bariatric surgery
were greatest for women in 2010 at 37 per 100,000 population per year, and in 2012 for men at 10 per
100,000 population per year. Disparity between genders was greatest in the youngest patients, aged
20–34 years, with peak rates of 15 per 100,000 per year in women and 3 per 100,000 per year in men.
LAGB was the most frequent procedure, accounting for 1297 (43%) of cases, followed by GBP in 1265
(42%) participants and SG in 477 (16%). LAGB accounted for 97% of 104 procedures performed from
2002 to 2005. The use of GBP and SG increased over time while LAGB declined (Figure 7). During
2012–14, GBP accounted for 55% of procedures, while SG accounted for 25% and LAGB accounted for
20% (see Table 17).
TABLE 17 Characteristics of patients receiving first bariatric surgery procedures from 2002 to 2014. Figures are
frequencies (column %) unless otherwise indicated
Measure 2002–5 2006–8 2009–11 2012–4 p-value
Number of procedures 104 607 1406 922
Type of procedure < 0.001
Gastric banding 101 (97) 518 (85) 497 (35) 181 (20)
GBP 2 (2) 51 (8) 701 (50) 511 (55)
SG 1 (1) 38 (6) 208 (15) 230 (25)
Age at procedure (years), mean (SD) 43.4 (8.6) 44.4 (10.0) 46.1 (10.4) 46.8 (10.0) < 0.001
Female 89 (86) 504 (83) 1118 (80) 691 (75) < 0.001
BMI (kg/m2), mean (SD) 40.6 (7.1) 42.7 (8.3) 44.2 (8.2) 44.8 (8.3) < 0.001
BMI category (kg/m2)
30–34.9 29 (28) 108 (18) 162 (12) 95 (10) < 0.001
35.0–39.9 24 (23) 161 (27) 301 (21) 189 (21)
≥ 40 51 (49) 338 (56) 943 (67) 638 (69)
Diabetes 20 (19) 124 (20) 428 (30) 302 (33) < 0.001
Depression 61 (59) 320 (53) 762 (54) 540 (59) 0.148
Current smoking 20 (19) 104 (17) 231 (16) 146 (16) 0.323
Antihypertensive 42 (40) 278 (46) 728 (52) 509 (55) < 0.001
Statins 20 (19) 123 (20) 418 (30) 301 (33) < 0.001
SD, standard deviation.
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FIGURE 6 Rates of first bariatric surgery procedures in a large primary care population for (a) men; and (b) women.
The denominator is the population registered in CPRD. Blue line, 20–34 years; green line, 35–54 years; black line
55–84 years.
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Changes in case mix
Patient characteristics at the index date are presented in Table 17. The mean age at operation increased
from 43.4 to 46.8 years during the study (p< 0.001), and the proportion of women declined from 86% to
75% (p< 0.001). The mean recorded BMI increased from 40.6 kg/m2 to 44.8 kg/m2 (p< 0.001). The
proportion of participants with diabetes increased from 19% to 33%, while the proportion of patients
prescribed antihypertensive drugs and statins also increased (all p< 0.001). More than half of all
participants had depression recorded at some time before the procedure. As a consequence of these
trends, there were important differences in case mix for patients undergoing LAGB as compared with GBP
and SG (Table 18). LAGB patients were generally operated on in an earlier period, were younger, more
often female, less obese and less likely to have diabetes, hypertension or hypercholesterolaemia.
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FIGURE 7 (a) Trends in the utilisation of different bariatric surgical procedures from 2002 to April 2014; and
(b) total number of procedures per year. Green line, LAGB; blue line, GBP; black line, SG.
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Secondary procedures
There were three deaths within 30 days of the date of the initial procedure. Rates of band removal and
reoperation following LAGB are presented in Table 19. The most common procedure was removal of a
gastric band, found in 82 (6.3%) cases. This was equivalent to a rate of 1.6 (95% CI 1.3 to 2.0) per 100
person-years and the median time between gastric band insertion and removal was 144 weeks (IQR)
69–203 weeks). There were 60 (4.6%) of LAGB patients who had a subsequent medical code recorded
indicating a GBP or SG procedure, with a rate of 1.2 (95% CI 0.9 to 1.5) per 100 patient-years. There
were 10 patients who received SG, who later had codes for GBP recorded; and six patients with GBP, who
later had codes for LAGB (n= 4) or SG recorded (n= 2). The validation study confirmed 86% and 33% of
these reoperations, respectively, with two procedures secondary to SG attributed to hiatal hernia repair.
Long-term follow-up
Recording of BMI values into primary care EHRs after bariatric surgical procedures was generally poor. From
3039 participants, 486 had BMI values recorded in the first year following the procedure and 332 and 241
in the second and third years, representing 18%, 15% and 13% of those remaining under observation,
respectively. Evaluation of body weight values indicated a mean reduction in BMI of 6.98 kg/m2 (95% CI 6.3 to
7.6 kg/m2) in the first postoperative year and 9.99 kg/m2 (95% CI 9.1 to 10.9 kg/m2) in the second
postoperative year.
TABLE 19 Reoperation using a second type of procedure and band removal following initial bariatric
surgical procedures
First procedure
Subsequent
procedure Frequency (%)
Median interval
(IQR, weeks)
Rate per 100
patient-years
(95% CI)
LAGB (1297) Band removed 82 (6.3) 144 (69–203) 1.6 (1.3 to 2.0)
Subsequent
bypass or sleeve
60 (4.6) 108 (58–200) 1.2 (0.9 to 1.5)
TABLE 18 Variables associated with use of GBP or SG rather than gastric banding
Variables LAGB (N= 1297)
GBP/SG
(N= 1742) OR (95% CI) p-value
Period of procedure, n (%)
2002–5 101 (8) 3 (0) 0.21 (0.06 to 0.68) 0.009
2006–8 518 (40) 89 (5) Reference
2009–11 497 (38) 909 (52) 11.7 (8.61 to 15.9) < 0.001
2012–14 181 (14) 741 (43) 26.0 (18.7 to 36.3) < 0.001
Age (years), mean (SD) 44.3 (10.0) 47.1 (10.2) 1.017 (1.007 to 1.027) 0.001
Female, n (%) 1103 (85) 1299 (75) 0.66 (0.53 to 0.82) < 0.001
BMI (kg/m2), mean (SD) 41.3 (7.3) 46.0 (8.4) 1.08 (1.07 to 1.09) < 0.001
Diabetes, n (%) 244 (19) 630 (36) 1.49 (1.18 to 1.89) 0.001
Depression, n (%) 715 (55) 968 (56) 1.03 (0.86 to 1.24) 0.754
Current smoking, n (%) 229 (18) 272 (16) 0.95 (0.75 to 1.21) 0.663
Antihypertensive, n (%) 572 (44) 985 (57) 1.00 (0.83 to 1.22) 0.960
Statins, n (%) 255 (20) 607 (35) 1.20 (0.91 to 1.59) 0.198
SD, standard deviation.
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Discussion
Summary of findings
This analysis provides a large-scale population-based evaluation of the utilisation of bariatric surgical
procedures in the UK. The study complements a recently published bariatric surgical registry report,133
which presents data reported by bariatric surgeons. The present results demonstrate that EHRs, including
those from primary care, represent a valuable resource for evaluating the utilisation and outcomes of
bariatric surgery. The reliability study demonstrated high levels of agreement between primary care EHRs
and questionnaire responses obtained directly from GPs. We caution that errors may be present in either
data source, and we do not have evidence to show which is the more likely to be correct, but high levels
of agreement between the two sources of information lend support to the validity of EHR data.
The rate of bariatric surgery recorded in primary care medical records increased rapidly between 2002 and
2014. Initially, LAGB accounted for most procedures, but the use of GBP and, to a lesser extent, SG has
increased since 2008. There have been changes in case mix, with procedures now being performed in
older patients, with greater BMI and a higher prevalence of diabetes.
Comparison with other results
The large increase in number of bariatric surgery procedures identified in CPRD over the last 10 years is
consistent with findings reported from analysis of hospital utilisation statistics.36 The gender disparity, age
profile of surgery patients and changing patterns of surgery were also comparable with the trends seen in
data for hospital utilisation and the bariatric surgical registry.36,133,134 Depression was recorded in > 50% of
participants at some time prior to surgery, a higher rate than reported elsewhere.135 This difference may
relate to using primary care rather than hospital setting as a data source, with a diagnosis of depression
more likely to be recorded in the former.
Following gastric banding, gastric band removal was observed in 1.6% of patients per year and 1.2% per
year were recorded as having a further additional procedure of GBP or SG, with a high level of validation
from GP responses. These findings confirm in population-based data that there is significant incidence of
band slippage or band intolerance requiring removal. The bariatric surgical registry recorded a much lower
proportion of patients undergoing revisional bariatric surgery (0.3%) after gastric banding.133 This
discrepency may reflect the short period (3 years) covered by registry data, problems with data linkage
occuring when reoperations are performed at different hospitals or under-reporting of reoperations
and revisions.
There were 10 patients who underwent SG who later had codes for GBP recorded, and six patients who
received GBP with subsequent codes for LAGB (n= 4) or SG recorded (n= 2). Validation confirmed
the majority of these secondary procedures, but coding errors may account for some of these, as
misclassification can arise through errors of recording in primary care records, especially when primary care
physicians may be unfamiliar with different bariatric surgical procedures. Nonetheless, it is clear that
surgical reintervention rate following either SG or GBP is lower than that following gastric banding.
Recording of weight data for bariatric surgery patients in primary care was poor. Clinical guidelines suggest
that all bariatric surgery patients are expected to undergo lifelong follow-up to monitor their weight, as
well as micronutrient monitoring in GBP patients.35 Recording of weight and BMI in primary care records is
known to be generally limited,44 but it is especially concerning that the majority of patients who have
undergone bariatric surgery are not being weighed regularly by their GP. The observed maximum weight
loss at 2 years is comparable with data from clinical trials,5,6,136 and gastric banding was associated with
lower weight loss that other surgery types in accordance with the literature.31,133 However, the high rate
of attrition in this study means that caution is required when interpreting these results. Additionally,
long-term follow-up in primary care may be biased by better attendance of patients whose surgery has
proved less successful or who have remained overweight.44
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Strengths and limitations
This study had the strengths of a large nationally representative data source with extended periods of
longitudinal follow-up. We acknowledge that clinical information has several limitations when used for
research purposes, including missing data values due to opportunistic data collection and recording, but a
reliability study suggested a high level of agreement between EHR records and GP reports for primary
surgeries. Recording of body weight in primary care was poor subsequent to bariatric surgery.
Conclusions
This is the first large-scale analysis to use EHRs for the evaluation of bariatric surgical utilisation for obesity;
and demonstrates rapid increases in the use of such procedures and a move away from gastric banding
towards GBP and SG, with a shift in case mix towards more severely affected patients.
DOI: 10.3310/hsdr04170 HEALTH SERVICES AND DELIVERY RESEARCH 2016 VOL. 4 NO. 17
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Gulliford et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
45

Chapter 7 Reduced incidence of clinical diabetes
mellitus after bariatric surgery
Introduction
This chapter uses primary care EHRs to analyse the incidence of new diabetes following bariatric surgery.
The possible impact of bariatric surgery on T2DM is of particular importance because some 3% of morbidly
obese individuals develop diabetes each year8 and we have demonstrated that comorbidity is a key driver of
health-care costs in obesity (see Chapter 5). In the SOS study,8 a total of 1658 non-diabetic patients were
followed over a 15-year period, showing a 76% reduction in the incidence of diabetes following bariatric
surgery. However, the majority of participants in the Swedish study underwent vertical band gastroplasty,
an operation which is no longer widely performed because of the high incidence of weight regain.
Participants in research studies may undergo intensive follow-up that may not be typical of care provided in
routine clinical practice. The aim of this study, therefore, was to employ a population-based cohort, with
matched controls, drawn from a database of primary care EHRs to provide a pragmatic evaluation of the
effect of bariatric surgery on the development of clinical diabetes in obese individuals. This analysis has
been published open access in The Lancet Diabetes and Endocrinology as ‘Incidence of type 2 diabetes after
bariatric surgery: population-based matched cohort study’7 under the terms of the Creative Commons
Licence CC BY 3.0.
Results
There were 4793 participants with bariatric surgery recorded; 1324 participants with bariatric surgery
first recorded < 1 year after the start of the patient record were excluded, as were 14 participants aged
< 20 years at the index date, and 401 participants with either no BMI record before surgery or BMI values
< 30 kg/m2 prior to surgery. There remained 3054 obese participants aged ≥ 20 years who received
bariatric surgery while their EHR was active in CPRD. There were 878 participants who were already
diagnosed with diabetes before the date of surgery, who were excluded. Nine participants with a record of
gastric band removal before the index date were also excluded. There were then 2167 obese, non-diabetic
participants who received first bariatric surgery procedures who were compared with 2167 matched
control participants. The median duration of follow-up was 2.8 years (IQR 1.3–4.5 years), with a maximum
of 7 years’ follow-up.
The type of bariatric surgery was classified according to the procedure recorded on the index date. There
were 1053 (49%) participants who received LAGB, 795 (37%) received GBP procedures and 317 (15%)
received SG as the index procedure. Two participants had codes for more than one type of procedure
recorded on the index date.
Baseline characteristics for the bariatric surgery participants and controls are presented in Table 20. Values
are those most recently recorded before the index date. The two groups were generally well matched for
age, gender and BMI. The mean [standard deviation (SD)] age of participants undergoing surgery was
44.4 years (SD 10.1 years), and 84% were women. The index BMI was > 40 kg/m2 in 60% of participants.
A diagnosis of depression was ever recorded before the index date for 55% of bariatric surgery participants
and 32% of controls. Bariatric surgery participants were more likely to have recorded elevated blood
pressure or raised total cholesterol values and to be treated with antihypertensive or lipid-lowering drugs.
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The onset of diabetes in bariatric surgery and control participants is presented in Table 21/Figure 8. In the
first 7 years, there were 38 new diagnoses of diabetes in bariatric surgery participants and 177 in control
participants. None of the diabetes participants was recorded as being type 1 diabetes. Three controls and
one bariatric surgery participant with diabetes were treated with insulin within 6 months of the diabetes
diagnosis date. There were 10 controls and three cases whose diabetes was associated with codes for
gestational diabetes, which were excluded as a sensitivity analysis. A Kaplan–Meier graph showing the
development of diabetes in bariatric surgery and control participants is presented in Figure 8. By the end of
the seventh year of follow-up, 4.3% (95% CI 2.9% to 6.5%) of bariatric surgery participants and 16.2%
(95% CI 13.3% to 19.6%) of non-surgery controls had developed diabetes. The incidence of diabetes was
28.2 (95% CI 24.4 to 32.7) per 1000 person-years in control participants and 5.7 (95% CI 4.2 to 7.8)
per 1000 in BS participants.
TABLE 20 Baseline characteristics of participants who underwent bariatric surgery and controls. Figures are
frequencies (column %) unless otherwise indicated
Characteristics BS cases Controls p-value
Number 2167 2167
Female 1812 (84) 1878 (87) Matched
Age (years), mean (SD) 44.4 (10.1) 44.6 (14.1) Matched
BMI (kg/m2), mean (SD) 43.0 (8.1) 43.2 (8.6) Matched
BMI category Matched
Obese (BMI 30–34.9 kg/m2) 339 (16) 332 (15)
Severe obesity (BMI 35–39.9 kg/m2) 535 (25) 551 (24)
Morbid obesity (BMI ≥ 40 kg/m2) 1293 (60) 1284 (59)
Index year
2002–5 84 (4) 113 (5) Matched
2006–8 483 (22) 442 (20)
2009–11 979 (45) 1014 (47)
2012–14 621 (29) 598 (28)
HbA1c category
42mmol/mol 208 (10) 195 (9)
42 to < 48mmol/mol 54 (2) 50 (2)
Not recorded 1905 (88) 1922 (89)
CHD 60 (3) 58 (3) 0.847
Stroke 20 (1) 26 (1) 0.381
Previous depression diagnosis 1198 (55) 701 (32) < 0.001
Current smoker 376 (17) 386 (18) 0.583
BP recorded > 140/90mmHg 581 (27) 464 (21) < 0.001
Total cholesterol recorded > 5mmol/l 845 (39) 387 (18) < 0.001
Treatment for hypertension 906 (42) 519 (24) < 0.001
Lipid-lowering treatment 270 (12) 183 (8) < 0.001
BP, blood pressure; BS, bariatric surgery.
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The unadjusted HR for diabetes in bariatric surgery participants compared with controls was 0.20 (95% CI
0.14 to 0.30; p< 0.001). Multivariable adjustment for baseline characteristics including matching variables,
comorbid cardiovascular disease and depression, smoking, hypertension and hypercholesterolemia and
associated treatment had negligible effect on the magnitude of the estimated HR. The fully adjusted HR
for bariatric surgery was 0.20 (95% CI 0.13 to 0.30; p< 0.001). After allowing for bariatric surgery,
baseline characteristics were generally not associated with the risk of developing diabetes except for an
increased hazard associated with elevated baseline HbA1c (Table 22).
TABLE 21 New diabetes diagnoses up to 7 years in BS and control participants
Year
BS cases Controls
At risk, N
Diabetes
diagnoses, n
Per cent with
diabetes (95% CI)a At risk, N
Diabetes
diagnoses, n
Per cent with
diabetes (95% CI)a
1 1759 14 0.7 (0.4 to 1.2) 1847 73 3.5 (2.8 to 4.4)
2 1369 4 1.0 (0.6 to 1.5) 1317 41 5.9 (5.0 to 7.1)
3 1017 5 1.4 (0.9 to 2.1) 857 23 7.9 (6.7 to 9.3)
4 692 6 2.1 (1.4 to 3.0) 558 20 10.4 (8.8 to 12.2)
5 440 4 2.7 (1.9 to 4.0) 358 10 12.4 (10.5 to 14.7)
6 264 3 3.6 (2.4 to 5.2) 238 5 13.8 (11.6 to 16.3)
7 154 2 4.3 (2.9 to 6.5) 132 5 16.2 (13.3 to 19.6)
BS, bariatric surgery.
a Per cent with diabetes is evaluated from time-to-event data and not from aggregate figures shown in columns at left.
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FIGURE 8 Incidence of T2DM in bariatric surgery participants and matched controls within 7 years after procedure.
Green line, bariatric surgery; black line, non-surgery controls.
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Table 23 shows HRs for diabetes divided by subgroups of age, gender and BMI category. The effect of
bariatric surgery was generally similar in men and women and across age groups. There was no interaction
of bariatric surgery and age. Estimates were also similar for time periods between 2002 and 2014 even
though gastric banding accounted for 96% of procedures in the earliest period and only 24% in the
latest. However, there was evidence of a trend towards greater effect of bariatric surgery with increasing
BMI category (interaction term, p= 0.0819). Table 3 presents the incidence of diabetes by type of
procedure. In the fully-adjusted model, which included adjustment for index year as well as other
covariates, HRs were slightly lower for both GBP and SG than for LAGB (p= 0.0714), although each type
of procedure was associated with lower incidence of diabetes than in the control group. There were small
numbers for some subgroups; LAGB, GBP and SG were associated with 30, six and two new diagnoses of
diabetes, respectively.
Sensitivity analyses
The association of bariatric surgery with lower incidence of diabetes was found to be robust in a number
of sensitivity analyses. When the entire comparison cohort of 103,502 obese non-diabetic individuals,
rather than selected matched controls, was used for reference, the adjusted HR associating bariatric
surgery with diabetes incidence was 0.16 (95% CI 0.11 to 0.22; p< 0·001). Diagnosis of diabetes might
be more likely soon after the index date because of increased medical surveillance. However, when cases
of diabetes diagnosed within the first year following the index date were excluded, the adjusted HR
was 0.20 (95% CI 0.12 to 0.32; p< 0.001). Exclusion of participants associated with gestational diabetes
diagnoses gave an adjusted HR of 0.19 (95% CI 0.13 to 0.30; p< 0.001). In a competing risks analysis,
allowing for the competing risk of death, the adjusted HR was 0.20 (95% CI 0.13 to 0.31; p< 0.001).
Analyses that used only clinical criteria, and not HbA1c, for diagnosis of diabetes gave similar results.
TABLE 22 Hazard ratios for diabetes incidence from fully adjusted model
Variable HRa (95% CI) p-value
Bariatric surgery 0.20 (0.13 to 0.30) < 0.001
Female 0.73 (0.50 to 1.07) Matched
Age (years) 1.02 (1.01 to 1.04) Matched
BMI (kg/m2) 1.03 (1.02 to 1.04) Matched
Prevalent CHD 1.25 (0.65 to 2.40) 0.513
Prevalent stroke 1.23 (0.46 to 3.30) 0.675
Previous depression diagnosis 1.26 (0.96 to 1.66) 0.092
Current smoker 1.17 (0.81 to 1.70) 0.399
BP recorded > 140/90mmHg before index date 1.27 (0.91 to 1.79) 0.163
Total cholesterol recorded > 5mmol/l before index date 0.92 (0.61 to 1.41) 0.716
HbA1c 42 to < 48mmol/mol 3.73 (1.69 to 8.25) Matched
Treatment for hypertension before index date 1.23 (0.86 to 1.76) 0.249
Lipid-lowering treatment before index date 1.15 (0.69 to 1.93) 0.595
BP, blood pressure; BS, bariatric surgery.
a Also adjusted for index year.
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Discussion
Summary of findings
This analysis demonstrates that in a large population-based cohort of obese participants undergoing
bariatric surgery using contemporary procedures, the risk of developing T2DM is substantially reduced over
a maximum of 7 years of follow-up. The risk of diabetes was reduced by 80%, compared with control
participants who did not undergo surgery. This is perhaps the first large-scale pragmatic study to evaluate
the impact of current bariatric surgical procedures on diabetes incidence in the context of usual care
settings. Even in patients observed in routine clinical practice, our results demonstrate that newer bariatric
surgical procedures have particular efficacy for diabetes prevention in obese individuals.
TABLE 23 Effect of bariatric surgery on risk of diabetes by age group, gender, BMI category and procedure type
Variable
Diabetes incidence rate per
1000 person-years (95% CI)
Adjusteda HR (95% CI) p-valueBS Controls
All participants 5.7 (4.2 to 7.8) 28.2 (24.4 to 32.7) 0.20 (0.13 to 0.30) < 0.001
Sex
Men 6.8 (3.2 to 14.3) 38.5 (26.7 to 55.4) 0.17 (0.06 to 0.46) < 0.001
Women 5.5 (3.9 to 7.8) 26.8 (22.8 to 31.5) 0.21 (0.13 to 0.33) < 0.001
Baseline BMI category (kg/m2)
30–34.9 6.1 (2.9 to 12.9) 15.7 (9.7 to 25.2) 0.39 (0.11 to 1.42) 0.153
35–39.9 5.9 (3.2 to 10.9) 22.1 (16.0 to 30.5) 0.24 (0.12 to 0.49) < 0.001
≥ 40 5.5 (3.6 to 8.4) 35.0 (29.3 to 41.7) 0.15 (0.09 to 0.25) < 0.001
Age group (years)
20 to 34 1.7 (0.4 to 7.0) 17.3 (11.8 to 25.2) 0.14 (0.03 to 0.63) 0.010
35 to 54 6.3 (4.4 to 9.3) 26.3 (21.1 to 32.7) 0.21 (0.13 to 0.34) < 0.001
≥ 55 7.0 (3.5 to 14.1) 42.1 (33.3 to 53.2) 0.18 (0.08 to 0.38) < 0.001
Type of procedureb
Laparoscopic gastric banding 7.3 (5.1 to 10.5) 24.9 (20.2 to 30.6) 0.29 (0.18 to 0.48) < 0.001
GBP 3.2 (1.4 to 7.1) 33.3 (26.0 to 42.7) 0.10 (0.04 to 0.25) < 0.001
SG 2.9 (0.7 to 11.7) 31.7 (21.4 to 47.0) 0.07 (0.01 to 0.30) < 0.001
Index period
2002–5 3.8 (1.0 to 15.3) 29.7 (18.9 to 46.5) 0.12 (0.03 to 0.52) 0.004
2006–8 8.3 (5.4 to 12.9) 25.8 (19.7 to 33.9) 0.32 (0.18 to 0.57) 0.002
2009–11 4.2 (2.5 to 7.3) 28.2 (22.6 to 35.4) 0.14 (0.06 to 0.31) < 0.001
2012–14 4.4 (1.4 to 13.7) 32.4 (22.5 to 46.6) 0.10 (0.03 to 0.36) < 0.001
BP, blood pressure; BS, bariatric surgery.
a Adjusted for age, gender, BMI, CHD, stroke, depression, smoking status, elevated total cholesterol, high blood pressure,
HbA1c category, use of antihypertensive drugs and statins, and year of procedure.
b Three cases with more than one procedure coded on index date were excluded.
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An effect of bariatric surgery on diabetes incidence was observed in both men and women and across all
ages. GBP and SG procedures were associated with slightly lower relative hazards for diabetes than LAGB
but we caution against drawing firm conclusions concerning the comparative effectiveness of different
procedures from a non-randomised study because selection for different procedures may be associated
with the underlying risk of developing diabetes and some of these subgroup analyses were based on small
numbers of outcome events.
Comparison with other results
Previous studies of bariatric surgery and the prevention of T2DM include the SOS study8 as well as several
case series.137–139 In the SOS study,8 69% of patients underwent vertical banded gastroplasty, 19%
underwent banding and 12% received GBP surgery. Both the incidence of diabetes in bariatric surgical
patients and controls, and the relative risk reduction associated with bariatric surgery, are very similar to
those observed in the present study. The present results, therefore, provide important confirmation from a
population-based sample, with intervention using current surgical procedures.
Strengths and limitations
Our analysis had the strengths of a large population-based sample with prolonged follow-up and
prospective documentation of clinical diabetes in primary care. However, we acknowledge several
limitations. We identified the three major procedures used in bariatric surgical practice in the UK. However,
there may be less frequently performed procedures, such as the duodenal switch, which were not
included. The control group did not receive standardised non-surgical intervention for obesity, and during
the study period intensive multimodal weight-loss programmes in primary care were rare. Ascertainment
of diabetes outcomes was comprehensive; diagnoses recorded into CPRD records are generally valid.42
However, we were not able to document subclinical diabetes that might have been confirmed through
testing all participants for evidence of hyperglycaemia. We excluded cases in which antidiabetes drugs
were prescribed for polycystic ovary syndrome but it is possible that some prescriptions might be for
diabetes prevention rather than treatment. Body weight, and other relevant measures, during the period
of study were not recorded consistently. Preoperative BMI category might have been misclassified and it
was not possible to relate differences in diabetes incidence to changes in body weight, though it should
be noted that the effects of bariatric surgery are not entirely mediated by changes in body weight.136
Observed weight reductions following surgery were consistent with those of previous reports.
Access to bariatric surgery is presently very limited in the UK and, consequently, those receiving surgery
represent a highly selected group. The higher prevalence of previous depression diagnoses in the surgical
group suggests that patients with depression were more likely to be referred with the belief that weight
loss may improve their depressive symptoms. This belief is likely to be misplaced in the long term.90
Patients who received surgery might have been more adherent than controls to other diabetes prevention
advice including diet or exercise. However, we observed that participants who received surgery were more
likely to be prescribed antihypertensive drugs or statins, which may sometimes be associated with diabetes.
Control participants more often had missing values for blood pressure and plasma cholesterol, suggesting
that medical surveillance was lower in this group. Differential medical surveillance might have made
detection of diabetes or pre-diabetes more likely in patients considered for surgery. However, the higher
proportion of surgical cases on antihypertensive or lipid-lowering therapy might suggest a selection bias in
the opposite direction. We included relevant confounders in the analysis but misclassification and missing
values might lead to residual bias. In a non-randomised study, residual confounding from unmeasured
genetic, social or environmental variables is a concern. However, we fitted several different models and
performed sensitivity analyses that provided evidence that the main findings of the study were robust.
Nearest neighbour matching gave a comparison group that was not exactly matched for key variables.
However, covariate adjustment had minimal effect and very similar results were obtained when the entire
source cohort was used for reference. A method of analysis that did not allow for matching might give
slightly wider CIs and larger p-values than a matched analysis,24 but the present results did not raise
concerns of statistical error.
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Conclusions
The present results, together with those of previous studies,60 suggest that bariatric surgery may be a
highly effective method for preventing diabetes in patients with severe and morbid obesity. This raises
questions concerning how surgery for obesity should be integrated into strategies for the control of obesity
and prevention of diabetes in the population at risk. Further research is needed to understand the
outcomes of different levels of uptake of obesity surgery, as well as the long-term outcomes for patients
who receive current surgical procedures for obesity.
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Chapter 8 Bariatric surgery in people with
diabetes: diabetes control and utilisation of
antidiabetes drugs
Introduction
This chapter presents a pragmatic analysis of changes in diabetes control and antidiabetic drug utilisation
following bariatric surgery. Remission of diabetes will be included as an input to the model as comorbidity
is the greatest contributor to health-care costs in obesity. The potential role of bariatric surgery in the
treatment of diabetes in individuals with severe obesity is increasingly recognised.35,74,140 A systematic
review found that use of bariatric surgery in obese patients with T2DM was associated with remission of
diabetes in approximately 70% of patients over the first 2 years following surgery.74 However, most
randomised trials have evaluated outcomes for small samples of patients, with outcomes reported more
than 2 years following surgery only for a few patients.6 There are similarly few non-randomised studies
that have reported on outcomes of diabetic patients more than 2 years after bariatric surgery.140 The
largest and longest-running study, the SOS study, reported rates of remission of 38% at 10 years’ and
30% at 15 years’ follow-up, with fewer microvascular and macrovascular complications of diabetes in
patients receiving surgery.141 The majority of participants in the SOS cohort received the vertical band
gastroplasty procedure, which is no longer widely utilised. More recently, Brethauer et al.142 reported a
long-term complete remission rate of 24% in 217 patients undergoing bariatric surgery; Adams et al.14
reported remission rates of 62% in 418 participants following GBP, while Sultan et al.15 reported remission
in 40% of 102 participants up to 5 years following gastric banding. Data remain especially limited for SG,
the most recently introduced procedure. Few studies have provided direct comparisons of the outcomes of
different bariatric surgical procedures.140 Most reported studies have been carried out in selected patients
at specialist centres and there are few pragmatic studies of the outcomes of patients treated in usual
clinical practice.
The present analysis utilised primary care EHRs from a large database of UK family practices. This data
resource enabled us to conduct a population-based study of adult patients receiving currently used
bariatric surgical procedures, including adjustable gastric banding, GBP and SG, with comparison with
matched obese subjects who did not undergo surgery. In a previous report,7 we evaluated the effect of
bariatric surgery in non-diabetic subjects. In this study, we aimed to compare the effect of the three
different bariatric surgical procedures, gastric banding, GBP and SG, on diabetes remission and utilisation
of antidiabetes medications over a maximum of 6 years of follow-up.
Results
There were 4793 obese participants with bariatric surgery recorded; 1324 were excluded as prevalent
cases because the index code was within 12 months of the start of the record, 14 were excluded with age
< 20 years, 401 were excluded because their BMI was < 30 kg/m2 or no values were recorded before
surgery, and 2176 were excluded as non-diabetic, leaving 878 obese participants with T2DM of whom
52 were excluded with gestational diabetes ever recorded. There were then 826 obese participants with
T2DM diagnosed before surgery who were matched with 826 obese diabetic controls who did not
receive surgery.
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Bariatric surgery participants had procedures performed between 2002 and 2014. In the years up to and
including 2007, procedures numbered 77. Procedures increased over time reaching a maximum of 160 in
2012. The mean duration of follow-up was more than 6 years for participants receiving procedures in
2007 or before. Participants were registered at 360 general practices, of which 92% continued their
participation in CPRD until 2013 or later; there were 69 participants that ended their registration with a
CPRD practice before 2013. There were 20 bariatric surgery participants and 33 controls who died during
the period of follow-up, including nine bariatric surgery participants and six controls who died within
12 months of the index date. Registered causes of death were not available for analysis.
Baseline characteristics of the bariatric surgery participants and controls are shown in Table 24. Bariatric
surgery participants and controls were generally similar with respect to age, gender and index year but
baseline BMI was higher in the bariatric surgery participants. Bariatric surgery participants also had longer
TABLE 24 Baseline characteristics of bariatric surgery participants and controls. Figures are frequencies (column %)
unless otherwise indicated
Characteristics
Control
participants
BS
participants p-valuea LAGB GBP SG p-valueb
Number 826 826 220 449 153
Female 524 (63) 542 (66) 0.390 165 (75) 288 (64) 87 (57) 0.001
Age (years),
mean (SD)
49.1 (13.8) 50.0 (9.6) 0.118 49.0 (9.8) 50.1 (9.4) 51.3 (10.1) 0137
BMI (kg/m2) 44.2 (6.5) 46.7 (8.3) < 0.001 44.8 (8.0) 46.8 (7.8) 49.3 (9.7) < 0.001
Index year,
median (IQR)
2011
(2010 to 2012)
2011
(2009 to 2012)
0.495 2009
(2007 to 2010)
2011
(2010 to 2012)
2011
(2010 to 2012)
< 0.001
Diabetes duration
(years), median
(IQR)
3.1 (0.3–7.1) 5.5 (2.4–9.3) < 0.001 5.2 (2.6–8.4) 6.4 (2.5–10.2) 4.0 (2.1–7.6) 0.003
Mean HbA1c
(mmol/mol)
8.3 (2.1) 8.0 (2.0) 8.1 (1.9) 8.1 (2.0) 7.7 (2.2) 0.204
Antidiabetes treatment
Insulin 147 (18) 201 (24) 0.074 48 (22) 127 (28) 26 (17) 0.012
Sulphonylureas 164 (20) 182 (22) 0.634 49 (22) 101 (22) 32 (21) 0.126
Metformin 476 (58) 588 (71) 0.008 145 (66) 332 (74) 110 (72) 0.038
Other
antidiabetes
drug
157 (19) 250 (30) < 0.001 41 (19) 156 (35) 52 (34) < 0.001
None 261 (32) 161 (19) < 0.001 53 (24) 70 (15) 35 (23) 0.014
Antihypertensive
therapy
517 (63) 632 (77) < 0.001 169 (77) 347 (77) 114 (75) 0.781
Blood pressure
> 140/90mmHg
287 (35) 247 (30) 0.027 72 (33) 127 (28) 48 (31) 0.445
Statin therapy 451 (55) 579 (70) < 0.001 136 (62) 336 (75) 105 (69) 0.002
Total cholesterol
> 5mmol/l
257 (31) 217 (26) < 0.001 69 (31) 107 (24) 39 (25) 0.031
Current smoking 189 (23) 117 (14) < 0.001 30 (14) 69 (15) 17 (11) 0.487
BS, bariatric surgery.
a Test for difference between BS participants and controls.
b Test for difference among three surgical groups (four participants with undefined procedure omitted).
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duration of diabetes, with a median duration of 5.5 years since diagnosis, compared with 3.1 years for
controls. Bariatric surgery participants were more likely to be treated with statins and antihypertensive
drugs, with lower blood pressure and cholesterol values, and were less likely to be current smokers.
There were 672 (81%) bariatric surgery participants, and 240 (29%) controls, who received antiobesity
drugs, including sibutramine or orlistat, before the index date and 154 (19%) BS participants and 76 (9%)
controls who received antiobesity drugs after the index date, indicating that not all antiobesity drugs were
stopped immediately after surgery.
There were 220 (27%) bariatric surgery patients who received LAGB, 449 (54%) who received GBP
procedures and 153 (19%) who received SG. Type of procedure was undefined for four participants
with more than one operation type coded on the index date. LAGB procedures were used in clinical
practice at an earlier time having a median index year of 2009, compared with 2011 for GBP or SG.
Table 25 shows data for the number of participants contributing person time to the analysis, from
3 years before to 6 years after the bariatric surgery procedure. The proportion of participants contributing
person-time in each postoperative year declined rapidly because > 50% of procedures were within the last
4 years and only 13% of participants contributed person-time in the sixth year of follow-up. Participants
receiving LAGB contributed a higher proportion of person-time at long-term follow-up. The proportion of
participants with HbA1c values recorded generally ranged between 60% and 80% (see Table 25). At the
time of surgery, slightly more bariatric surgery patients had HbA1c values recorded, but at longer durations
of follow-up HbA1c recording was more complete in controls than in bariatric surgery patients.
Trends in mean HbA1c and proportion with HbA1c < 48mmol/mol (< 6.5%) are shown by year following
surgery in Figure 9. The mean HbA1c value in the year before the index date was 64mmol/mol (8.0%) in
bariatric surgery cases and 67mmol/mol (8.3%) in controls. The mean HbA1c value in bariatric surgery cases
declined to 51mmol/mol (6.8%), 48mmol/mol (6.5%) and 51mmol/mol (6.8%) in the first 3 years
following surgery, but remained unchanged at 65mmol/mol (8.1%), 66mmol/mol (8.2%) and 66mmol/mol
(8.2%), respectively, in controls. The proportion of bariatric surgery cases with HbA1c values < 48mmol/mol
(< 6.5%) was 17% before operation, increasing to 44%, 47% and 39% in the first 3 postoperative years.
No consistent trend in the proportion of controls with HbA1c < 48mmol/mol (< 6.5%) was observed. Trends
in the proportion of participants without antidiabetes drug prescriptions and the mean number of drug
prescriptions per participant year are also shown in Figure 9. The proportion of bariatric surgery cases
without antidiabetic drugs or insulin prescriptions increased from 15% before operation to 41%, 53% and
55% in the first 3 years after surgery, while the opposite trend was observed in controls.
The proportion of bariatric surgery cases in remission was 5% before operation, increasing to 21%, 30%
and 25% in the first 3 years after surgery (see Table 25), while the proportion of controls in remission
tended to remain constant over time. In the first year after surgery, the proportion of participants in
remission was lower for LAGB patients (7%, 95% CI 4% to 11%) than for patients receiving either GBP
(25%, 95% CI 21% to 29%) or SG (31%, 95% CI 24% to 39%). HbA1c values were not recorded for
every participant in every year. When remission was evaluated only including participants with HbA1c values
recorded in a given year, then the proportion of participants in remission for the first and subsequent years
following the procedure was 27%, 41%, 39%, 33%, 35% and 26%; the equivalent figures for controls
were 6%, 5%, 7%, 5%, 7% and 7%. The proportion of participants either with HbA1c < 6.5% or not
taking medications was higher than the proportion of participants in remission, which required both
criteria to be met. Of the 744 person-years in remission among bariatric surgery cases, 175 (24%) were
not in complete remission (HbA1c < 6.0%). The proportion of bariatric surgery participants in complete
remission in the second year after the procedure was 26%.
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TABLE 25 Diabetes remission before and after surgery for BS participants and controls and by procedure type.
Remission was defined, as HbA1c < 48mmol/mol (< 6.5%) and no diabetes prescriptions in year. Figures are
frequencies (column %) unless otherwise indicated
Measure
Years from procedure
–3 to –2 –2 to –1 –1 to 0 0 to 1 1 to 2 2 to 3 3 to 4 4 to 5 5 to 6
Controls
Participants
contributing PT
399 567 826 826 733 464 272 161 101
HbA1c recorded 278 (70) 388 (68) 626 (76) 612 (74) 536 (73) 309 (67) 185 (68) 113 (70) 81 (80)
In diabetes
remission
20 (5) 29 (5) 32 (4) 34 (4) 27 (4) 27 (4) 9 (3) 8 (5) 6 (6)
All BS cases
Participants
contributing
692 752 826 826 674 499 336 212 109
HbA1c recorded 506 (80) 607 (81) 698 (85) 663 (80) 499 (74) 321 (64) 321 (64) 125 (59) 69 (63)
In diabetes
remission
26 (4) 32 (4) 39 (5) 177 (21) 204 (30) 124 (25) 71 (21) 44 (21) 18 (17)
RR (95% CI)a Reference Reference Reference 4.66
(3.80 to
5.73)
7.16
(5.79 to
8.86)
6.68
(5.21 to
8.56)
6.17
(4.60 to
8.28)
7.05
(5.03 to
9.88)
5.90
(3.72 to
9.34)
LAGB
Participants
contributing PT
175 197 220 220 201 177 143 115 81
In diabetes
remission
7 (4) 9 (5) 7 (3) 15 (7) 40 (20) 32 (18) 28 (20) 21 (18) 11 (14)
RR (95% CI)a Reference Reference Reference 1.40
(0.80 to
2.44)
4.16
(2.84 to
6.11)
4.01
(2.56 to
6.29)
4.34
(2.73 to
6.89)
4.06
(2.44 to
6.75)
3.19
(1.70 to
5.97)
GBP
Participants
contributing
344 413 449 449 361 249 155 81 17
In diabetes
remission
13 (4) 14 (3) 19 (4) 112 (25) 122 (34) 70 (28) 33 (21) 18 (22) 3 (18)
RR (95% CI)a Reference Reference Reference 5.83
(4.55 to
7.48)
8.55
(6.67 to
11.0)
7.77
(5.82 to
10.4)
6.27
(4.36 to
9.02)
8.78
(5.68 to
13.6)
11.7
(5.15 to
26.6)
SG
Participants
contributing
107 138 153 153 109 70 36 14 10
In diabetes
remission
6 (6) 8 (6) 13 (9) 48 (31) 41 (38) 22 (31) 9 (25) 5 (36) 4 (40)
RR (95% CI)a Reference Reference Reference 6.21
(4.59 to
8.41)
6.21
(4.59 to
8.41)
6.96
(4.65 to
10.4)
6.15
(3.27 to
11.6)
8.63
(4.07 to
18.3)
8.63
(4.07 to
18.3)
BS, bariatric surgery; PT, person-time; RR, relative rate.
a Adjusted for age, gender, BMI, diabetes duration quartile, prevalent CHD, stroke, depression, smoking status, elevated
total cholesterol, high blood pressure, use of antihypertensive drugs and statins, and year of procedure.
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FIGURE 9 Changes by year before and after bariatric surgery. (a) Mean (standard error) HbA1c ; (b) mean (standard
error) diabetes prescriptions per year; (c) per cent with HbA1c < 6.5%; and (d) percentage not prescribed insulin
or oral hypoglycaemic drugs. BS, bariatric surgery. Green symbols, bariatric surgery participants; black symbols,
control participants. (continued )
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Multivariable adjusted analyses were conducted using participant years as observations (see Table 25).
The adjusted relative rate of diabetes remission across all types of bariatric surgery, relative to person time
without surgery, was 4.66 (95% CI 3.80 to 5.73) in the first year after surgery increasing to 7.16 (95% CI
5.79 to 8.86) in the second year. By the sixth year of follow-up, the adjusted relative rate was 5.90
(95% CI 3.72 to 9.34). In participants receiving LAGB, compared with all controls, the adjusted relative
rate of diabetes remission was not elevated in the first postoperative year but increased to 4.16 (95% CI
2.84 to 6.11) in the second postoperative year. The rate of remission remained elevated for the sixth year
of follow-up (3.19, 95% CI 1.70 to 5.97). For either GBP or SG, the rate of diabetes remission was
increased in the first year following the procedure (GBP 5.83, 95% CI 4.55 to 7.48; SG 6.21, 95% CI
4.59 to 8.41) and remained elevated until the end of the sixth year of follow-up (GBP 11.7, 95% CI 5.15
to 26.6; SG 8.53, 95% CI 3.75 to 19.4). For these procedures, adjusted rate ratios were higher than for
LAGB, though CIs overlapped. There were small numbers of observations for the later years of follow-up
for GBP and SG. Associations of confounders with remission were generally of small magnitude except for
a graded association of duration of diabetes, with the highest quartile of diabetes duration (diabetes
diagnosed more than 8.6 years before surgery) being associated with reduced relative risk of remission of
0.23 (95% CI 0.16 to 0.33; p< 0.001).
Table 26 presents adjusted rate ratios for diabetes remission for combining the 6 years of follow-up.
The adjusted relative rate of diabetes remission after bariatric surgery compared with controls was 5.97
(95% CI 4.86 to 7.33; p< 0.001). The three types of bariatric surgery each resulted in a significantly higher
rates of diabetes remission compared with controls (all p< 0.001). However, the rate of remission was lower
after LAGB 3.32 (95% CI 2.27 to 4.86) than after GBP (7.16, 95% CI 5.64 to 9.08) or SG (6.82, 95% CI
5.05 to 9.19). Among participants who received bariatric surgical procedures, compared with LAGB as
reference, either GBP (1.94, 95% CI 1.42 to 2.65; p< 0.001) or SG (2.00, 95% CI 1.40 to 2.86; p< 0.001)
was associated with higher rates of remission than LAGB. SG was associated with similar rates of remission
as GBP as reference (1.03, 95% CI 0.82 to 1.30; p= 0.781). The relative rate of diabetes remission was
slightly higher in men than in women. The relative rate of diabetes remission increased with increasing
BMI category, being 6.74 (95% CI 5.29 to 8.58) at BMI ≥ 40 kg/m2 but 4.23 (95% CI 1.98 to 9.03) at BMI
≥ 30 kg/m2. The relative rate of diabetes remission was highest in participants aged 35–54 years.
There were 204 bariatric surgery participants in remission in the second postoperative year. Of those
remaining under follow-up, 41%, 48%, 46% and 52% had a HbA1c value ≥ 48mmol/mol (≥ 6.5%)
recorded in the third to sixth postoperative years, respectively. However, additional patients were recorded
in remission in these later years.
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FIGURE 9 Changes by year before and after bariatric surgery. (a) Mean (standard error) HbA1c ; (b) mean (standard
error) diabetes prescriptions per year; (c) per cent with HbA1c < 6.5%; and (d) percentage not prescribed insulin
or oral hypoglycaemic drugs. BS, bariatric surgery. Green symbols, bariatric surgery participants; black symbols,
control participants.
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Discussion
Summary of findings
In a population of obese patients with T2DM undergoing bariatric surgery there is evidence of improved
blood glucose control, reduced requirement for antidiabetic medicines and an increased proportion of
participants in diabetes remission for up to 6 years following the procedure. These benefits appear to be
greatest among those with class III (morbid) obesity but procedure type was associated with BMI and this
might have introduced confounding by indication. Participants receiving either GBP or SG procedures,
rather than gastric banding, showed earlier onset and higher rates of diabetes remission. The SG and GBP
groups differed at baseline, with low numbers beyond 3 years for SG, making it difficult to draw
conclusions with respect to the comparative effectiveness of these procedures.
Bariatric surgery was associated with a fourfold increase in diabetes remission compared with no bariatric
surgery. The proportion of patients in remission declined over time following surgery and there was
biochemical evidence that individual patients showed relapse of diabetes after a period of remission. About
one-third of all participants who received bariatric surgery were diabetic, indicating positive selection of
diabetes patients for this intervention, consistent with current policy recommendations that bariatric
surgery should be utilised in the management of obesity-associated comorbidity.
TABLE 26 Association of bariatric surgery with diabetes remission by age group, gender, BMI category and
procedure type
Variable Adjusteda rate ratio (95% CI) p-value
All BS procedures 5.97 (4.86 to 7.33) < 0.001
Type of procedureb
Laparoscopic gastric banding 3.32 (2.27 to 4.86) < 0.001
GBP 7.16 (5.64 to 9.08) < 0.001
SG 6.82 (5.05 to 9.19) < 0.001
Sex
Men 7.70 (5.26 to 11.3) < 0.001
Women 5.32 (4.16 to 6.81) < 0.001
Baseline BMI category (kg/m2)
30–34.9 4.23 (1.98 to 9.03) < 0.001
35–39.9 3.59 (2.16 to 5.97) < 0.001
≥ 40 6.74 (5.29 to 8.58) < 0.001
Age group (years)
20–34 5.38 (2.81 to 10.3) < 0.001
35–54 6.69 (5.05 to 8.86) < 0.001
≥ 55 5.52 (3.91 to 7.80) < 0.001
BS, bariatric surgery.
a Adjusted for age, gender, BMI, diabetes duration quartile, prevalent CHD, stroke, depression, smoking status, elevated
total cholesterol, high blood pressure, use of antihypertensive drugs and statins, and year of procedure.
b Three cases with more than one procedure coded on index date were excluded.
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Comparison with other results
Changes in mean HbA1c in our study were similar to those reported in previous studies,72 but rates of
diabetes remission after surgery reported in the present study were generally lower than those noted
in published reviews, which ranged from 59% to 92%.6,32,70 However, case definitions have varied.
We used a stringent definition of remission that required a normal HbA1c value to be recorded in each
year. Patient-years with missing values for HbA1c in the present sample could have led to underestimation
of remission rates. When remission rates were re-estimated, including only participants with HbA1c values
recorded in year, the proportion of participants in remission was higher. However, the pattern of missing
HbA1c values may be related to diabetes control, possibly with less frequent recording in participants
who are either in remission or in good control. In clinical practice, some patients may be continued on
metformin therapy even in the setting of apparent biochemical remission but such participants were not
classified as being in remission for this study. Underestimation of remission may also occur if patients
receive repeat prescriptions for medicines they no longer require. Conversely, relapse after previous
remission may not be detected if blood glucose control is not evaluated. Even allowing for these
limitations, this pragmatic study raises questions concerning whether or not the results achieved in routine
practice may be as favourable as those reported from research studies. Control participants generally
had poorly controlled diabetes, as did bariatric surgery patients before the procedure, raising questions
concerning the quality of diabetes care received. We do not have information on whether the primary
purpose of surgery was weight reduction or improved diabetic control. We caution against concluding that
bariatric surgery is the only method for improving blood glucose control in obese patients.
Previous studies suggest that GBP is more effective for the treatment of diabetes than LAGB.42,74,142
Fewer data have been reported for SG and data with long follow-up are not available. A randomised trial
of 60 participants suggested that GBP might be more effective than SG.143 A recent randomised trial found
biliopancreatic diversion may have greater success than GBP, but was also associated with more nutritional
side effects and lower quality of life.144 Our results suggest that both SG and GBP may be more effective
than LAGB and do not support the hypothesis that duodenal exclusion is important. We caution that in a
non-randomised study procedures may be used selectively for patients with different baseline risks, and are
more susceptible to bias than results from randomised trials. Higher remission rates with greater weight
loss have also been reported.74 Although we did not investigate weight loss as a predictor of diabetes
remission due to limited follow-up, a higher baseline BMI category was positively associated with remission
and greater baseline BMI is known to be associated with greater weight loss.6 Our results offer some
suggestion that the effect of bariatric surgery may decline over time. However, LAGB comprised a higher
proportion of procedures at long follow-up. There is a clear need for longer-term follow-up studies to
evaluate the long-term diabetes outcomes of bariatric surgery.
The safety of bariatric surgery also requires careful consideration. The report of the UK National Bariatric
Surgery Register11 estimated that postoperative mortality in hospital following bariatric surgery was
approximately 0.07%, with rates of complications, including anastomotic leakages, of approximately
2.9% following first procedures. In the longer term, band removal may be required following adjustable
gastric banding, and there are risks of intestinal herniation and strangulation, which may have serious
consequences. These risks require better quantification.
Strengths and limitations
This analysis was based on primary care EHRs of a large population-based sample of patients, enabling
comparison of the benefits of bariatric surgery over standard medical care for the treatment of diabetes.
However, we acknowledge several limitations. As the analysis was based on primary care data, there was
limited information concerning surgical details including whether operations were open or laparoscopic or
whether or not there were surgical complications, and assessment of the safety of bariatric surgery was
beyond the scope of this research. The problem of missing and inconsistently recorded data has been
referred to above. Weight records in primary care were insufficiently recorded to relate study outcomes to
weight loss. Preoperative BMI might have been misclassified through infrequent recording.
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Control participants were matched with bariatric surgery patients on BMI, age, sex and index year, but
there remained differences between groups with respect to important confounders including length of
diagnosis of diabetes, smoking history and hypertension. Analyses were adjusted for these confounders in
a multiple regression model. An alternative approach might have employed propensity score matching,
but results obtained using this technique are generally similar to those obtained with the regression
adjustment approach adopted here.145 Multiple controls per case could have been sampled but there was
no evidence of lack of statistical power. We acknowledge that diabetes care was not standardised and
quality of diabetes care might have differed between bariatric surgery patients and controls. The
control patients may have had a different length of diagnosis or may have suffered different levels of
complications from the surgery group. Given the highly selective access to bariatric surgery in the UK we
would anticipate that surgery patients would have diabetes for longer and possibly experience more
complications than controls. It is possible that surgery patients had better access to specialist diabetes care
in the run-up to their surgery. In this pragmatic study, we used HbA1c values to evaluate diabetes
remission, but we acknowledge that greater sensitivity for diabetes might have been achieved through
systematic use of glucose tolerance tests.146
Cases and controls were matched but there were residual differences for some variables, including BMI.
This may be expected as patients who receive surgery differ from those who do not receive surgery in
many ways. Analyses were additionally adjusted for BMI, as well as other confounders. Nevertheless,
residual confounding might bias the results. The median year of procedure was 2011 and only a minority
of participants had operations more than 5 years before the study close in April 2014. We also
acknowledge that the available duration of follow-up was generally shorter for more recently adopted
procedures, including GBP and SG, than for LAGB. The analysis was on an ‘intention-to-treat’ basis and
although small numbers of participants might have had conversion, revisional or reversal procedures, these
were not excluded. A randomised trial remains the preferred design for evaluating the outcome of these
procedures and results from a non-randomised comparison must be treated with caution, as noted above.
Conclusions
The findings of this analysis suggest that bariatric surgery may facilitate diabetes control in obese patients
treated in routine primary care settings. The three most commonly used surgical techniques were associated
with increased rates of remission, improved blood glucose control and reduced use of antidiabetes
medications for T2DM over a maximum of 6 years’ follow-up period. SG and GBP were generally associated
with more favourable diabetes outcomes than LAGB. Rates of remission tended to decline over time
and there was biochemical evidence of relapse in some participants. These results, from a pragmatic
non-randomised evaluation, add to current evidence, which is composed largely of data from specialist
centres. Further investigation is required to evaluate the effect of bariatric surgery on longer-term clinical
and patient outcomes, including the incidence of complications and mortality.
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Chapter 9 Impact of bariatric surgery on
clinical depression
Introduction
In Chapter 5, we identified depression as a major driver of health-care costs in obese patients. This analysis
uses EHRs to investigate the possible impact of bariatric surgery on clinical depression. Obese people are at
higher risk of depression but depression is also a predictor of weight gain and future obesity.147 People
who are obese experience the onset of morbidity at younger ages than those with lower body weight3 and
the multiple morbidities associated with obesity may contribute to a higher prevalence of depression.51
Patients selected for bariatric surgery often have a high prevalence of clinical depression.18,148 However,
evidence for an effect of bariatric surgery on depression is limited. Several longitudinal studies have
explored the relationship between bariatric surgery and depression, identifying significant reductions in
depression149 and depressive symptoms150,151 following surgery. One study found a decrease in depression
from 32.7% at baseline, to 16.5% at 6–12 months, and 14.3% at 2–3 years following surgery.152
However, other studies suggest that improvements following surgery may not be maintained after the first
postoperative year151 and depressive symptoms may deteriorate in some patients.153 Previous reports have
often drawn on data from hospital-based series that did not include control groups, often with short
durations of follow-up.
This analysis aimed to evaluate whether or not bariatric surgery is associated with a reduction in clinical
depression up to a maximum of 7 years following the procedure. A population-based cohort provided the
data source for an interrupted time-series design with matched controls, facilitating a pragmatic evaluation
of the impact of bariatric surgery on clinical depression recorded in primary care EHRs. The results in this
chapter were published open access in the Journal of Affective Disorders in 201590 under the terms of the
Creative Commons Licence CC BY-NC-ND 4.0.
Results
There were 4793 participants with bariatric surgery recorded; 1324 participants with bariatric surgery first
recorded < 1 year after the start of the patient record were excluded, as were 14 participants aged
< 20 years at the index date, and 401 participants with either no BMI record before surgery or BMI values
< 30 kg/m2 prior to surgery. Nine participants with a record of gastric band removal before the index date
were also excluded. There were then 3045 participants identified as having bariatric surgery for obesity and
3045 matched controls. Bariatric surgery procedures included LAGB in 1297 (43%), GBP in 1265 (42%), SG
in 477 (16%) and six of undefined type. Utilisation of bariatric surgery increased over the period and LAGB
accounted for 97% of 104 procedures before 2006, but only 20% of 924 procedures from 2012 onwards,
with increasing use of GBP and SG. The median year of procedure was 2010 and, consequently, only a
minority of participants contributed more than 3 years of follow-up data.
Characteristics of the surgery and control participants at the index date are presented in Table 27. The
majority of surgical procedures were conducted in women (79%) and in participants with morbid obesity
(65%). The mean age at surgery was 45.9 years. Participants undergoing bariatric surgery more frequently
had T2DM (29% vs. 14%; p< 0.001), hypercholesterolemia (35% vs. 25%; p= 0.022) and were more
likely than controls to be prescribed antihypertensive drugs and statins.
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Table 28 shows the number of participants analysed by year before and after surgery. There were 63%
contributing to follow-up after the end of 2 years and 31% in the fifth year of follow-up. In the year prior
to surgery, 36% of surgery participants met the criteria for prevalent clinical depression in comparison with
21% of control participants (Figure 10 and see Table 28). In the 2 years following surgery, this reduced to
32% in the participants who underwent surgery before rising to pre-surgery levels (37%) in the seventh
year of follow-up. Rates of depression in control participants remained stable. In the surgery group, 41%
of participants were prescribed antidepressants in the year leading up to surgery, falling to 36% in the
subsequent year. The proportion of participants prescribed antidepressants began to rise again after the
first year and surpassed pre-surgery levels in the fifth year following bariatric surgery.
Table 29 presents the results of the multiple logistic regression model for the outcomes of clinical
depression and antidepressant prescribing. Compared with control participants, the between-group effect
shows that bariatric surgery participants were more likely to be diagnosed with clinical depression (OR
2.02, 95% CI 1.75 to 2.33; p< 0.001) or to be prescribed antidepressant drugs (OR 1.97, 95% CI 1.72 to
2.25; p< 0.001). There was evidence of increasing trends in diagnosis of depression and prescription of
antidepressant drugs over the study period. Estimation of the effect of time since surgery, in comparison
with all person-time without surgery from both groups, revealed a reduction in clinical depression and
antidepressant prescribing in the first 3 years following the procedure. The adjusted relative odds of clinical
depression were 0.82 (95% CI 0.78 to 0.87; p< 0.001) and 0.83 (95% CI 0.76 to 0.90; p< 0.001) in the
first 2 years following the procedure. Similar changes were observed for the related outcome of
antidepressant prescribing. However, from the fourth postoperative year onwards there was no longer any
evidence for a reduction in clinical depression or antidepressant prescribing.
TABLE 27 Comparison of baseline characteristics of BS participants and controls. Figures are frequencies
(column %) unless otherwise indicated
Variable BS cases Controls p-value
Frequency 3045 3045
Female (%) 2406 (79) 2521 (83) Matched
Age (years), mean (SD) 45.9 (10.2) 44.3 (14.8) Matched
BMI (kg/m2), mean (SD) 44.0 (8.3) 43.5 (7.6) Matched
BMI category (kg/m2)
30.0 to 34.9 394 (13) 351 (12) Matched
35.0 to 39.9 677 (22) 681 (22)
≥ 40.0 1974 (65) 2013 (66)
Comorbidity
Diabetes 878 (29) 424 (14) < 0.001
CHD 134 (4) 102 (3) 0.034
Stroke 36 (1) 38 (1) 0.815
Current smoking 502 (16) 675 (22) < 0.001
Blood pressure ≥ 140/90mmHg 834 (27) 900 (30) 0.001
Cholesterol ≥ 5mmol/l 1080 (35) 760 (25) 0.022
Antihypertensive drugs prescribed 1561 (51) 1074 (35) < 0.001
Statins prescribed 864 (28) 486 (16) < 0.001
Index year (median IQR) 2010 (2009 to 2012) 2010 (2009 to 2012) Matched
BS, bariatric surgery.
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FIGURE 10 Prevalence of clinical depression for bariatric surgery cases (black) and controls (green) for 3 years
before and 7 years after index date.
TABLE 28 Changes before and after surgery in diagnosis and treatment of depression. Figures are frequencies for
person-years and row per cent for depression and antidepressant prescribing
Year
Participants
contributing
person-time in year
Antidepressants
prescribed in year
(row %)
Depression recorded
in year (row %)
Meeting criteria of
clinical depression in
year (row %)
BS cases Controls BS cases Controls BS cases Controls BS cases Controls
–3 to –2 2856 2560 38 19 12 6 34 16
–2 to –1 3045 3045 40 22 12 7 34 19
–1 to 0 3045 3045 41 25 9 7 36 21
0 to 1 3045 3045 36 25 6 6 32 21
1 to 2 2488 2786 37 24 7 4 32 20
2 to 3 1916 2014 38 24 7 5 33 20
3 to 4 1392 1369 40 23 6 4 34 19
4 to 5 935 914 43 23 6 4 34 18
5 to 6 574 570 44 24 7 4 37 19
6 to 7 335 369 43 26 6 2 37 20
BS, bariatric surgery.
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There was no evidence that the effect of bariatric surgery varied by type of procedure (test for interaction,
p= 0.2885). Table 30 presents the prevalence of depression for each of the three procedures included in
the study, after omitting six with undefined procedure type. There were more participants with LAGB at
long durations of follow-up while fewer than 25% of participants receiving SG, and 35% receiving GBP,
contributed data after the end of 3 years’ follow-up because these procedures were utilised more recently.
The effect in each subgroup was generally similar to the one observed overall, and in the absence of an
interaction effect, possible subgroup differences were not explored further.
There was no evidence that the effect of bariatric surgery on clinical depression varied by type of
procedure (test for interaction, p= 0.2885).
Table 31 shows the results divided by depression status in the preoperative year. Among participants who
were not depressed in the preoperative year, the prevalence of depression increased to 18% in the sixth
postoperative year, while up to 9% were depressed 2 years before the procedure. Among participants
who were depressed in the preoperative year, the prevalence of depression was generally close to 75%
postoperatively. However, in the second preoperative year, 77% were depressed. These results are
consistent with depression being episodic and frequent in this population.
TABLE 29 Logistic regression analysis of the association of bariatric surgery with clinical depression and
antidepressant prescribing
Measure
Clinical depression,
OR (95% CI) p-value
Antidepressant
prescribing, OR (95% CI) p-value
Effect of groupa
Control group Reference Reference
Bariatric surgery group 2.02 (1.75 to 2.33) < 0.001 1.97 (1.72 to 2.25) < 0.001
Effect of study yearb
Year 1.02 (1.01 to 1.04) 0.007 1.04 (1.03 to 1.06) < 0.001
Effect of time since surgeryc
Time without surgery Reference Reference
First postoperative year 0.82 (0.78 to 0.87) < 0.001 0.79 (0.74 to 0.84) < 0.001
Second postoperative year 0.83 (0.76 to 0.90) < 0.001 0.79 (0.72 to 0.86) < 0.001
Third postoperative year 0.87 (0.78 to 0.97) 0.014 0.82 (0.73 to 0.91) < 0.001
Fourth postoperative year 0.89 (0.78 to 1.02) 0.100 0.87 (0.76 to 0.99) 0.039
Fifth postoperative year 0.87 (0.74 to 1.04) 0.123 0.87 (0.74 to 1.03) 0.107
Sixth postoperative year 1.01 (0.82 to 1.25) 0.910 0.99 (0.80 to 1.22) 0.912
Seventh postoperative year 0.99 (0.76 to 1.29) 0.959 1.04 (0.81 to 1.35) 0.747
a Effect of group across all years, adjusted for study year and time since surgery.
b Effect of study year adjusted for group and time since surgery.
c Effect of time since surgery, using time before surgery for reference, adjusting for group and study year.
ORs were adjusted for each of the variables shown as well as age, sex, index year, type of procedure, prevalent diabetes,
stroke and CHD, high blood pressure, high cholesterol, smoking, prescription of antihypertensive drugs and statins.
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TABLE 31 Prevalence of depression by year following bariatric surgery divided by presence or absence of
depression in preoperative year
Year
Depressed in preoperative year Not depressed in preoperative year
n Depression (%) n Depression (%)
–3 to –2 1036 77 1820 9
–2 to –1 1097 84 1948 6
–1 to 0 1097 100 1948 0
0 to 1 1097 79 1948 5
1 to 2 889 74 1599 8
2 to 3 664 74 1252 12
3 to 4 479 75 913 13
4 to 5 320 73 615 14
5 to 6 203 73 371 18
6 to 7 113 77 222 16
TABLE 30 Clinical depression following different bariatric surgical procedures
Year
LAGB GBP SG
n Depression (%) n Depression (%) n Depression (%)
–3 to –2 1207 32 1195 36 448 34
–2 to –1 1297 33 1265 35 477 35
–1 to 0 1297 37 1265 36 477 33
0 to 1 1297 31 1265 33 477 31
1 to 2 1160 32 980 32 344 29
2 to 3 1003 35 682 33 227 30
3 to 4 826 34 444 36 119 27
4 to 5 645 35 229 32 59 27
5 to 6 478 38 65 37 30 27
6 to 7 300 37 18 33 17 29
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Discussion
Summary of findings
Patients undergoing bariatric surgery have higher levels of depression than other obese patients with
similar BMI and of the same age and sex. Frequent comorbidities, including diabetes mellitus, might be
associated with this increased frequency of depression. The results of this analysis indicate that bariatric
surgery in obese patients may be associated with a modest reduction in the prevalence of depression,
and the use of antidepressant medications in primary care, but these effects do not appear to persist
more than 3 years following the procedure. The reasons why patients with depressive illness are
disproportionately represented among patients undergoing bariatric surgery in this population are unclear.
In the UK, only a very small minority of patients with severe obesity undergo bariatric surgery and it is
possible that psychological symptoms may be one of the considerations that influence whether or not an
obese patient receives surgery. Obese patients seeking treatment may generally have higher levels of
psychological distress. In a study in Germany, Herpertz et al.154 found that patients undergoing bariatric
surgery had similar levels of depression to those receiving non-surgical weight-loss therapy, with both
being higher than obese controls. Comparison of patients who were either depressed or not depressed in
the preoperative year showed a decline in depression in the former and an increase in the latter after
surgery. This is compatible with regression to the mean and is consistent with the episodic nature of
depression symptoms. Our results do not provide strong evidence that patients should be prioritised in the
hope that bariatric surgery will provide long-term relief of clinical features of depression, even though
short-term effects might be judged clinically relevant.
Comparison with other results
Previous studies have generally shown larger effects than the present study but these generally used samples
drawn from specialist centres that might be susceptible to bias. One of the largest studies was conducted by
the Longitudinal Assessment of Bariatric Surgery-2 (LABS-2) group. The included 2148 participants from
10 US hospitals with Beck Depression Inventory recorded at baseline and at least 1 follow-up within 3 years
of the procedure. There were 40% who reported treatment for depression before surgery, while 28% had
mild depressive symptoms and 5% moderate or severe depressive symptoms. The proportion with any
depressive symptoms was < 10% in the first year after surgery but increased to 16% at 3 years. A similar
pattern of change in depressive symptoms over time was reported by Burgmer et al.,155 in a 4-year study of
148 participants. However, changes in use of antidepressant medication in the LABS-2 study were modest,
with 35% using antidepressant medication before operation and 28% in the second and third years
following the procedure. These results emphasise the importance of long follow-up in future studies as well
as the evaluation of different measures of depression. In the SOS study, a battery of health-related quality of
life measures, including the Hospital Anxiety and Depression Scale, showed improvement followed by
deterioration.92 An initial improvement is associated with the period of greatest weight loss in the first
2 years following surgery, sometimes viewed as a ‘honeymoon period’,156 followed by a subsequent
deterioration associated with weight regain.92 However, in the SOS study there was evidence of some
improvement in depression symptoms up to 10 years of follow-up. Premorbid depression was less frequent
in the SOS study than in the present sample.
Strengths and limitations
This analysis had the strengths of a large, population-based sample of patients undergoing bariatric
surgery with prospectively recorded data for depression diagnoses and antidepressant prescribing.
The interrupted time-series design is generally considered to be more resistant to bias than other
non-randomised designs.157 However, there were clear differences between the intervention and matched
comparison group with respect to the outcome of interest, indicating that individuals undergoing surgery
represent a highly selected group that is not typical of all patients with the same BMI, age and sex.
Patients undergoing surgery may receive a package of supportive care and improved clinical management
to prepare them for surgery, which may confound the effect of the surgical procedure. Patients in the
control group received the usual care offered at their general practice, which was unlikely to include
standardised management of obesity or depression.
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The types of surgical procedure and patient case mix changed over time and, though access remained
restricted, the numbers of procedures increased. There were small numbers of patients with long follow-up
with reduced statistical power for evaluation of later time points. Furthermore, there is a risk of bias
because patients operated on longer ago may have different characteristics from those operated on more
recently, with shorter periods of follow-up. Use of clinical data may also introduce bias because patients
must consult with their physician, and have their symptoms recognised, before a depression diagnosis may
be recorded. Some evidence shows rates of diagnosed clinical depression are lower than those found in
epidemiological studies.158 An important limitation is that there was very limited recording of body weight
during the period of follow-up and we cannot determine whether changes in depression were associated
with weight loss or regain.
Our assessment of depression was based on clinical diagnoses and antidepressant prescribing; the limited
changes observed over time might result from difficulty in stopping antidepressant therapy once initiated.
A previous CPRD study found that depression is often treated with short-term courses of antidepressant
medications, with only a small proportion of patients being prescribed drugs over a long period for
chronic depression.157 The high rates of antidepressant use observed in this study may represent met
need and not merely the result of repeat prescribing to patients who might no longer require clinical
treatment for depression. Several previous studies used self-report measures to evaluate depressive
symptoms and these measures might be associated with greater sensitivity for depression and responsiveness
to change.159,160 For all of the reasons, it would be desirable to test hypotheses using well-designed
randomised trials with prospective documentation of depression.
Conclusions
The results of this analysis suggest that bariatric surgery may have only a limited and short-lived effect on
clinical depression. However, we caution that patients are presently highly selected for bariatric surgery.
If bariatric surgery were to be more widely accessible, it is possible that different effects might be
observed. Randomised studies of the effect of bariatric surgery on depression are required.
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Chapter 10 Rapid review of the clinical
effectiveness and cost-effectiveness of
bariatric surgery
Research objectives
The objectives of the rapid review were to:
l quantify the effect of bariatric surgery on the incidence of obesity-related morbidities in comparison to
standard weight management. The morbidities investigated were diabetes, CHD, stroke and cancer
l establish the effect of bariatric surgery on diabetes remission in participants who have diabetes at the
time of surgery
l quantify the effect of bariatric surgery on the prevalence of clinical depression and use of
antidepressant medications
l assess changes in mortality after bariatric surgery compared with standard weight management
l investigate the cost-effectiveness of bariatric surgery for the treatment of obesity.
Results
The literature search identified 11,996 articles (with duplicates), of which 247 were selected on the title for
further investigation. After checking the abstracts 87 full-text papers were checked for inclusion. The final
analysis included 31 systematic reviews and 7 single studies. A flow chart outlining study selection is
presented in Figure 11. A summary of the key results from the systematic reviews is presented in Table 32.
EMBASE and MEDLINE (n = 9719)
PubMed (n = 2026) 
Cochrane Database (n = 251)
Systematic reviews (n = 31)
Single studies (n = 7)
Selected on titles
(n = 247)
Full text reviewed
(n = 87)
Identified from reference lists
(n = 8)
Literature search results
Included in the review
FIGURE 11 Flow chart showing selection of studies for the rapid review.
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TABLE 32 Summary of main findings from systematic reviews
Study details
Intervention and study designs
included Main findings
Picot (2009),31 narrative
synthesis
GBP; BPD; SG; AGB; VBG
Systematic reviews, controlled clinical
trials and prospective (controlled) cohort
studies
T2DM incidence: one cohort study (SOS)
included at 2- and 10-year follow-up. Two-year
rate in surgery group 1% vs. control 8%
(p< 0.001); 10-year 7% vs. 24% (p< 0.001)
Cancer incidence: one cohort study (SOS),
11-year follow-up, HR 0.74 adjusted (p= 0.011)
T2DM remission: one RCT, 2-year follow-up,
RR 5.5 (95% CI 2.2 to 14.0); one cohort (SOS)
at 2- and 10-year follow-up. Two-year rate in
surgery group 72% vs. control 21% (p< 0.001);
10-year 36% vs. 13% (p< 0.001)
Mortality: one cohort study (SOS), < 16-year
follow-up, HR 0.76 (95% CI 0.59 to 0.99)
Padwal (2011),85
narrative synthesis
BPD; SG; GBP; AGB; VBG
Economic analyses
Cost-effectiveness: 13 studies; ICERs ranged
from US$1000 to US$40,000 per QALY. More
cost-effective in diabetes
Pontiroli (2011),83
meta-analysis
GBP; SG; AGB
Controlled clinical trials (RCT and cohort)
Mortality: eight cohorts < 12-year follow-up,
OR 0.55 (95% CI 0.49 to 0.63)
Picot (2012),75 narrative
synthesis
LAGB
Controlled clinical trials (RCT and cohort)
BMI 30–40 kg/m2
T2DM remission: one cohort study (SOS), 2-year
follow-up remission in > 70% of surgery, 13% in
control (p< 0.001)
Chang (2013),32
meta-analysis
GBP; AGB; VBG; SG
RCT and observational studies
T2DM remission: eight RCTs, rate in surgery
group 92% vs. control 18%; 43 cohorts rate in
surgery group 86% vs. control
Mortality: 15 RCTs, rate in surgery group 0.31%
vs. control?; 32 RCTs, rate in surgery group
0.35% vs. control
Gloy (2013),6
meta-analysis
GBP; BPD; SG; AGB
RCTs
T2DM remission: four RCTs > 2-year follow-up,
RR 5.3 (95% CI 1.8 to 15.8); p= 0.003
Guo (2013),71
meta-analysis
GBP; SG; BPD; gastric band
RCT
T2DM remission: two RCTs, RR 9.74 (95% CI
1.36 to 69.66)
Maggard-Gibbons
(2013),74 narrative
analysis
GBP; AGB; SG
Systematic reviews, RCTs and controlled
cohorts
BMI 30–35 kg/m2
T2DM remission: three CCT vs. non-surgery,
two head-to-head, one matched trial, 26
observational. BS in BMI 30–35 kg/m2 with
diabetes have better intermediate glucose
outcomes. Insufficient evidence to say more
Tee (2013),63
meta-analysis
Gastric band; VBG; GBP
RCT, controlled cohort, case–control
Cancer incidence: six cohorts, RR 0.55 (95% CI
0.41 to 0.73); women 0.68 (95% CI 0.60 to
0.77), men 0.99 (95% CI 0.74 to 1.32)
Wang (2013),84
narrative synthesis
GBP; SG; AGB
Economic analyses
Cost-effectiveness: six studies ICERs ranged
from around US$1500 to ≈US$17,000 per QALY
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TABLE 32 Summary of main findings from systematic reviews (continued )
Study details
Intervention and study designs
included Main findings
Yip (2013),77
meta-analysis
SG; GBP
Clinical studies (excluding case reports)
T2DM remission: comparison of SG and GBP
two RCTs, OR 5.0 (95% CI 0.7 to 38.1)
Afshar (2014),67
meta-analysis
GBP; VBG
RCTs, controlled cohort, case–control
Cancer incidence (colorectal cancer): four
cohorts, RR 0.73 (95% CI 0.58 to 0.90);
p= 0.004
Casagrande (2014),64
meta-analysis
GBP; AGB; VGB
Controlled studies
Cancer incidence: four cohorts, OR 0.40
(95% CI 0.23 to 0.72), two studies removed
to lower heterogeneity, OR 0.74 (95% CI
0.65 to 0.85)
Colquitt (2014),73
narrative synthesis
GBP; AGB; SG
RCT
T2DM remission: five RCTs < 12 months’
follow-up reported greater remission in surgery
Kwok (2014),62
meta-analysis
Gastric band; VBG; GBP
RCTs, controlled cohorts
Stroke incidence: four cohorts, OR 0.63
(95% CI 0.49 to 0.80)
Mortality: 10 cohorts, OR 0.60 (95% CI 0.49 to
0.74) based on adjusted estimates
Merlotti (2014),60
meta-analysis
AGB; GBP; VBG
RCT, controlled non-randomised studies
BMI ≥ 30 kg/m2
T2DM incidence: three controlled clinical trials,
OR 0.1 (95% CI 0.02 to 0.49)
Merlotti (2014),60
meta-analysis
AGB; GBP; VBG
RCT, controlled non-randomised studies
Included non-obese
T2DM incidence: four controlled clinical trials,
OR 0.16 (95% CI 0.11 to 0.24)
Ribaric (2014),72
meta-analysis
AGB; GBP; VBG
RCTs and controlled cohort studies
T2DM remission: 11 cohorts and five RCTs,
1- to 2-year follow-up, OR 9.81 (95% CI
6.06 to 15.87)
Zhang (2014),80
meta-analysis
GBP; SG
RCT, controlled trials and cohort studies
T2DM remission: comparison of SG and GBP
at 2 years’ follow-up, seven cohorts, RR 1.05
(95% CI 0.90 to 1.23)
Cho (2015),79
meta-analysis
SG; GBP
RCT and cohort studies
T2DM remission: comparison of SG and GBP,
two RCTs, nine cohorts < 1-year follow-up,
RR 0.90 (95% CI 0.81 to 1.01)
Maestro (2015),65
narrative synthesis
GBP; VBG; gastric band
Systematic reviews and observational
studies
Cancer incidence: one meta-analysis, three
narrative reviews and nine cohorts. Surgery
associated with lower morbidity and mortality
from cancer
Müller-Stich (2015),76
meta-analysis
BPD; SG; GBP; AGB
RCTs and cohort studies
BMI < 40 kg/m2
T2DM remission: five RCTs, three cohorts
< 3-year follow-up, OR 14.11 (95% CI
6.67 to 29.86)
Ricci (2015),61
meta-analysis
BPD; AGB; GBP; SG; VBG
RCT and cohort studies
T2DM incidence: 22 cohorts, RR 0.33 (95% CI
0.26 to 0.41)
Upala (2015),161
meta-analysis
GBP; VGB
RCT and non-randomised trials and
observational studies
Cancer incidence (endometrial cancer): three
female cohorts, RR 0.43 (95% CI 0.26 to 0.72)
continued
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TABLE 32 Summary of main findings from systematic reviews (continued )
Study details
Intervention and study designs
included Main findings
Yang (2015),66
meta-analysis
GBP; VBG
RCTs and observational studies
Cancer incidence (obesity-related): five
cohorts, OR 0.22 (95% CI 0.14 to 0.35)
Zhang (2015),78
meta-analysis
GBP; SG
RCT and controlled studies
T2DM remission: comparison of SG and GBP
four cohorts, five RCTs, OR 3.29 (95% CI
1.98 to 5.49)
AGB, adjustable gastric band; BPD, biliopancreatic diversion; BS, bariatric surgery; RR, relative rate; VBG, vertical
banded gastroplasty.
Disease incidence
Type 2 diabetes mellitus
Four systematic reviews reported on the incidence of T2DM after bariatric surgery. Picot et al.31 reported
on the incidence of T2DM based on the SOS study at 2 and 10 years for this outcome.162 There were
two systematic reviews produced on T2DM prevention by various methods by a single team, with one
focusing on obese participants (BMI ≥ 30 kg/m2) and the other without this criterion. In the bariatric
surgery component they included three and four controlled clinical trials, respectively, and reported ORs
of 0.10 (95% CI 0.02 to 0.49) and 0.16 (95% CI 0.11 to 0.24).60,163 The most recent review was
published in 2014 and summarised 22 randomised and non-randomised trials, giving a relative risk of
0.33 (95% CI 0.26 to 0.41). In a subgroup analysis of four malabsorptive procedures, the relative risk was
0.14 (95% CI 0.03 to 0.73).61 The result from the CPRD analysis conducted in Chapter 7 gave a HR of 0.20
(95% CI 0.13 to 0.30) for follow-up of up to 7 years after surgery. This finding is comparable with results
from the SOS study and was employed in the health economic model.
Coronary heart disease and stroke
We did not identify any systematic reviews or individual studies that reported the incidence of CHD after
bariatric surgery. One systematic review reported on stroke incidence after bariatric surgery.62 A meta-analysis
of adjusted HRs from three cohort studies gave a result of 0.63 (95% CI 0.49 to 0.80), with the inclusion of
an additional non-adjusted estimate altering the result to 0.49 (95% CI 0.32 to 0.75). For the health
economic model we utilised the relative risk estimate of 0.67 (95% CI 0.54 to 0.83) from the SOS study.
Cancer
There were four systematic reviews that investigated incidence of cancers after bariatric surgery. Two used
meta-analysis to combine the results of controlled cohort studies. The first, based on six papers, reported a
relative risk of 0.55 (95% CI 0.41 to 0.73), and performed subgroup analysis by gender finding that
bariatric surgery was protective in women but not in men.63 However, four of the papers included in this
meta-analysis used data from the same two cohorts. The second review using meta-analysis was based on
the four non-duplicate cohorts and gave a pooled OR of 0.42 (95% CI 0.24 to 0.73).64 Two of the studies
were conducted in morbidly obese patients only. The association between surgery and reduced risk of
cancer was maintained when two studies, one conducted only in women and one with controls taken
from a hospital population, were removed to reduce heterogeneity. One older review identified just one
relevant study,31 and another summarised the existing reviews.65
Three additional recently published reviews were identified that focused on the relationship between bariatric
surgery and specific cancers. A meta-analysis describing incidence of obesity specific cancers produced a
pooled OR of 0.43 (95% CI 0.27 to 0.69) based on five studies.66 Four studies on incidence of colorectal
cancer gave a pooled relative rate of 0.73 (95% CI 0.58 to 0.90),67 while three studies of endometrial cancer
gave a pooled relative rate of 0.43 (95% CI 0.26 to 0.72).161 For the health economic model, we utilised the
cancer incidence result reported by the SOS, as this is a large, well-established study with long-follow-up.89
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Type 2 diabetes remission
Remission of T2DM was the most commonly reported comorbidity measure in papers investigating the
clinical impact of bariatric surgery, reflecting the potential importance of surgery as a T2DM treatment. In
total we identified 18 systematic reviews published since 2000 that reported on remission of T2DM after
bariatric surgery. We focused on the more recently published reviews, as the older literature covered a
smaller evidence base.31,68–70,164
A number of reviews reported on T2DM remission results from RCTs and included largely the same studies
in their meta-analyses. Gloy et al.6 used meta-analysis to combine the results of four RCTs to give a relative
risk of 5.3 (95% CI 1.8 to 15.8) for T2DM remission at 1–2 years of follow-up when comparing surgery
with medical management, while a review by Guo et al.71 published in the same year included two RCTs
to give an OR of 9.74 (95% CI 1.36 to 69.66). One further review, again published in 2013, employed
meta-analysis to combine the results of eight RCTs to show a pooled estimate of 92% remission of T2DM
after surgical intervention compared with 18% in control groups.32 Subsequently, two further systematic
reviews of T2DM remission have been published. One incorporated RCTs and controlled cohorts both
separately and together into random-effect meta-analyses.72 Combining the 11 observational studies and
five RCTs together gave a pooled OR of 9.8 (95% CI 6.1 to 15.9). The other used narrative analysis to
discuss the results of five RCTs, four of which matched the former review.73
Three reviews focused on the potential of bariatric surgery to treat T2DM in patients who were not
morbidly obese (BMI< 40 kg/m2).74–76 The two older reviews identified one RCT of 60 patients with a
BMI of 30–40 kg/m2 who underwent adjustable gastric banding that reported on remission.165 After
2 years, 73% of the surgery group and 13% of the controls were in remission from T2DM (p< 0.001).
A statistically significant difference in remission was also reported in patients with a BMI< 35 kg/m2,
although this was based on just 13 patients. However, the most recent review identified two RCTs and six
observational studies that were conducted in patients with a BMI < 35 kg/m2, with five of these reporting
on T2DM remission.76 Meta-analyses of the five studies, combined with an additional three publications
that included patients with mild obesity non-exclusively, gave a pooled OR of 14.1 (95% CI 6.7 to 29.9).
Four reviews compared SG with GBP. Three of these concluded that there was no difference in T2DM
remission after the two procedures, and were based on RCTs alone77 and by combining randomised and
non-randomised studies.78,79 The fourth review included four RCTs and five controlled studies to give a
pooled OR of 3.29 (95% CI 1.98 to 5.49) favouring GBP over SG.80
We identified four additional recently published studies through the literature search that were not
included in existing literature reviews. Two prospective cohorts compared GBP and SG for T2DM remission.
The first focused on patients with a BMI of 28–35 kg/m2 and was conducted on 64 Chinese diabetic
patients. They found complete T2DM remission at 3 years in 85% of GBP and 78% of SG patients
(p= 0.525). A third arm who received lifestyle treatment had no patients in remission at the end of the
study.166 The second larger study did find a significant difference in remission rates at 1 year after surgery
in patients with a BMI ≥ 50 kg/m2, with remission in 48% of SG and 71% of GBP patients.167 The third
study, a RCT of patients with BMI 30–40 kg/m2, compared GBP, gastric banding and an intensive lifestyle
intervention. At 3-year follow-up complete remission was found in 15% of bypass, 5% of banding and
0% of lifestyle participants.168 A second RCT was conducted in 60 patients with BMI≥ 35 kg/m2. After
5 years, 50% of the bariatric surgery group were in remission from T2DM: 37% of the GBP patients and
63% of those who underwent biliopancreatic diversion.144
In our own analyses of CPRD data we identified a relative rate of remission from T2DM of 5.90 (95% CI
3.72 to 9.34) after 6 years. The heterogeneity of studies relating to the length of follow-up, choice of
measure and different procedures makes it difficult to compare our results against the literature, although
the majority of systematic reviews included papers that generally had follow-up periods of just a few years.
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Depression
We identified two systematic reviews that focused on psychological health in relation to bariatric surgery.81,82
Both included uncontrolled studies which did not fit with our inclusion criteria. Both also highlighted the SOS
study as presenting the highest-quality evidence available on bariatric surgery and depressive symptoms, which
has found a dose–response relationship between weight loss and depressive symptoms up to 4 years.169
More recently, we identified one cohort study that compared patients who underwent surgery (gastric
banding or vertical banded gastroplasty) with medical management of obesity and a no treatment
group.170 At 9 years’ follow-up they found that the surgical group had higher depression scores, using the
Hospital Anxiety and Depression Scale, than the other groups after adjustment for baseline scores.
Additionally, they found that scores in the surgery group were not significantly different from baseline,
although they had been lower at a 4-year follow-up.
The CPRD analysis identified a reduction in clinical depression in surgery patients for the first 3 years after
the procedure. Although we relied on clinical data rather than research questionnaires, our findings are
similar to the literature in showing only a temporary effect as a result of surgery.
Mortality
Four systematic reviews presented data on long-term mortality after bariatric surgery. One of these reported
data from just one study,31 and another included uncontrolled studies and so was able to report mortality
rates in the treatment arm only.32 Pontiroli and Morabito83 pooled eight controlled clinical trials to give an OR
of 0.55 (95% CI 0.49 to 0.63) for mortality after the perioperative period. These results were also divided
into deaths from cardiovascular disease (OR 0.58, 95% CI 0.46 to 0.73) and not from cardiovascular disease
(OR 0.70, 95% CI 0.59 to 0.84), and by surgery type with similar results from gastric banding and bypass.
More recently, Kwok et al.62 reviewed the literature and combined the adjusted results from 10 cohorts to
give a pooled OR of 0.60 (95% CI 0.49 to 0.74). There was a high level of overlap with studies identified by
Pontiroli and Morabito, plus the addition of more recently published papers.
Two further studies of interest have been published since the reviews. Both were retrospective cohorts
with the first comparing patients who had GBP to non-surgical controls. They found an OR of 0.43
(95% CI 0.25 to 0.73) for long-term mortality in favour of surgery at 10 years, with similar results when
just diabetic participants were included. A significant difference in mortality was apparent at 5 years of
follow-up but not at 2 years.171 The second study had a mean follow-up of 7 years, and found a HR
of 0.45 (95% CI 0.36 to 0.56) in years 1–4 after surgery, and 0.47 (95% CI 0.39 to 0.58) at 5–10 years.10
Cost-effectiveness
Two systematic reviews evaluated the cost-effectiveness of bariatric surgery for obesity. The most recent was a
narrative review of six economic models.84 The models varied in structure, time horizon, comparators and
setting, and the ICERs ranged from US$1500 to US$17,000. The highest ICER was attributed to open
Roux-en-Y GBP. The second review was a narrative analysis of 13 studies, including RCTs, cohorts and literature
reviews.85 Again, the heterogeneity of the sources led to a large variation in estimated ICERs, from US$1000 to
US$40,000 per QALY. Surgery was found to be more cost-effectiveness in diabetic study populations.
The literature search identified five modelling studies that evaluated the cost-effectiveness of bariatric
surgery that were not included in the above reviews. Two of these were UK-based; the first estimated the
ICER to be £20,159 at 2 years, £4969 at 5 years and £1635 at 20 years.75 The second focused only on
diabetic patients undergoing LAGB and calculated the ICER as £3602 using a 40-year time horizon.172 An
Australian study considering LAGB for BMI ≥ 35 kg/m2 and using disability adjusted life-years rather than
QALYs estimated the mean ICER using a lifetime horizon to be AU$2154.173 A US study predicted ICERs of
US$6600 for GBP and US$6300 for gastric banding over a lifetime perspective and based on normal BMI
trajectories post surgery. For open GBP the estimate was far higher at US$17,300. The authors also
produced separate estimates for the post-surgery BMI being maintained and maximum weight regain.174
Finally, a Markov model using Swedish data estimated the ICER at 2 years to be €26,985.175
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Chapter 11 Costs and outcomes of offering
greater access to bariatric surgery for morbid obesity
Introduction
In spite of the important potential benefits, the role of bariatric surgery in the management of obesity
remains controversial. Access to bariatric surgery is often limited in publicly funded health-care systems.
In the UK, approximately 10,000 bariatric surgery procedures are performed annually11 but there are more
than 1 million individuals with morbid obesity who could potentially benefit from the procedure.176 This
limited access to bariatric surgery may be related to perceptions of the cost of surgery and the resources
required to offer it more readily. A recent study concluded that ‘bariatric surgery does not reduce overall
health-care costs in the long-term’ and suggested that ‘future studies should focus on the potential benefit
of improved health and well-being of persons undergoing the procedure rather than cost-savings.’177
The purpose of the present research was to explore the potential impacts of bariatric surgery deployed at
scale for severe and morbid obesity. We aimed to evaluate the cost-effectiveness of bariatric surgery,
including laparoscopic gastric banding, GBP and SG procedures, in comparison with standard non-surgical
health-care management of obesity. We aimed to incorporate new evidence concerning the long-term
effects of bariatric surgery on morbidity and mortality outcomes. We also aimed to determine whether
there were population subgroups defined by age, gender, socioeconomic position, obesity category and
comorbidity for whom bariatric surgery might be more, or less, cost-effective.
Methods
The methods for the health economic modelling study are given in Chapter 3 (see Markov modelling for
health economic evaluation). A Markov model was designed. Empirical data inputs to the model were
provided through analysis of data for a large population registered in primary care, derived from the CPRD.
Estimates for the clinical effectiveness of bariatric surgery were derived from CPRD data analysis and
updated systematic reviews. Probabilistic simulations, run using the model, provided estimates of lifetime
incremental costs and QALYs aggregated across the population at risk. A summary of the simulation
scenarios is provided in Table 33.
In the base case, the population entering the Markov model comprised 200,000 participants with BMI
≥ 40 kg/m2. These included equal numbers of men and women, with mean age of 46 years and ages
ranging from 20 to 74 years. There were 19% with T2DM and 4% with CHD, the remainder having no
chronic comorbidity (Table 34). The structure of the model is presented in Figure 12.
Estimates of cost-effectiveness were sensitive to the cost of the surgical procedure. However, even when
the cost of the procedure was 100% higher than in the base case (£18,328 instead of £9164), bariatric
surgery was cost-effective at £11,365 per QALY. Simulations in which the procedure cost was set at zero
confirmed that incremental health-care costs remained positive. When the intervention effect from bariatric
surgery was allowed to diminish markedly over time following the procedure, there was only a modest
impact on estimated cost-effectiveness (see Table 38), reflecting the smaller contribution made by
discounted costs and QALYs from later periods of follow-up.
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TABLE 34 Distribution of initial population in the base case
Measure Bariatric surgery No bariatric surgery
Number 200,000 200,000
Age (years), mean (range) 46 (20–74) 46 (20–74)
Men 100,000 100,000
Women 100,000 100,000
No morbidity 153,846 (77%) 153,846 (77%)
Diabetes mellitus 38,462 (19%) 38,462 (19%)
CHD 7692 (4%) 7692 (4%)
TABLE 33 Summary of simulations performed
BMI category Condition Category Start population
≥ 40 kg/m2 All Synthetic population of 100,000 each of men and
women, aged 20–74 years, with morbid obesity
including 19% with T2DM and 4% with CHD
≥ 40 kg/m2 Gender Men 100,000 men with morbid obesity as above
Women 100,000 women with morbid obesity as above
≥ 40 kg/m2 Age group (years) 20–34 Synthetic population of 100,000 each of men and
women, in the specified age group, with morbid
obesity including 19% with T2DM and 4% with
CHD
35–54
55–74
≥ 40 kg/m2 Deprivation category Least deprived As in ‘All’ above
Most deprived As in ‘All’ above
≥ 40 kg/m2 Diabetes BMI ≥ 40 kg/m2 BMI ≥ 40 kg/m2 Synthetic population of 75,000 each of men and
women, in the specified age group, with morbid
obesity and T2DM
35–39 kg/m2 BMI 35–39 kg/m2 BMI 35–39 kg/m2 Synthetic population of 75,000 each of men and
women, aged 20–74 years, with morbid obesity
and no comorbidity
≥ 40 kg/m2 Costs of procedure 50% higher As in ‘All’ above
100% higher As in ‘All’ above
Zero procedure cost As in ‘All’ above
≥ 40 kg/m2 Decline of intervention
effect over time
Year –0.25 As in ‘All’ above
Year –0.50 As in ‘All’ above
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Estimates of intervention effects of bariatric surgery on disease incidence and mortality that were
incorporated into the model are outlined in Table 35. CPRD derived estimates were employed for T2DM
incidence and remission, and for the effect of bariatric surgery on depression. Bariatric surgery was
modelled as associated with 40% of patients entering remission; this was based on analysis of patients
with complete data. The choice of estimate was also influenced by recognition that RCTs have generally
reported higher remission rates than were observed in CPRD. Estimates from the SOS study were used for
cardiovascular disease and cancer. Estimates from the SOS study were used as the largest study with long
follow-up. The effect of bariatric surgery on mortality was derived from the study by Arterburn et al.10 as
the most recent large, authoritative study on bariatric surgery and mortality. It was considered to be
beyond the scope of the present project to pursue in-depth analysis of each of CHD, stroke, cancer
and mortality within CPRD. This was because problems of confounding may be more difficult to address
with these outcomes. There have been large changes in uptake of interventions that contribute to
cardiovascular prevention including antihypertensive therapy, statins and smoking cessation. There are also
important issues of confounding by indication and contraindication that might require to be addressed.
For these reasons, we preferred to draw on previously published reports for these measures.
At risk DM CHD Stroke Cancer
At risk DM CHD Stroke Cancer Dead
Non-BS
At risk DM CHD Stroke Cancer
At risk DM CHD Stroke Cancer Dead
BS
Start population
stratified by 
BMI category 
and condition
FIGURE 12 Showing the structure of the model. Each state is stratified by BI category. Model states are further
divided into ‘depressed’ and ‘not depressed’. Participants occupying each state are stratified by gender and single
year of age. ‘At risk’ denotes participants without comorbidities included in the model; BS, bariatric surgery;
DM, diabetes mellitus.
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Results
Results are presented in Table 36 for a comparison of bariatric surgery with no bariatric surgery in morbid
obesity. Results are presented as the mean and 95% range for 1000 simulations, with values expressed as
rates per 1000 persons entering the model. Bariatric surgery was associated with an increase in total
life-years, accumulated over the lifetime of participants entering the model, of 6097 per 1000. There was
a substantial increase in the number of life-years lived free from chronic comorbidities of 10,297 per
1000 persons entering the model. There was a decrease in life-years lived with diabetes mellitus of
8320 per 1000 participants entering the model. There were modest increases in life-years lived with CHD,
stroke and cancer following bariatric surgery. This resulted from the increase in the population at risk for
these conditions over the lifetime of the model.
TABLE 35 Intervention effects associated with bariatric surgery
Item Value Source
Operative mortality (%) 0.07 NBSR11
T2DM remission (%) 40 CPRD (see Chapter 8)
Incidence, relative risk (95% CI)
DM 0.20 (0.13 to 0.30) CPRD7 (see Chapter 7)
CHD 0.67 (0.54 to 0.83) SOS9
Stroke 0.67 (0.54 to 0.83) SOS9
Cancer 0.58 (0.44 to 0.77) SOS89 (women only)
Mortality, relative risk (95% CI) 0.45 (0.36 to 0.56) Arterburn et al.10
Depression, relative risk (95% CI)
Year 1 0.82 (0.78 to 087) CPRD90
Year 2 0.83 (0.76 to 0.90)
Year 3 0.87 (0.78 to 0.97)
Decrement in utility associated with BMI category (kg/m2)
25–29 0 Hakim et al.91
30–34 –0.085
35–39 –0.17
≥ 40 –0.255
TABLE 36 Model outputs per 1000 participants entering model. Figures are frequencies except where indicated
Measure Bariatric surgery No bariatric surgery Incremental value (mean, 95% range)
Total person-years lived 41,869.28 35,772.21 6097 (6022 to 6171)
No morbidity, person-years 22,296.44 11,998.61 10,297 (10,152 to 10,452)
Diabetes mellitus, person-years 9434.01 17,754.62 –8320 (–8502 to –8123)
CHD, person-years 5321.58 3771.50 1550 (1473 to 1626)
Stroke, person-years 1309.54 633.92 676 (647 to 705)
Cancer, person-years 3507.70 1613.56 1894 (1830 to 1957)
Depression, person-years 4393.11 4385.58 8 (–8 to 23)
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Table 37 presents the results of the cost–utility analysis. Figures are presented as values per 1000 persons
entering the model. The total undiscounted health-care costs over a lifetime for 1000 persons with morbid
obesity were estimated to be £97.82M in the absence of bariatric surgery and £126.84M with bariatric
surgery. The undiscounted incremental cost associated with bariatric surgery was £29.01M, or £15.26M
when discounted at 3.5%. As the cost of the bariatric surgical procedure is estimated to be £9.16M
per 1000 participants, it can be concluded that bariatric surgery is associated with increased lifetime
health-care costs associated with greater longevity. This is reflected in the greater estimated undiscounted
QALYs after bariatric surgery of 28,345 per 1000 persons, compared with 22,772 in the absence of
bariatric surgery. The net gain in discounted QALYs from bariatric surgery was 2142 per 1000 persons.
The estimated value for discounted cost per QALY gained was £7129 per QALY, with a 95% range
from 1000 simulations of £6775 to £7506 per QALY. Graphs of the cost-effectiveness plane and the
cost-effectiveness acceptability curve are presented in Figure 13. If each QALY gained is valued at £30,000,
then the net benefit associated with bariatric surgery performed in 1000 persons with morbid obesity is
approximately £49M, or £28M if a value of £20,000 per QALY is used.
TABLE 37 Cost–utility analysis of bariatric surgery in morbid obesity
Measure Bariatric surgery No bariatric surgery Incremental value (mean, 95% range)
Health-care costs per 1000 (UK£M)
Not discounted 126.84 97.82 29.01 (28.78 to 29.23)
Discounted 1.5% 93.06 72.38 20.68 (20.53 to 20.81)
Discounted 3.5% 67.25 51.99 15.26 (15.18 to 15.33)
QALYs per 1000 (QALYs)
Not discounted 28,345 22,772 5572 (5422 to 5728)
Discounted 1.5% 20,547 17,022 3524 (3397 to 3655)
Discounted 3.5% 14,509 12,367 2142 (2032 to 2256)
Cost (£) per QALY
Not discounted 5208 (5075 to 5338)
Discounted 1.5% 5868 (5662 to 6073)
Discounted 3.5% 7129 (6775 to 7506)
Net monetary benefit per 1000 (UK£M)
£30,000 per QALY 49.02 (45.72 to 52.41)
£20,000 per QALY 27.59 (25.40 to 29.85)
Net health benefit per 1000 (QALYs)
£30,000 per QALY 1634 (1524 to 1747)
£20,000 per QALY 1380 (1270 to 1493)
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FIGURE 13 Graphs showing (a) cost-effectiveness plane of incremental cost per QALY; and (b) cost-effectiveness
acceptability curve.
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Table 38 presents the results of analyses in subgroups of the population, as well as sensitivity analyses that
varied underlying assumptions. Additional data are presented in Appendix 2. All estimates were discounted
at 3.5%. Incremental costs and QALYs were slightly lower in men than in women, reflecting their general
lower life expectancy, but estimates of costs per QALY were similar in men and women. Older participants
generally incurred lower total costs and fewer total QALYs, consistent with their shorter life expectancy,
but incremental costs and QALYs were higher as a result of the higher absolute risk reductions obtained in
a population at higher baseline risk. Nevertheless, cost-effectiveness estimates were generally consistent
across age groups. Comparing the use of bariatric surgery in most and least deprived quintiles of
deprivation, total costs were greater and total QALYs were lower in the most deprived quintile but
incremental costs and QALYs were similar in each deprivation category as were cost-effectiveness
estimates. The model was run using an initial population with severe obesity and the procedure was found
to be only slightly less cost-effective in this group, with estimated cost of £7669 per QALY. When the
initial population was confined to morbidly obese persons with T2DM the estimated cost per QALY was
£6176 (95% CI £5894 to £6457).
TABLE 38 Cost–utility analyses for subgroup and sensitivity analyses. Figures are expressed as rates per 1000
persons entering the model unless otherwise indicated. Please refer to Appendix 2 for additional results
Variable Condition
Bariatric surgery
arm Incremental
Cost per QALY
(mean, 95% range) (UK£)
Total costs
(UK£M)
Total
QALYs
Incremental
costs (UK£M)
Incremental
QALYs
All BMI ≥40kg/m2 67.25 14,509 15.26 2142 7129 (6775 to 7506)
Gender Men 63.99 14,332 14.97 2087 7188 (6662 to 7796)
Women 70.51 14,680 15.55 2201 7076 (6581 to 7638)
Age group (years) 20–34 68.18 17,153 13.62 1866 7344 (6478 to 8421)
35–54 70.79 15,030 15.00 2139 7027 (6511 to 7569)
55–74 59.49 11,545 17.01 2355 7230 (6862 to 7613)
Deprivation category Least deprived 61.49 14,791 14.46 2052 7056 (6688 to 7448)
Most deprived 70.00 14,187 16.32 2242 7287 (6930 to 7665)
Diabetes BMI
≥ 40 kg/m2
BMI ≥40kg/m2 68.47 14,468 15.04 2437 6176 (5894 to 6457)
BMI 35–39 kg/m2 BMI 35–39kg/m2 68.08 14,708 15.00 1995 7675 (7339 to 8037)
Costs of procedure 50% higher 71.83 14,511 19.84 2144 9261 (8800 to 9795)
100% higher 76.41 14,512 24.42 2148 11,376 (10,763 to 11,950)
Zero procedure
cost
58.09 14,512 6.10 2148 2842 (2701 to 2998)
Decline of intervention
effect over time
Year–0.25 64.25 13,786 12.25 1422 8637 (8009 to 9400)
Year–0.50 63.15 13,516 11.16 1152 9720 (8860 to 10,706)
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Discussion
Summary of findings
This study drew on recently published evidence for the effects of bariatric surgery on incidence of
disease,7,8 mortality10 and health-care costs12,13 following the procedure. This research modelled the lifetime
health benefits from bariatric surgery. The results project substantial increases in life-years and reductions
in years lived with diabetes. Bariatric surgery is expected to be associated with increased health-care costs
arising from the costs of the procedure, as well as increased lifetime health-care costs associated with
increased life expectancy. When health benefits and costs are combined into a single metric, using
accepted values of cost per QALY, use of bariatric surgery is expected to yield substantial net monetary
benefits amounting, over a lifetime, to £49M per 1000 persons. Net health benefits may amount to 1634
QALYs per 1000 persons. Bariatric surgery has similar cost-effectiveness in men and women, at different
ages and in different deprivation categories. Bariatric surgery is also expected to be cost-effective in
individuals with severe obesity (BMI 35–39 kg/m2). Bariatric surgery will be cost-effective even if the cost of
the procedure is twice as high as we have estimated, or if the effect of the procedure declines over time so
that only 32% of the initial effect remains after 10 years.
Comparison with other results
There have been several previous cost-effectiveness analyses of bariatric surgery for morbid obesity.
One of the most authoritative was the 2009 study by Picot et al.31 Their study reported a model in
which weight loss following surgery was viewed as the main mediator of longer-term changes in health
outcomes. The study found that bariatric surgery was a cost-effective intervention for morbid obesity,
with ICERs ranging between £2000 and £4000 per QALY gained over a 20-year time horizon.31 A more
recent study suggested that bariatric surgery may be cost saving for health-care systems through reduced
morbidity,175 though this conclusion has been disputed.178 Although bariatric surgery does not appear to
generate cost savings, its use is associated with substantial health gains at costs that are well below
accepted thresholds for cost-effectiveness.
This analysis updates previous studies by including those surgical procedures that are currently utilised
including adjustable gastric banding, GBP and SG. The analysis also updated the costs of surgery to
present-day values. The present model incorporated direct evidence concerning the long-term outcomes of
bariatric surgery in contrast to previous studies, which have used changes in intermediate measures of
surgical effect including body weight, blood pressure and lipid profiles to model the long-term outcomes
of bariatric surgery. Our analysis recognised that the effects of surgery, particularly those on diabetes, are
not entirely weight dependent and our model therefore did not include weight change as an intermediate
outcome. The model was informed by recent measures of the effects of surgery on substantive long-term
health outcomes and health-care costs, additionally informed by analysis of CPRD EHRs. In spite of this
difference of approach, our analyses are consistent with previous reports in showing that bariatric surgery
is likely to be very cost-effective. We do not find that bariatric surgery is cost saving. This would not be
expected, however, as it is unlikely for a procedure that reduces mortality in a population that experiences
a heavy burden of morbidity to reduce lifetime health expenditures.177
Strengths and limitations
This research was based on empirical data for disease incidence, mortality and costs of health-care
utilisation estimated from the EHRs of a large sample of participants managed in primary care in the UK
between 2008 and 2013. We caution that the small proportion of very obese patients who had bariatric
surgery means there is a real possibility that they differ from other patients whose characteristics on health
records are similar. The study also drew on recently published and authoritative estimates of the effects
and costs of bariatric surgery with an emphasis on those bariatric surgical procedures that are currently
utilised. Both the empirical and abstracted inputs were consistent with estimates from systematic reviews
of the effects of surgery on related morbidities. We have used conservative assumptions including that
costs of health-care utilisation following surgery are not associated with weight loss; that any gain in utility
associated with BMI reduction declines rapidly over time; and that remission from diabetes following
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surgery occurs in 40% of patients, as estimated from CPRD, which is lower than levels observed in other
reported studies. We acknowledge that any model represents a simplification of reality. There are other
forms of morbidity that were not represented in the model. However, the costs of health-care utilisation
from such conditions will have been included in cost estimates from CPRD, which encompassed all
health-care utilisation. We included the major complications of surgery including operative mortality,
costs of leaks following surgery, and reoperations in 2% of patients per year. There may be additional
costs associated with surgery but a sensitivity analysis showed that even if total costs of surgery were to be
twice as high as estimated in the base case, bariatric surgery would still be cost-effective. We modelled
bariatric surgery as having a constant effect in the postoperative period, but we showed that even if the
effects declined over time surgery would still be cost-effective.
Conclusions
Bariatric surgery is not cost saving but increased immediate and long-term health-care costs are
outweighed by health benefits to obese individuals. This study shows that bariatric surgery is highly
cost-effective and that substantial net health or monetary benefits may be anticipated from wider used of
bariatric surgical procedures in patients with severe and morbid obesity. Similar cost-effectiveness may be
anticipated in diverse groups of obese individuals including men and women, wide ranges of ages and
different levels of deprivation. Bariatric surgery may have the potential to reduce obesity-related
inequalities in health. This is in contrast to presently available non-surgical interventions for obesity, which
generally have only small and generally short-lived effects.29,96,97 Based on these results, the wider use of
bariatric surgery may be justified in the management of people with severe and morbid obesity. A major
concern remains that the social and environmental drivers of the increase in morbid obesity should not
remain unchecked.100 As a ‘downstream’ procedure, bariatric surgery will not stem the global increase
in obesity. The role of surgery in treating disorders apparently rooted in individual lifestyle is also
questioned.179 There are also concerns relating to the capacity of health services to deliver safe,
high-quality services for patients with severe and morbid obesity,180 which were recognised in national
guidance on bariatric surgery.181 Nevertheless, people with severe and morbid obesity share the right of all
individuals to the highest attainable standard of health, and bariatric surgery may often offer important
health gains at a reasonable level of investment.
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Chapter 12 Conclusions
Statement of principal findings
This study used EHRs to analyse changes in disease status and health-care utilisation in obese patients who
underwent bariatric surgery. These results were incorporated into a health economic model to estimate the
cost-effectiveness of increasing access to bariatric surgical procedures for the treatment of obesity.
For patients with morbid obesity, the chance of attaining normal weight or maintaining clinically relevant
weight loss is very low, with the implication that present obesity treatment frameworks grounded in
community-based weight management programmes are ineffective. The evidence on transitions between
obesity categories, and weight cycling, from the large number of electronic records analysed in the study
provide robust estimates which add to the evidence base for radical action on obesity and associated
morbidity. Health-care costs are considerably increased in obesity, primarily because of the greater burden
of comorbidity.
The numbers of bariatric surgical procedures performed have increased since 2002, with increasing use of
GBP and SG and declining use of LAGB. Rates of bariatric surgery per 100,000 population remain low and
provide evidence of limited access to bariatric surgical procedures in relation to need. Bariatric surgery is
associated with reduced incidence of clinical diabetes, in obese participants without diabetes at baseline, and
remission of diabetes in obese patients with T2DM. Diabetes outcomes may be generally more favourable
after GBP or SG than LAGB. Psychological comorbidity is frequent among individuals selected to undergo
bariatric surgery, but any modest improvement over the initial postoperative years is not maintained.
Bariatric surgery is cost-effective relative to standard weight management across a wider range of BMI
levels than currently recommended, and is more cost-effective in diabetes mellitus, with results robust to
gender, age and deprivation differences.
Increasing access to bariatric surgery for patients with obesity is associated with increased health-care
costs, but these are outweighed by expected health benefits to obese individuals. Bariatric surgery is a very
cost-effective intervention. Bariatric surgery appears unlikely to reduce the population prevalence of severe
and morbid obesity unless factors driving the increase in obesity are addressed. Development of more
effective obesity prevention strategies is urgently required.
Box 1 presents a summary of findings.
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BOX 1 Summary of principal findings
Epidemiology of obesity
l The probability of an obese person attaining normal body weight is very small.
l Maintaining a 5% loss of body weight over 2–5 years is also unlikely.
l Obese people incur higher health costs, which are largely associated with physical and
psychological comorbidity.
Access to bariatric surgery
l Utilisation of BS is presently at very low levels.
l Over time, the use of BS has shifted to older, heavier patients with greater comorbidity.
l Sleeve and partial gastrectomy procedures, which are more costly but more effective, are
increasingly utilised.
l Men are much less likely to receive BS than women.
l In a sample of 78 procedures sampled from CPRD, 32 (41%) were performed privately.
Outcomes of bariatric surgery
l In obese patients without diabetes, BS is associated with lower incidence of diabetes for up to 7 years
following the procedure, when compared with controls of the same age, sex and BMI. These results
confirm findings from the SOS study.
l In obese patients with diabetes, remission is substantially higher than in controls for at least up to 6 years
following the procedure. There is improved blood glucose control and lower utilisation of antidiabetes
medications. These results confirm findings from small RCTs.
l BS may be associated with a transient reduction in clinical depression following the procedure but many
patients have significant psychological comorbidity.
Cost-effectiveness of bariatric surgery
l The immediate cost of a bariatric surgical procedure is approximately £9164.
l In people with morbid obesity, BS is a highly cost-effective intervention.
l If QALY gains are valued at £30,000 per QALY, use of bariatric surgery is expected to yield substantial net
monetary benefits amounting, over a lifetime, to £49M per 1000 persons.
l BS would be cost effective even if it were to be more costly than is presently the case.
l BS would be cost-effective even if the benefits of surgery declined over time.
l BS is equally cost-effective in men and women.
l BS has similar cost-effectiveness at different ages between 20 and 74 years.
l BS has similar cost-effectiveness at different levels of deprivation including the most and least deprived.
l BS is not cost saving owing to the increased life-expectancy and associated increase in life time
health-care costs.
BS, bariatric surgery.
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Implications of these research findings
The prevalence of morbid obesity in England is 1.8% in men and 3.9% in women aged 20–75 years,
based on data for the Health Survey for England from 2011 to 2013.182 In a primary care organisation
with a population of 250,000 in this age group, there will be about 7163 people with morbid obesity,
comprising 4875 women and 2288 men (Table 39). In this group of people, there will be approximately
200 new cases of diabetes each year, based on incidence rates reported in Chapter 7. There are important
socioeconomic differences in the prevalence of morbid obesity (Figure 14). Among the least deprived,
1.3% of men and 2.3% of women have morbid obesity, but among the most deprived the prevalence of
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FIGURE 14 Prevalence of morbid obesity by gender and deprivation category. Data are for adults aged 20–75 years
from Health Survey for England 2011–13 (n= 18,454).182
TABLE 39 Implications for a CCG with a population of 250,000
Measure Estimate Source
Total population aged 20–74 years 250,000
Number with morbid obesity 7163 (4875 women;
2288 men)
Prevalence of obesity from Health
Survey for England 2011–13
combined182
Number with morbid obesity and diabetes 1406 (763 women;
643 men)
Prevalence of diabetes by BMI
category from Health Survey for
England 2011–13 combined182
Cost of 1000 bariatric surgical procedures, with 50% in
people with diabetes
£9.164M Table 7 in this report
Total increase in NHS costs over patients’ lifetime £15.260M See Chapter 11
Number of new cases of diabetes prevented over 10 years 112 See Chapter 7
Number of diabetes cases in remission over next 5 years 200 See Chapter 8
Health gain in QALYs 2142 See Chapter 11
Net monetary benefits over patients’ lifetime
(£30,000 per QALY)
£49M See Chapter 11
Number with morbid obesity if the CCG is in the most
deprived quintile (IMD2010)
10,813 (7663 women;
3150 men)
Prevalence of obesity by deprivation
quintile from Health Survey for
England 2011–13 combined182
Number with morbid obesity if the CCG is in the least
deprived quintile (IMD2010)
4413 (2838 women;
1575 men)
CCG, Clinical Commissioning Group.
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morbid obesity is 2.5% in men and 6.1% in women. A primary care organisation with an affluent
population may have only 4413 people with morbid obesity, compared with 10,813 in a deprived area.
Among adults, T2DM is largely a condition affecting those who are overweight or obese (Figure 15).
In England, the prevalence of diabetes is 3.3% in men of normal weight but 28.1% among those with
morbid obesity. In women, the equivalent figures are 1.4% and 15.6%. Among ethnic minority groups,
diabetes may be more frequent among women. In a typical primary care organisation, there may be
1406 people with morbid obesity and diabetes mellitus.
At present rates of bariatric surgery, reported in Chapter 6, there may be 25 bariatric surgery procedures
per year, of which between 8 and 12 may be performed privately (see Chapter 6). The empirical data
and modelling results presented in this report identify the likely costs and outcomes of increasing access
to bariatric surgery within a primary care organisation (see Table 39). If a decision is made to invest in
1000 bariatric surgical procedures over a defined period of time, then the immediate NHS costs will
amount to £9.2M at 2014 prices. The total additional costs to the NHS, over the patients’ lifetime, are
estimated to be £15.3M. If bariatric surgery procedures are divided equally between those with diabetes
and those without, then there will be 112 fewer new diagnoses of diabetes over the next 10 years among
the 500 non-diabetic patients who receive bariatric surgery (see Chapter 7). Among the 500 diabetic
patients who receive bariatric surgery, at least 200 are expected to enter remission, with improved diabetes
control and reduced antidiabetic drug utilisation among the remainder (see Chapter 8). Other modelled
benefits from bariatric surgery include reduced incidence of cardiovascular diseases and cancer, lower
mortality and increased well-being (see Chapter 11). Together, these are predicted to contribute 2142
additional QALYs over these patients’ lifetime. There may be additional benefits from bariatric surgery, for
example on respiratory disorders or arthritis, that have not been included in the model. If the modelled
health gains are valued at £30,000 per QALY, then these may be equated with a gain of £64.3M.
There will be a net monetary benefit of £49M.
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FIGURE 15 Prevalence of diabetes mellitus by obesity category. Data are for adults aged 20–75 years from Health
Survey for England 2011–13 (n= 18,454).
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Efforts to expand access to bariatric surgery will need to address the question of which patients should
receive surgery:
l Morbid obesity is strongly associated with deprivation, as noted above. If patients are referred and
selected for surgery on an equitable basis, then health benefits from bariatric surgery will generally flow
to more deprived groups. The cost-effectiveness of bariatric surgery is not expected to differ greatly
between socioeconomic groups (see Chapter 11).
l Bariatric surgery has mainly been utilised by women, with 80% of the CPRD cohort being female (see
Chapter 6). Estimates of cost-effectiveness do not suggest that there are important gender differences
that could justify continuing gender differences in access to bariatric surgery (see Chapter 11).
l Bariatric surgery is presently utilised most frequently between the ages of 35 and 54 years (see
Chapter 6). Estimates of cost-effectiveness do not favour a clear strategy with respect to age. Younger
patients have a greater life expectancy, but lower incidence of disease, while older adults have a higher
incidence of disease that may be associated with greater absolute risk reductions from intervention.
However, there is presently insufficient evidence to stratify intervention effects of bariatric surgery
by age.
l Use of bariatric surgery by people with diabetes appears to be slightly more cost-effective, with higher
incremental QALYs and slightly lower incremental costs, than for non-diabetic individuals. As noted
above, bariatric surgery in 500 individuals without diabetes may reduce new diabetes diagnoses by 112
over 10 years, while bariatric surgery in 500 diabetic individuals might lead to 200 cases of diabetes
remission. This calculation might suggest that a secondary prevention strategy is to be preferred, but
the simplifying assumption that the prognosis of individuals who previously had diabetes is similar to
that of individuals who never had diabetes may not be justified. Research has not been conducted to
compare policies of targeting bariatric surgery at diabetic as compared with non-diabetic individuals.
Both diabetic and non-diabetic individuals have clear capacity to benefit from bariatric surgery and the
present results do not determine whether a primary or a secondary prevention strategy is to be
preferred with respect to diabetes. Within the diabetic population, evidence may be insufficient to
distinguish policies of intervening with bariatric surgery for morbid, severe or simple obesity, as
proposed by the IDF, with bariatric surgery presently being utilised only at low levels even among
people with morbid obesity.
Strengths and limitations
Empirical data analyses for this study were based on representative patient cohorts, with long-term
follow-up of participants. Health-care costs were derived prospectively and represented actual use rather
than relying on an indirect measure such as subsequent insurance claims data. However, as a consequence
of using clinical data there are also limitations to consider. First, bariatric surgery is offered to a very highly
selected group of eligible patients in the UK, and these patients are likely to have characteristics that
distinguish them from other very obese patients who have not been selected clinically, or through
self-referral, for bariatric surgery. For instance, they may have a different morbidity profile and receive
greater levels of care and surveillance than other patients. These factors may have introduced bias into our
estimates of morbidity improvement when compared with matched controls who did not undergo surgery.
We estimated a lower rate of diabetes remission than much of the published literature. Despite the
potential differences in medical care provided to surgery patients, recording of body weight subsequent to
surgery was poor. Although it would have been of great interest to be able to investigate changes in body
weight after surgery using primary care records, we were less concerned about their importance for
estimating changes in morbidity, as these effects are at least partly independent of weight loss.
Nonetheless, we relied on matched cohort studies to assess the relationship between surgery and disease
outcomes. Although the majority of these estimates were supported by the published literature, this does
not reverse the need for more long-term studies on the outcomes of bariatric surgery, including RCTs.
We acknowledge that we did not conduct a full systematic review of the outcomes of bariatric surgery
because this was beyond the scope of this research. Instead, we conducted a rapid review that focused on
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recently reported systematic reviews and meta-analyses. In addition to this qualification, bariatric surgical
procedures continue to evolve with new procedures developed and changes in the epidemiology of those
popularly used and the patients upon which they are performed. Although our results are based on the
three most commonly used procedures currently, these changes need to be considered and up-to-date
evidence provided over time.
Patient and public involvement
Below we outline the ways in which we have sought to both include patient perspectives into the study
and its findings as well as engage with the public.
Media interaction
The findings of this research have been reported widely within the media. The research team gave radio
interviews to BBC London Live and the Today programme on BBC Radio 4. A summary of newspaper and
online articles is presented in Box 2.
Patient engagement
Members of the research team attended a meeting of post-bariatric surgery patients at St George’s
Hospital in London. The team presented information relating to the study and invited the 16 patients
present to feedback comments and ideas relating to the project and future research. The study was well
received by the group and elicited a good deal of feedback. Areas that the patients commented on
included the need for better support both prior and subsequent to the procedure, particularly in relation to
dealing with the psychosocial issues that encouraged their overeating. A key point was the need to
improve support for patients in addition to increasing access to surgery. The demotivating effect of trying
to reach a ‘normal’ BMI rather than focusing on weight lost was also discussed. Some patients reported
their anxiety about weight regain and unpleasant side effects from surgery, such as loose skin and hair
loss. Favourable comments were also made about the weight loss and diabetes remission. We plan to
disseminate findings of the study to patients by producing a short summary leaflet and attending a further
patient group meeting.
Presentation of results to professionals
Members of the research team have presented aspects of the study findings at the following conferences
and meetings:
l International Federation for the Surgery of Obesity and Metabolic Disorders, Montreal, Canada,
26–30 August 2014
l Social Society for Medicine, Oxford, UK, 10–12 September 2014
l Obesity Week, California, USA, 2–6 November 2015.
Overview of patient and public involvement
It was very informative for the team to attend the patient meeting and hear their thoughts on the
research. We took on board their suggestions for future research, and although we were not able to
include them in the current analyses we have included them in the research recommendations and have
referred to them in the interpretation of our results where possible. We were delighted that the
publications produced during the study received attention in the mainstream media. As a result of this
coverage we were contacted by health professionals who work with bariatric surgery patients, who said
that they would be communicating the findings to their patients.
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BOX 2 Summary of articles
Eunjung Cha A. Could radical weight-loss surgery help prevent type 2 diabetes? The Washington Post,
3 November 2014. URL: www.washingtonpost.com/news/to-your-health/wp/2014/11/03/could-radical-weight-
loss-surgery-help-prevent-type-2-diabetes/.
Lehman S. Weight loss surgery may help prevent diabetes. Reuters, 18 November 2014. URL: www.reuters.
com/article/us-bariatric-surgery-diabetes-idUSKCN0J22MU20141118.
Willey J. New research says surgery could be key to beating diabetes. Express, 3 November 2014.
URL: www.express.co.uk/life-style/health/530689/Surgery-key-to-beating-diabetes.
Weight loss surgery reduces diabetes risk. The Times of India, 3 November 2014. URL: http://timesofindia.
indiatimes.com/life-style/health-fitness/health-news/Weight-loss-surgery-reduces-diabetes-risk/articleshow/
45020847.cms.
Sifferlin A. Weight loss surgery lowers risk for Type 2 Diabetes, study suggests. TIME, 3 November 2014.
URL: http://time.com/3554426/weight-loss-type-2-diabetes/.
Weight loss surgery cuts diabetes risk in very obese. NHS Choices, 3 November 2014. URL: www.nhs.uk/news/
2014/11November/Pages/Weight-loss-surgery-cuts-diabetes-risk-in-very-obese.aspx.
Gallagher J, Weight loss surgery reduces diabetes risk. BBC News, 3 November 2014. URL: www.bbc.co.uk/
news/health-29847059.
Monbiot G. Obesity is an incurable disease. So why is the government intent on punishing its sufferers? The
Guardian, 11 August 2015. URL: www.theguardian.com/commentisfree/2015/aug/11/obesity-incurable-disease-
cameron-punishing-sufferers.
Norton A. Most obese people will never reach normal weight. WebMD, 16 July 2015. URL: www.webmd.com/
diet/obesity/20150716/most-obese-people-will-never-reach-normal-weight-study.
Lay K. Obese men have a one in 210 chance of slimming down. The Times, 17 July 2015. URL: www.thetimes.
co.uk/tto/health/news/article4500533.ece.
Spencer B. Losing weight really IS impossible: the vast majority of people who pile on the pounds never
lose them in the long run. Daily Mail, 16 July 2015. URL: www.dailymail.co.uk/health/article-3164042/
Majority-people-pile-pounds-never-lose-them.html.
Obesity: ‘slim chance’ of return to normal weight. BBC News, 17 July 2015. URL: www.bbc.co.uk/news/
health-33551498.
Odds are against reaching normal body weight for adults with obesity. Healio, Endocrine Today, 17 July 2015.
URL: www.healio.com/endocrinology/obesity/news/online/%7B71c46386-9b44-4eb8-8506-0c9f05b96e57%7D/
odds-are-against-reaching-normal-body-weight-for-adults-with-obesity.
McCall B. Only one in 210 obese men reach healthy weight. Medscape, 23 July 2015. URL: www.medscape.
com/viewarticle/848544.
Last accessed date for URLs: 4 March 2016.
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Were the initial research objectives of the project met?
The research has provided new knowledge concerning the expected costs and outcomes of increasing
access to bariatric surgery. The initial objectives of the research specifically aimed to evaluate three
intervention strategies:
1. Expanding access within existing recognised indications for bariatric surgery as defined by NICE: this
objective has been fully met. We have evaluated the costs and outcomes of increasing access to
bariatric surgery for patients with morbid obesity, as well as severe obesity and diabetes. Diabetes is the
chronic disease that is most strongly associated with obesity.
2. Expanding access to bariatric surgery for people with T2DM as proposed by the IDF: the
recommendations of the IDF are for increased use of bariatric surgery among people with severe and
morbid obesity. This has been evaluated as part of the research for objective 1. The IDF also made a
recommendation that bariatric surgery should be considered for patients with BMI 30–34.9 kg/m2 who
had poorly controlled diabetes with medical therapy, or who were at increased risk of cardiovascular
disease. This second part of the IDF recommendation has not been fully addressed. We judged that the
group of patients with BMI ≥ 35 kg/m2 would generally take priority in the selection of patients for
bariatric surgery. We also concluded that issues of clinical judgement in patient selection would be of
critical importance in implementing the second part of the IDF recommendation. We also concluded
that trial evidence would require reviewing separately for patients with simple obesity and diabetes.
There were therefore several reasons why this part of the IDF recommendation was not considered in
this project, which aimed to have a broad population focus.
3. Expanding access with a focus on the distributional consequences of different intervention strategies:
the research provided evidence of the extent to which health outcomes and costs of bariatric surgery
vary by gender, age group and among socioeconomic groups, thus evaluating the potential impacts on
inequalities in health related to obesity.
Research recommendations
Methodological
This research demonstrates the value of EHRs for long-term follow-up of participants who have received
defined health care interventions. Future research might aim to recruit patients into randomised studies
with long-term follow-up of substantive clinical outcomes.
Basic research
Improved understanding of the mechanisms of effect of bariatric surgical procedures may yield insights
that can be used to inform more effective interventions for people with morbid obesity.
Health technology assessment
l Research is needed, using efficient study designs, to evaluate the long-term effects of currently used
bariatric surgical procedures, across a comprehensive range of outcome measures.
l Estimates of intervention effects from bariatric surgery should be stratified by age group and morbidity
category (especially diabetes status). This might enable evaluation of optimal age and morbidity
distributions to be prioritised to receive bariatric surgery and inform patient selection.
l The value of CPRD for deriving current clinical data on bariatric surgery use and outcomes has been
established during this project. Continued observation of this cohort over time may provide further
insights into the evolving use of procedures and related outcomes.
l Research to define interventions to improve mental health outcomes of people with morbid obesity.
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Service organisation and delivery research
l Research to map and quantify disparities in access to bariatric surgery in relation to need.
l Multi-method research on organisational and service barriers to accessing bariatric surgery,
incorporating views and experiences of policy-makers, commissioners, managers, clinicians
and patients.
l Research on patient experience including pre- and post-operative patient support, weight regain after
surgery, weight loss targets and how this information is presented to patients.
l Evaluation of strategies for scaling up bariatric surgery for the treatment of obesity, while maintaining a
safe service.
l Research to define strategies for organising and delivering care to optimise mental and physical health
outcomes of people with morbid obesity. This includes primary disease prevention, in the context of
NHS Health Checks, and secondary prevention, in the context of primary care management of
multi-morbidity.
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Appendix 1 General practitioner questionnaire on
bariatric surgery patients
1. Based on your knowledge of the patient and review of the medical record, does this patient 
ever have a confirmed record of bariatric surgery? 
 
  YES      NO  
 
If YES, please state date of first bariatric surgery procedure: _______________________ 
 
2. If YES to 1), what type of first bariatric surgery procedure did this patient undergo? 
 
  Laparoscopic gastric banding 
  Gastric bypass 
  Sleeve gastrectomy 
  Other, please specify___________________________________________ 
 
If YES to 1), how was this first bariatric surgery funded? 
 
  NHS     Private 
 
3. If YES to 1), please list any complications following this first bariatric surgery: 
_____________________________________________________________
_____________________________________________________________
_____________________________________________________________
_________________________________ 
 
4. If YES to 1), based on your knowledge of the patient and review of the medical record, does 
this patient ever have a confirmed record of: 
 
(a)  Gastric band removal following bariatric surgery?   YES    
NO  
 
If YES, please state date of gastric band removal procedure: 
__________________________ 
 
(b)  Operation reversal following bariatric surgery?   YES    NO  
  
If YES, please state date of operation reversal: _______________________________ 
 
5. Based on your knowledge of the patient and review of the medical record, does this patient 
have a confirmed record of a second or repeat bariatric surgery procedure? 
 
  YES     NO  
 
If YES to 5, please state date of second or repeat procedure: 
__________________________ 
If YES to 5, please give details of type of second or repeat procedure: 
__________________________________________________________________________
__________________________________________________________________________ 
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Appendix 2 Additional results tables
TABLE 40 Simulation results for participants with morbid obesity for all participants and by gender. Figures are
expressed per 1000 participants entering the model and are means of 1000 simulations
Measure
All Male Female
BS No BS BS No BS BS No BS
Costs 126,836,121.81 97,822,340.46 118,400,495.64 91,241,063.75 135,276,143.77 104,409,362.78
Costs DC35 67,251,683.64 51,993,824.43 63,992,984.42 49,024,080.05 70,511,968.19 54,965,655.38
CostDC15 93,060,030.17 72,384,665.60 87,708,897.53 67,884,550.81 98,413,843.50 76,888,406.05
QALYs 28,345.05 22,772.64 27,526.08 22,284.14 29,158.05 23,253.09
QALYs DC35 14,509.41 12,366.93 14,332.44 12,245.47 14,680.41 12,479.21
QALYs DC15 20,547.16 17,022.33 20,128.72 16,757.24 20,959.56 17,278.53
All life-years 41,869.28 35,772.21 40,407.82 34,770.96 43,332.07 36,775.17
Depression
life-years
4393.11 4385.58 2758.75 2788.49 6026.91 5982.95
Life-years at risk 22,296.44 11,998.61 19,548.83 10,699.63 25,046.19 13,296.59
Life-years DM 9434.01 17,754.62 9556.05 17,985.37 9310.55 17,527.22
Life-years CHD 5321.58 3771.50 6031.45 4167.85 4607.14 3374.40
Life-years stroke 1309.54 633.92 1264.04 624.09 1354.88 643.91
Life-years cancer 3507.70 1613.56 4007.44 1294.02 3013.32 1933.06
BS, bariatric surgery; DC15, discounted at 1.5%; DC35, discounted at 3.5%; DM, diabetes mellitus.
TABLE 41 Simulation results for participants with morbid obesity by age group. Figures are expressed per 1000
participants entering the model and are means of 1000 simulations
Measure
Age 20–34 years Age 35–54 years Age 55–74 years
BS No BS BS No BS BS No BS
Costs 162,802,898.40 130,904,334.92 132,488,841.51 103,034,399.09 88,562,965.62 62,590,058.83
Costs DC35 68,175,090.26 54,554,520.65 70,788,350.76 55,790,378.00 59,487,707.66 42,481,582.10
Costs DC15 106,243,818.53 86,314,167.65 97,908,327.02 77,166,636.27 73,479,839.77 52,375,922.36
QALYs 39,870.46 33,278.70 29,223.34 23,491.96 18,055.45 13,586.00
QALYs DC35 17,153.23 15,286.99 15,029.65 12,890.59 11,545.05 9190.42
QALYs DC15 26,444.01 22,878.23 21,308.87 17,707.97 14,684.95 11,352.60
All life-years 58,730.38 51,778.08 43,178.24 36,892.51 26,609.23 21,528.20
Depression
life-years
6670.78 6728.21 4633.74 4629.18 2202.50 2141.60
Life-years at risk 33,304.16 18,911.61 22,506.81 11,947.94 13,618.81 6914.29
Life-years DM 13,262.11 25,823.41 9817.97 18,480.57 5794.04 10,254.75
Life-years CHD 6274.47 4340.60 5725.48 4060.51 3795.53 2763.76
Life-years stroke 1461.65 691.69 1347.01 650.45 1117.75 557.43
Life-years cancer 4427.99 2010.77 3780.97 1753.04 2283.10 1037.97
BS, bariatric surgery; DC15, discounted at 1.5%; DC35, discounted at 3.5%; DM, diabetes mellitus.
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TABLE 42 Simulation results for participants with severe obesity (BMI 35.0–39.9 kg/m2). Figures are expressed per
1000 participants entering the model and are means of 1000 simulations
Measure BS No BS
Costs 128,590,497.64 100,136,128.52
Costs DC35 68,079,271.04 53,082,707.75
Costs DC15 94,294,469.84 74,019,668.93
QALYs 28,750.58 23,440.04
QALYs DC35 14,708.08 12,752.62
QALYs DC15 20,836.07 17,534.38
All life-years 42,373.22 36,526.57
Depression life-years 4195.70 4176.40
Life-years at risk 23,389.70 13,875.47
Life-years DM 8521.00 15,902.53
Life-years CHD 5356.61 4077.79
Life-years stroke 1342.90 736.52
BS, bariatric surgery; DC15, discounted at 1.5%; DC35, discounted at 3.5%; DM, diabetes mellitus.
TABLE 43 Simulation results for participants with morbid obesity and T2DM. Figures are expressed per 1000
participants entering the model and are means of 1000 simulations
Measure BS No BS
Costs 129,642,865.44 100,534,065.50
Costs DC35 68,469,090 53,428,942
Costs DC15 94,912,795 74,358,651
QALYs 28,518.57 22,383.33
QALYs DC35 14,467.6 12,030.81
QALYs DC15 20,579.67 16,650.46
36,055.78
All life-years 42,278.46 4949.024
Depression life-years 4890.988 0
Life-years At Risk 10,542.28 36,055.78
Life-years DM 27,745.59 0
Life-years CHD 1711.461 0
Life-years stroke 618.7119 0
Life-years cancer 1660.417 0
BS, bariatric surgery; DC15, discounted at 1.5%; DC35, discounted at 3.5%; DM, diabetes mellitus.
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TABLE 45 Sensitivity analysis of decay of intervention effect from bariatric surgery over time. Figures are expressed
per 1000 participants entering the model and are means of 1000 simulations
Measure
No decay Decay parameter 0.25 Decay parameter 0.5
BS No BS BS No BS BS No BS
Costs 126,836,121.81 97,822,340.46 115,432,021.05 97,824,395.51 111,739,915.22 97,822,175.85
Costs DC35 67,251,683.64 51,993,824.43 64,248,388.82 51,994,746.65 63,152,883.89 51,994,120.43
Costs DC15 93,060,030.17 72,384,665.60 86,840,368.81 72,386,082.30 84,717,546.61 72,384,838.15
QALYs 28,345.05 22,772.64 25,712.42 22,770.51 24,838.51 22,770.49
QALYs DC35 14,509.41 12,366.93 13,786.42 12,364.36 13,515.67 12,363.83
QALYs DC15 20,547.16 17,022.33 19,086.64 17,019.87 18,575.23 17,019.61
All life-years 41,869.28 35,772.21 37,996.29 35,772.62 36,716.33 35,771.92
Depression
life-years
4393.11 4385.58 4281.87 4385.85 4242.26 4385.69
Life-years at risk 22,296.44 11,998.61 17,432.68 11,997.65 15,720.39 11,998.08
Life-years DM 9434.01 17,754.62 12,649.89 17,756.23 13,753.63 17,755.13
Life-years CHD 5321.58 3771.50 4561.94 3771.01 4303.96 3771.05
Life-years stroke 1309.54 633.92 933.13 633.77 823.67 633.81
Life-years cancer 3507.70 1613.56 2418.66 1613.96 2114.68 1613.84
BS, bariatric surgery; DC15, discounted at 1.5%; DC35, discounted at 3.5%; DM, diabetes mellitus.
TABLE 46 Simulation results for participants with morbid obesity by deprivation category. Figures are expressed
per 1000 participants entering the model and are means of 1000 simulations
Measure
Least deprived Most deprived
BS No BS BS No BS
Costs 117,745,667.26 91,107,021.29 131,069,648.77 99,175,584.91
Costs DC35 61,493,790.82 47,034,946.43 69,995,133.48 53,670,281.45
Costs DC15 85,705,625.18 66,476,663.19 96,595,623.78 74,078,377.12
QALYs 29,252.01 23,877.93 27,258.26 21,506.09
QALYs DC35 14,790.50 12,738.97 14,186.56 11,944.26
QALYs DC15 21,073.32 17,689.68 19,927.40 16,260.29
All life-years 43,082.07 37,342.02 40,398.39 33,977.36
Depression life-years 3703.37 3732.77 5161.74 5057.53
Life-years at risk 23,052.80 12,791.42 20,894.34 10,834.98
Life-years DM 9444.79 18,077.73 9540.41 17,464.53
Life-years CHD 5069.20 3761.28 5874.08 3895.64
Life-years stroke 1195.94 608.61 1363.94 612.80
Life-years cancer 4319.33 2102.97 2725.63 1169.41
BS, bariatric surgery; DC15, discounted at 1.5%; DC35, discounted at 3.5%; DM, diabetes mellitus.
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Appendix 3 Protocol amendments
Amendment 1: dated 10 February 2014
On page 12 of the proposal, it reads ‘An additional sample that only includes individuals who have
received bariatric surgery procedures will also be sampled to provide empirical data inputs to the model’.
The protocol already specifies substantive outcome measures of disease incidence and mortality. The
purpose of this amendment is to add as measures of interest, intermediate measures of outcome of
bariatric surgery (BS). We wish to add that ‘the analysis will include comparison of changes over time in
intermediate measures, and their management, between obese participants who received BS and those
who did not receive BS. These measures include body weight, body mass index, blood pressure, serum
cholesterol, HbA1c and smoking. Other medical therapies that impact on these measures will be evaluated
including: diet advice and obesity drugs, use of antihypertensive drugs (including beta-clockers, calcium
channel antagonists, diuretics and drugs acting on the renin-angiotensin system), cholesterol lowering
drugs (including primarily statins), diabetes drugs (including insulin and oral hypoglycaemic drugs) and
smoking advice and smoking prescriptions. Smoking is included because of its importance as a cause of
morbidity in obese individuals. This will enable us to present observational data from CPRD on these
intermediate measures in obese individuals and those who had bariatric surgery’. We note that several of
these measures were covered in an earlier protocol (07_054).
Amendment 2: dated 14 July 2014
One page 13 of the proposal it reads ‘Incidence and mortality rates will be estimated in a time-to-event
framework which will provide estimates from which probabilities can be estimated for the model.(54)’.
On evaluating the data it is clear that the distribution of BMI values is considerably different for bariatric
surgery cases as compared to controls. Results may seem to lack credibility if mean BMI values differ
greatly between surgery cases and controls. Therefore, we will draw a sample of matched controls for
comparison including obese individuals sampled from CPRD who did not receive bariatric surgery and were
not older than the maximum age of the bariatric surgery cases. Controls will be matched for age, body
mass index, sex and index year. Nearest neighbour matching will be performed without replacement. The
index date for controls will be the date of the earliest BMI record on which the patient attained their
highest BMI category. Since prevalent cases of disease must be excluded from analyses to estimate the
incidence of each outcome, a separate set of controls will be sampled for the analysis of each
outcome measure.
With respect to outcome measures, in order to simplify the model, asthma and back and joint pain will be
omitted. All malignant neoplasms (Read code B0 to B6) will be included in place of obesity
associated cancers.
Amendment 3: dated 26 November 2014
This proposed amendment is for a validation study aiming to confirm the date, type of procedure,
occurrence of complications, revision/reversal and repeat procedures following bariatric surgery.
The proposed questionnaire for the study is appended.
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The questionnaire will be sent to GPs relating to patients with CPRD records of bariatric surgery. The
sample will be stratified according to procedure type recorded in CPRD, participants with undefined type
of initial procedure or records of second procedures will be specifically sampled. The sample size will be
up to 150.
Amendment 4: dated 28 January 2015
This proposed amendment is to utilise linked Hospital Episode Statistics data in the estimation of health
care utilisation.
On page 13 the text should be altered to read ‘We will estimate rates of health care utilisation from CPRD
records with linked Hospital Episode Statistics data. Utilisation rates will be based on person-time at risk.
Estimates for the unit cost of health service use will be obtained from reference sources (55). Unit costs will
be applied to each category of health care utilisation in order to estimate health care costs’.
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